<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003709.pub4" GROUP_ID="ANAESTH" ID="921901082309583827" MERGED_FROM="" MODIFIED="2016-02-05 12:50:13 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="029" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2016-02-05 12:50:13 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2010-12-02 14:47:24 +0000" MODIFIED_BY="Harald Herkner">Vasopressors for hypotensive shock</TITLE>
<CONTACT MODIFIED="2016-02-05 12:50:13 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="12150" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Harald</FIRST_NAME><LAST_NAME>Herkner</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Assoc. Prof. Emergency Medicine</POSITION><EMAIL_1>harald.herkner@meduniwien.ac.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><ADDRESS_1>Vienna General Hospital;</ADDRESS_1><ADDRESS_2>Währinger Gürtel 18-20 / 6D</ADDRESS_2><CITY>Vienna</CITY><ZIP>1090</ZIP><COUNTRY CODE="AT">Austria</COUNTRY><PHONE_1>+ 431404001964</PHONE_1><PHONE_2>+ 436764071311</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-02-05 12:50:13 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="12581" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gunnar</FIRST_NAME><LAST_NAME>Gamper</LAST_NAME><EMAIL_1>gunnar.gamper@chello.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Cardiology</DEPARTMENT><ORGANISATION>Universitätsklinikum Sankt Pölten</ORGANISATION><CITY>Sankt Pölten</CITY><COUNTRY CODE="AT">Austria</COUNTRY></ADDRESS></PERSON><PERSON ID="12591" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christof</FIRST_NAME><LAST_NAME>Havel</LAST_NAME><EMAIL_1>christof.havel@meduniwien.ac.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><ADDRESS_1>Währinger Gürtel 18-20 / 6D</ADDRESS_1><CITY>Vienna</CITY><ZIP>A-1090</ZIP><COUNTRY CODE="AT">Austria</COUNTRY><PHONE_1>+43 1 40400 ext: 1964</PHONE_1><FAX_1>+43 1 40400 1965</FAX_1></ADDRESS></PERSON><PERSON ID="2E3188E882E26AA2010AB3F26DD77741" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jasmin</FIRST_NAME><LAST_NAME>Arrich</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>jasmin.arrich@meduniwien.ac.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><ADDRESS_1>Währinger Gürtel 18-20 / 6D</ADDRESS_1><CITY>Vienna</CITY><ZIP>1090</ZIP><COUNTRY CODE="AT">Austria</COUNTRY><PHONE_1>+ 43 1 40400 1964</PHONE_1><FAX_1>+ 43 1 40400 1965</FAX_1></ADDRESS></PERSON><PERSON ID="12606" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heidrun</FIRST_NAME><LAST_NAME>Losert</LAST_NAME><EMAIL_1>heidrun.losert@meduniwien.ac.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><CITY>Vienna</CITY><COUNTRY CODE="AT">Austria</COUNTRY></ADDRESS></PERSON><PERSON ID="11792" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Nathan Leon</FIRST_NAME><LAST_NAME>Pace</LAST_NAME><SUFFIX>MD, MSTAT</SUFFIX><POSITION>Professor of Anesthesiology</POSITION><EMAIL_1>n.l.pace@utah.edu</EMAIL_1><EMAIL_2>nathan.pace@hsc.utah.edu</EMAIL_2><URL>http://ace.cochrane.org/</URL><MOBILE_PHONE>001 8012051019</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anesthesiology</DEPARTMENT><ORGANISATION>University of Utah</ORGANISATION><ADDRESS_1>3C444 SOM</ADDRESS_1><ADDRESS_2>30 North 1900 East</ADDRESS_2><CITY>Salt Lake City</CITY><ZIP>84132-2304</ZIP><REGION>UT</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>001 8015816393</PHONE_1><PHONE_2>001 801 467 2925</PHONE_2><FAX_1>001 8015814367</FAX_1></ADDRESS></PERSON><PERSON ID="11794" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marcus</FIRST_NAME><LAST_NAME>Müllner</LAST_NAME><SUFFIX>MD MSc</SUFFIX><POSITION>Consultant Physician</POSITION><EMAIL_1>marcusmuellner@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Internistisches Zentrum Brigittenau</ORGANISATION><ADDRESS_1>Treustrasse 43</ADDRESS_1><CITY>Vienna</CITY><ZIP>1200</ZIP><COUNTRY CODE="AT">Austria</COUNTRY><PHONE_1>+43 6603759450</PHONE_1></ADDRESS></PERSON><PERSON ID="12150" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Harald</FIRST_NAME><LAST_NAME>Herkner</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Assoc. Prof. Emergency Medicine</POSITION><EMAIL_1>harald.herkner@meduniwien.ac.at</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><ADDRESS_1>Vienna General Hospital;</ADDRESS_1><ADDRESS_2>Währinger Gürtel 18-20 / 6D</ADDRESS_2><CITY>Vienna</CITY><ZIP>1090</ZIP><COUNTRY CODE="AT">Austria</COUNTRY><PHONE_1>+ 431404001964</PHONE_1><PHONE_2>+ 436764071311</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-01-18 13:19:12 +0000" MODIFIED_BY="Jane Cracknell">
<UP_TO_DATE>
<DATE DAY="24" MONTH="6" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="6" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="12" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-02-05 12:29:43 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-02-05 12:29:36 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="5" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>We included a network meta-analysis</P>
<P>A new author, Nathan Pace, joined the review team. Gunnar Gamper took the lead for this update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-02-05 12:29:43 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="5" MONTH="2" YEAR="2016"/>
<DESCRIPTION>
<P>We reran the search to June 2015. We included five new RCTs in this updated review (<LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Levy-2011" TYPE="STUDY">Levy 2011</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>). We updated all existing analyses, tables and figures for the newly included studies and for the new features of RevMan 5.3. Shortly before submission of the current update, we identified other studies that might be suitable for inclusion. These studies are listed under <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-11-16 11:33:40 +0000" MODIFIED_BY="Harald Herkner">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-11-16 11:33:40 +0000" MODIFIED_BY="Harald Herkner">
<DATE DAY="5" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-M_x00fc_llner-2004" TYPE="REFERENCE">Müllner 2004</LINK>) that included eight RCTs and excluded nine studies.</P>
<P>In the previous version we searched the databases until November 2003. In this updated version we reran the searches to March 2010. This updated version contains 15 new RCTs (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>: <LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>;) and two new excluded studies (<LINK REF="STD-Sperry-2008" TYPE="STUDY">Sperry 2008</LINK>; <LINK REF="STD-Schmoelz-2006" TYPE="STUDY">Schmoelz 2006</LINK>) and three new ongoing studies (Cohn 2007a; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>; <LINK REF="STD-Lienhart-2007" TYPE="STUDY">Lienhart 2007</LINK>).</P>
<P>These new studies changed the conclusion of our review, in particular for the comparison of norepinephrine versus dopamine.</P>
<P>Change in authors: Bernhard Urbanek (co-author <LINK REF="REF-M_x00fc_llner-2004" TYPE="REFERENCE">Müllner 2004</LINK>) has left the review team. A new author (Jasmin Arrich) has joined the review team of this updated version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-03-17 09:32:09 +0000" MODIFIED_BY="Harald Herkner">
<DATE DAY="5" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>In this updated systematic review we reorganized all analyses and present new analyses for all comparisons and sensitivity analyses, 'Risk of bias' tables, and a 'Summary of findings' table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-06-29 15:01:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Minor edit to text</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-06-29 15:01:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<INTERNAL_SOURCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<SOURCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<NAME>Medical University Vienna, where most of the review authors are employed</NAME>
<COUNTRY CODE="AT">Austria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-02-05 12:30:47 +0000" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2016-01-04 15:39:02 +0000" MODIFIED_BY="Jane Cracknell">Vasopressors for hypotensive shock</TITLE>
<SUMMARY_BODY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>
<B>Review question</B>
</P>
<P>This review seeks unbiased evidence about the effects of different drugs that enhance blood pressure on risk of dying in critically ill patients with impaired blood circulation.</P>
<P>
<B>Background</B>
</P>
<P>&#9679; Circulatory shock is broadly defined as a life-threatening condition of impaired blood flow resulting in inability of the body to maintain blood delivery to body tissue and to meet oxygen demands.</P>
<P>&#9679; Typical signs of shock include low blood pressure, rapid heartbeat and poor organ perfusion indicated by low urine output, confusion or loss of consciousness.</P>
<P>&#9679; Death in the intensive care unit ranges from 16% to 60%, depending on the underlying condition: treatment includes fluid replacement followed by use of vasopressor agents, if necessary.</P>
<P>&#9679; A vasopressor agent is a drug that causes a rise in blood pressure. Six vasopressor drugs are available and are used successfully to increase blood pressure to reverse circulatory failure in critical care. Differences in their effects on survival are discussed with controversy and must be investigated.</P>
<P>&#9679; This review aims to discover whether any of the drugs given alone or in combination were better or worse than the others.</P>
<P>
<B>Search date</B>
</P>
<P>Evidence is current to June 2015.</P>
<P>
<B>Study characteristics</B>
</P>
<P>Review authors identified 28 randomized controlled trials involving 3497 critically ill patients with circulatory failure, among whom 1773 died. Patients were followed up to one year.</P>
<P>The following drugs, given alone or in combination, were studied in 12 different comparisons: dopamine, norepinephrine, epinephrine, phenylephrine, vasopressin, and terlipressin.</P>
<P>
<B>Key results</B>
</P>
<P>In summary, researchers found no significant differences in risk of dying in any comparisons of different drugs given alone or in combination when latest reported death was considered.</P>
<P>Disturbances in the rhythm of the heart were observed more frequently in people treated with dopamine than in those treated with norepinephrine.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The quality of the evidence was high for the comparison of norepinephrine and dopamine, and was very low to moderate for the other comparisons.</P>
<P>Findings were consistent among the few large studies and studies of different quality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<ABS_BACKGROUND MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Initial goal-directed resuscitation for hypotensive shock usually includes administration of intravenous fluids, followed by initiation of vasopressors. Despite obvious immediate effects of vasopressors on haemodynamics, their effect on patient-relevant outcomes remains controversial. This review was published originally in 2004 and was updated in 2011 and again in 2016.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient-relevant outcomes and to assess the influence of bias on the robustness of our effect estimates.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015 Issue 6), MEDLINE, EMBASE, PASCAL BioMed, CINAHL, BIOSIS and PsycINFO (from inception to June 2015). We performed the original search in November 2003. We also asked experts in the field and searched meta-registries to identify ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-01-18 13:24:26 +0000" MODIFIED_BY="Jane Cracknell">
<P>Randomized controlled trials (RCTs) comparing various vasopressor regimens for hypotensive shock.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Two review authors abstracted data independently. They discussed disagreements between them and resolved differences by consulting with a third review author. We used a random-effects model to combine quantitative data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We identified 28 RCTs (3497 participants) with 1773 mortality outcomes. Six different vasopressors, given alone or in combination, were studied in 12 different comparisons.</P>
<P>All 28 studies reported mortality outcomes; 12 studies reported length of stay. Investigators reported other morbidity outcomes in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes. We classified 11 studies as having low risk of bias for the primary outcome of mortality; only four studies fulfilled all trial quality criteria.</P>
<P>In summary, researchers reported no differences in total mortality in any comparisons of different vasopressors or combinations in any of the pre-defined analyses (evidence quality ranging from high to very low). More arrhythmias were observed in participants treated with dopamine than in those treated with norepinephrine (high-quality evidence). These findings were consistent among the few large studies and among studies with different levels of within-study bias risk.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We found no evidence of substantial differences in total mortality between several vasopressors. Dopamine increases the risk of arrhythmia compared with norepinephrine and might increase mortality. Otherwise, evidence of any other differences between any of the six vasopressors examined is insufficient. We identified low risk of bias and high-quality evidence for the comparison of norepinephrine versus dopamine and moderate to very low-quality evidence for all other comparisons, mainly because single comparisons occasionally were based on only a few participants. Increasing evidence indicates that the treatment goals most often employed are of limited clinical value. Our findings suggest that major changes in clinical practice are not needed, but that selection of vasopressors could be better individualised and could be based on clinical variables reflecting hypoperfusion.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-02-05 12:30:47 +0000" MODIFIED_BY="Jane Cracknell">
<BACKGROUND MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<CONDITION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Shock is a state of severe systemic deterioration in tissue perfusion, characterized by decreased cellular oxygen delivery and utilization, as well as decreased removal of waste byproducts of metabolism. Hypotension, although common in shock, is not synonymous with shock. Individuals can have hypotension and normal perfusion, whereas patients who have a history of hypertension can have shock without hypotension in the early phase of cardiogenic shock. Shock is the final pre-terminal event in many diseases. Progressive tissue hypoxia results in loss of cellular membrane integrity, reversion to a catabolic state of anaerobic metabolism and loss of energy-dependent ion pumps and chemical and electrical gradients. Mitochondrial energy production begins to fail. Multiple organ dysfunction follows localized cellular death, and this is followed by death of the organism (<LINK REF="REF-Young-2008" TYPE="REFERENCE">Young 2008</LINK>). A widely used classification for mechanisms of shock consists of hypovolaemic, cardiogenic, obstructive and distributive (<LINK REF="REF-Hinshaw-1972" TYPE="REFERENCE">Hinshaw 1972</LINK>). Septic shock, a form of distributive shock, is the most common form of shock among patients admitted to the intensive care unit, followed by cardiogenic and hypovolaemic shock; obstructive shock is rare. As an example, in a trial of 1600 patients with undifferentiated shock, septic shock occurred in 62%, cardiogenic shock in 16%, hypovolaemic shock in 16%, other types of distributive shock in 4% (e.g. neurogenic shock, anaphylaxis) and obstructive shock in 2% (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>). 
</P>
<P>Currently, the definition of septic shock is more pragmatic because hypotension instead of hypoperfusion is the main clinical criterion. The current standard definition for septic shock (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>) in adults refers to a state of acute circulatory failure characterized by persistent arterial hypotension that is not explained by other causes. Hypotension is defined by systolic blood pressure &lt; 90 mm Hg, mean arterial pressure &lt; 60 mm Hg or a reduction in systolic blood pressure &gt; 40 mm Hg despite adequate volume resuscitation in the absence of other causes for hypotension (<LINK REF="REF-Levy-2003" TYPE="REFERENCE">Levy 2003</LINK>). A large study defined shock even more pragmatically, as haemodynamic compromise necessitating administration of vasopressor catecholamines (<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>).</P>
<P>Estimates of the incidence of shock in the general population vary considerably. From an observational study, 31 cases of septic shock per 100,000 population/y (<LINK REF="REF-Esteban-2007" TYPE="REFERENCE">Esteban 2007</LINK>) were reported. Many patients develop shock from severe sepsis, which has an incidence of 25 to 300 cases per 100,000 population/y (<LINK REF="REF-Angus-2001" TYPE="REFERENCE">Angus 2001</LINK>; <LINK REF="REF-Blanco-2008" TYPE="REFERENCE">Blanco 2008</LINK>; <LINK REF="REF-Sundararajan-2005" TYPE="REFERENCE">Sundararajan 2005</LINK>); among those, 30% are expected to develop septic shock (<LINK REF="REF-Esteban-2007" TYPE="REFERENCE">Esteban 2007</LINK>).</P>
<P>The frequency of shock at healthcare facilities is somewhat better described. In the large observational study of sepsis occurrence in acutely Ill patients (SOAP), among 3147 critically ill participants from 198 intensive care units (ICUs), 34% had shock; of those, 15% had septic shock (<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>). Recently a large French observational study published similar numbers indicating that among 10,941 patients admitted to participating ICUs between October 2009 and September 2011, 1495 (13.7%) presented with inclusion criteria for septic shock (<LINK REF="REF-Quenot--2013" TYPE="REFERENCE">Quenot 2013</LINK>). In another large European ICU cohort study, 32% were found to have septic shock. In a prospective observational study of 293,633 participants with ST-elevation myocardial infarction from 775 US hospitals, 9% developed cardiogenic shock (<LINK REF="REF-Babaev-2005" TYPE="REFERENCE">Babaev 2005</LINK>). From an observational study on 2445 participants admitted to a trauma level I centre, 22% were reported to already have shock on admission to the emergency department (ED) (<LINK REF="REF-Cannon-2009" TYPE="REFERENCE">Cannon 2009</LINK>).</P>
<P>Hospital mortality is high, at around 38% (<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>), among patients with shock but seems to depend much on shock type. For patients with septic shock, mortality ranges from 46% (<LINK REF="REF-Esteban-2007" TYPE="REFERENCE">Esteban 2007</LINK>; <LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>) to 61% (<LINK REF="REF-Alberti-2005" TYPE="REFERENCE">Alberti 2005</LINK>). Mortality in patients with traumatic shock was somewhat lower, at 16% (<LINK REF="REF-Cannon-2009" TYPE="REFERENCE">Cannon 2009</LINK>). Whereas the incidence of cardiogenic shock was almost constant between 1995 and 2004, mortality has decreased from 60% in 1995 to 48% over the years (<LINK REF="REF-Babaev-2005" TYPE="REFERENCE">Babaev 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressors are a heterogeneous class of drugs with powerful and immediate haemodynamic effects. Vasopressors can be classified according to their adrenergic and non-adrenergic actions.</P>
<P>Catecholamines are sympathomimetics that act directly or indirectly on adrenergic receptors. Their haemodynamic effects depend on their varying pharmacological properties. They may increase the contractility of myocardial muscle fibres and heart rate (via beta-adrenergic receptors), but they may also, and sometimes exclusively, increase vascular resistance (via alpha-adrenergic receptors). Many good textbooks have outlined the detailed mechanisms of action (e.g. see <LINK REF="REF-Hoffman-1992" TYPE="REFERENCE">Hoffman 1992</LINK>; <LINK REF="REF-Zaritsky-1994" TYPE="REFERENCE">Zaritsky 1994</LINK>).</P>
<P>The haemodynamic properties of vasopressin, a neurohypophysial peptide hormone, were first reported in 1926 (<LINK REF="REF-Geiling-1926" TYPE="REFERENCE">Geiling 1926</LINK>). Vasopressin and analogues like terlipressin display their vasopressor effects via vasopressin receptors and serve as newer treatments for patients with shock (<LINK REF="REF-Levy-2010" TYPE="REFERENCE">Levy 2010</LINK>).<BR/>
</P>
<P>Utilisation of different vasopressors was described recently in a large European multi-centre cohort study conducted in 198 ICUs (<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>). The most frequently used vasopressor was norepinephrine (80%), followed by dopamine (35%) and epinephrine (23%), given alone or in combination. Single-agent use was reported for norepinephrine (32%), dopamine (9%) and epinephrine (5%). A combination of norepinephrine, dopamine and epinephrine was used in only 2% of patients with shock. Vasopressin and terlipressin were not described in this report. Currently the choice of vasopressors seems to be based mainly on physicians' preferences (<LINK REF="REF-Leone-2004" TYPE="REFERENCE">Leone 2004</LINK>). Additionally, clinical guidelines suggest norepinephrine as the first-line vasopressor in shock states, such as septic shock (<LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Initial goal-directed resuscitation to support vital functions is essential in the management of shock. First-line treatment for the manifestation of circulatory failure usually consists of administration of intravenous fluids. If fluid treatment does not restore circulatory function, vasopressors such as norepinephrine, dopamine, epinephrine and vasopressin are recommended.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Effects of vasopressors on the cardiovascular system are largely undisputed. However, it remains unclear whether a vasopressor of choice is known for the treatment of patients with particular forms of shock or for the treatment of patients with shock in general. We are conducting this systematic review to explore uncertainty arising from conflicting results reported by several studies in this area.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient-relevant outcomes and to assess the influence of bias on the robustness of our effect estimates.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-02-05 12:30:47 +0000" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<CRIT_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We included randomized controlled trials (RCTs) undertaken to investigate the effects of vasopressors in the treatment of patients with any kind of circulatory failure. For simplicity, we refer to circulatory failure as 'shock' (see also search terms for shock). We were exclusively interested in patient-relevant outcomes (see below). Such endpoints, particularly death, can be assessed only through parallel-group trials. Therefore, we excluded cross-over trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We included trials with acutely and critically ill adult and paediatric participants. We excluded trials looking at pre-term infants with hypotension, as this patient group is covered in another Cochrane review (<LINK REF="REF-Subhedar-2003" TYPE="REFERENCE">Subhedar 2003</LINK>). We excluded animal experiments. The definition of 'hypotensive shock' used was that given by study authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>The intervention consisted of administration of different vasopressors, vasopressors versus intravenous fluids and vasopressors versus placebo with or without non-protocol vasoactive drugs (NPVDs).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<UL>
<LI>We looked at total mortality (in the ICU, in hospital and at one year) as the main endpoint. If mortality was assessed at several time points in a study, we used data derived from the latest follow-up time.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Other pre-defined outcomes included the following.</P>
<UL>
<LI>Morbidity, given as:</LI>
<UL>
<LI>ICU length of stay (LOS);</LI>
<LI>hospital LOS;</LI>
<LI>duration of vasopressor treatment;</LI>
<LI>duration of mechanical ventilation;</LI>
<LI>renal failure (as defined by study authors, such as oliguria or need for renal replacement therapy); and</LI>
<LI>other.</LI>
</UL>
<LI>Measures of health-related quality of life at any given time, and measures of anxiety and depression (together or separately) at any given time.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<ELECTRONIC_SEARCHES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 6) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, Search filter for CENTRAL); MEDLINE (1966 to June 2015) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>); EMBASE (1989 to June 2015) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, Search filter for EMBASE); PASCAL BioMed (1996 to June 2015); and BIOSIS (1990 to June 2015) (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>, Search filter for PASCAL BioMed, CINAHL and BIOSIS); PsycINFO (1978 to June 2015) (see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>, Search filter for PsycINFO) using the Ovid platform. We searched CINAHL (1984 to June 2015) via EBCSO.</P>
<P>We searched for key words describing the condition or describing the intervention and combined the results by using a methodological filter (RCT filter).</P>
<P>We used a validated RCT filter for MEDLINE and EMBASE (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We applied no language restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We searched ongoing clinical trials and unpublished studies via the Internet (date of latest search, 24 June 2015) on <A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A> by using the multiple database search option <I>meta</I>Register of Controlled Trials. This register includes International Standard Randomised Controlled Trial Number (ISRCTN) Register, Action Medical Research, Leukaemia Research Fund, Medical Research Council (UK), NHS Research and Development HTA Programme, ClinicalTrials.gov, Wellcome Trust and UK Clinical Trials Gateway.<BR/>
</P>
<P>Further, we searched textbooks and references of papers selected during the electronic search to look for relevant references. Finally, we contacted experts in the field to identify additional trials (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-02-05 12:30:47 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY_SELECTION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We entered all search results into bibliographic software (Endnote X7, The Thomson Corp, USA); we then removed duplicates. At least two review authors (GG, CH, JA, HL, HH) independently screened the studies by title and abstract for exclusion using a template that included inclusion and exclusion criteria. We recorded reasons for exclusion. For the remaining studies, we retrieved full papers. Two review authors independently recorded the inclusion and exclusion criteria in the first section of the data extraction form. We resolved all disagreements through arbitration by a third review author (GG, CH, JA, HL, HH).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>At least two review authors (GG, CH, JA, HL, HH) abstracted data independently onto a pre-defined data extraction form and entered the data into RevMan 5.3. We compared results and resolved disagreements by discussion amongst at least three review authors (GG, CH, JA, HL, HH).</P>
<P>Besides data on intervention and outcome, we recorded study and participant characteristics such as age; gender; severity of illness, as given (e.g. acute physiology and chronic health evaluation (APACHE), multiple organ failure (MOF) score, simplified acute physiology score (SAPS)); underlying diagnosis and particular type of shock, given definition of shock; duration of ICU stay before enrolment into study; duration of mechanical ventilation before enrolment; and study setting.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Two review authors independently abstracted data onto a pre-defined data extraction form. We abstracted whether adequate methods were used to generate a random sequence, whether allocation to treatment was concealed, whether inclusion and exclusion criteria were explicit, if data had been analysed by intention-to-treat, whether participant descriptions were adequate, whether care provided during the study period was identical in both groups, whether the outcome description was adequate, whether involved clinical staff were blinded to the intervention and whether the assessor of the outcome was blinded to the intervention. Noteworthy, for some interventions, is that performance bias is inevitable. We compared results and resolved disagreements by discussion amongst at least three review authors. We then entered data into RevMan. We produced a risk of bias graph and a risk of bias table.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>For binary outcomes, we used risk ratio as the standard effect measure. For continuous outcomes, we used the difference in means as the standard effect measure.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-02-05 12:30:47 +0000" MODIFIED_BY="Jane Cracknell">
<P>We did not include cluster-randomized or cross-over trials in any of the analyses; in the case of multiple treatment groups, we refrained from combining groups to create a single pair-wise summary comparison; and we declared studies as multi-arm comparisons to allow for adequate network meta-analyses.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We did not replace missing data by using any algorithm, but we contacted study authors if we considered missing data essential.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We assessed clinical and methodological heterogeneity by performing an informal inspection of study characteristics and clinical judgement. We measured statistical heterogeneity with the I<SUP>2</SUP> statistic and heterogeneity with Cochrane Q tests. We did not use a specific threshold of I<SUP>2</SUP> to judge heterogeneity, but as a general rule, we considered an I<SUP>2</SUP> statistic greater than 50% as showing substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We planned to assess reporting bias and small-study effects graphically by using funnel plots of standard errors versus effect estimates for the primary outcome. We also planned to formally test funnel plot asymmetry by using the arcsine test (<LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK>) if 10 or more studies per comparison were available for the primary outcome.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We combined data quantitatively only if clinical heterogeneity was assumed to be negligible. For standard meta-analyses, we used <LINK REF="REF-RevMan-5.3" TYPE="REFERENCE">RevMan 5.3</LINK>. We used a random-effects model to combine risk ratios by default because we expected several different comparisons to show at least some heterogeneity. In two trials (<LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>), some participants crossed over to the other treatment; these participants were analysed according to the intention-to-treat principle, that is, according to the group to which they were initially assigned.</P>
<P>In this update, we decided to add a network meta-analysis to demonstrate direct and indirect effects simultaneously (<LINK REF="REF-Salanti-2014" TYPE="REFERENCE">Salanti 2014</LINK>). For the analysis, we used the R package netmeta version 0.7 (<LINK REF="REF-R-Core-Team-2014" TYPE="REFERENCE">R Core Team 2014</LINK>). Network meta-analysis is a generalization of pair-wise meta-analysis, whereby all pairs of treatments are compared on the basis of the graph-theoretical method originally developed in electrical network theory. This method is considered equivalent to the frequentist approach to network meta-analysis (<LINK REF="REF-R_x00fc_cker-2012" TYPE="REFERENCE">Rücker 2012</LINK>). For network meta-analyses, we estimated both fixed-effect and random-effects models.</P>
<P>Conceptually, we identified two networks: one comparing different vasopressors or combinations of vasopressors (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, left-hand side), and the other comparing vasopressors in combination with otherwise vasoactive catecholamines (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, right-hand side). In both networks, the reference group was norepinephrine. We produced network plots indicating available direct comparisons, calculated effects relative to a baseline intervention and present network forest plots.</P>
<P>We calculated metrics for consistency/homogeneity. Using Rücker's frequentist approach, we derived this content from decomposition of the Q statistic and from the net heat plot (<LINK REF="REF-Krahn-2013" TYPE="REFERENCE">Krahn 2013</LINK>). We also present analyses on the strength of evidence obtained from matrices derived by the <I>netmeasures</I> function in R (<LINK REF="REF-K_x00f6_nig-2012" TYPE="REFERENCE">König 2012</LINK>).<B>
<BR/>
<BR/>
</B>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We planned no a priori subgroup analyses. We performed a post hoc subgroup analysis of participants with septic shock. We included studies performed in participants with septic shock and studies for which estimates were available for subgroups with septic shock. For this subgroup, we performed a network meta-analysis comparing different vasopressors or combinations of vasopressors. We used norepinephrine as the reference group because it is currently considered the vasopressor of first choice (<LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>). We did not perform a subgroup analysis for the network including otherwise vasoactive catecholamines because of the limited number of available studies.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>We planned to perform a sensitivity analysis to assess the influence of risk of bias on the main effects of interventions, and thereby on the robustness of our estimates. We classified studies as 'low risk of bias' and 'no low risk of bias'. We classified studies as having low risk of bias if they had adequate allocation concealment, and if the other bias items in the summary were not believed to have a major influence on the robustness of the single study effect. Unclear or inadequate allocation concealment in any case resulted in classification as a 'study with no low risk of bias'. Our primary outcome was mortality, which was generally considered robust against outcome assessor knowledge of treatment allocation. Lack of blinding of outcome assessors therefore had less influence on assessment of risk of bias for this outcome. On the contrary, this risk of bias item had a strong effect on outcomes for which assessment included individual judgement, as for measures of quality of life. In the sensitivity analysis, we grouped studies according to our classification of 'low risk of bias' and 'no low risk of bias' in a forest plot.</P>
<P>We also performed a post hoc sensitivity analysis to investigate the influence of different time points on mortality outcome assessment.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings'</HEADING>
<P>We used the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) to grade the quality of the body of evidence assessed in our review and constructed a 'Summary of findings' (SOF) table using GRADE software. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias.</P>
<P>We constructed &#8216;Summary of findings&#8217; tables that included information about (1) populations (including specification of medium-risk populations), interventions and comparisons for the standard meta-analysis of norepinephrine versus dopamine on mortality and for results of the network meta-analysis on mortality; (2) the source of external information used in the &#8216;Assumed risk&#8217; column; (3) the GRADE approach to assess the quality of the body of evidence as briefly described above; and (4) any departures from standard methods. We included information on the primary outcome (total mortality) and on arrhythmia within 28 days.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY_DESCRIPTION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>
<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<SUBSECTION>
<HEADING LEVEL="4">Search result</HEADING>
<P>The electronic search resulted in 1776 hits after removal of duplicates with bibliographic software and one reference from other sources (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). We identified and retrieved 168 potentially relevant articles (this number included 12 articles identified by reading the references of potentially relevant articles and writing to 14 specialists in the field, five of whom replied; see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>). Two trials were not retrievable (<LINK REF="STD-Hai-Bo-2002" TYPE="STUDY">Hai Bo 2002</LINK>; <LINK REF="STD-Singh-1966" TYPE="STUDY">Singh 1966</LINK>; see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). Of these 168 articles, 140 did not meet our inclusion criteria after closer inspection for the following reasons.</P>
<UL>
<LI>54 trials involved other interventions.</LI>
<LI>49 were not randomized.</LI>
<LI>24 were cross-over trials.</LI>
<LI>Three were animal studies.</LI>
<LI>Two trials were duplicates (abstract was presented at a scientific meeting and the report was subsequently published (<LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>)).</LI>
<LI>Four other publications (<LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>) did not meet criteria.</LI>
<UL>
<LI>Two were systematic reviews.</LI>
<LI>Two eligible RCTs provided none of the pre-defined outcomes (<LINK REF="STD-Morelli-2011" TYPE="STUDY">Morelli 2011</LINK>; <LINK REF="STD-Morelli-2011a" TYPE="STUDY">Morelli 2011a</LINK>).</LI>
</UL>
</UL>
<P>Of these 140 excluded reports, we identified 13 potentially relevant studies (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Finally, we included 28 studies in our review (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>In our original review (<LINK REF="REF-M_x00fc_llner-2004" TYPE="REFERENCE">Müllner 2004</LINK>), we included eight studies. In the updated review (<LINK REF="REF-Havel-2011" TYPE="REFERENCE">Havel 2011</LINK>), we included 15 new studies. This current update adds five new studies. In total, we have included 28 studies investigating several comparisons among 3497 participants (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Six different vasopressors, alone or in combination, were studied in 12 different comparisons. Details are presented in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Among these studies, eight were multi-centre studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>) and all but five (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>) were performed at university hospitals only.</P>
<P>Eighteen studies were performed in participants with septic shock (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>). Three studies included participants with peri-operative shock (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>). Two studies were performed in paediatric participants (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>).</P>
<P>Seventeen studies provided norepinephrine as an intervention (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>); another four studies examined the combination of norepinephrine + dobutamine (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>; <LINK REF="STD-Levy-2011" TYPE="STUDY">Levy 2011</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>); and one study used the combination of norepinephrine + dopexamine (<LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>).</P>
<P>Nine studies used dopamine (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>), and six studies used epinephrine (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>; <LINK REF="STD-Levy-2011" TYPE="STUDY">Levy 2011</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>). Eight studies used vasopressin (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>), and another seven studies used terlipressin (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>). Two studies used phenylephrine (<LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>), and five studies compared vasopressors versus placebo or non-protocolized vasopressors as add-on therapy (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>In total, we excluded 140 studies after full-text assessment, among which 13 studies are listed by reference. We have presented some details of the 13 excluded studies in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. We excluded 10 studies because they reported not on any of our pre-defined endpoints but on haemodynamic variables and other surrogate endpoints instead (<LINK REF="STD-Argenziano-1997" TYPE="STUDY">Argenziano 1997</LINK>; <LINK REF="STD-Hentschel-1995" TYPE="STUDY">Hentschel 1995</LINK>; <LINK REF="STD-Kinstner-2002" TYPE="STUDY">Kinstner 2002</LINK>; <LINK REF="STD-Levy-1999" TYPE="STUDY">Levy 1999</LINK>; <LINK REF="STD-Majerus-1984" TYPE="STUDY">Majerus 1984</LINK>; <LINK REF="STD-Morelli-2011" TYPE="STUDY">Morelli 2011</LINK>; <LINK REF="STD-Morelli-2011a" TYPE="STUDY">Morelli 2011a</LINK>; <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Totaro-1997" TYPE="STUDY">Totaro 1997</LINK>; <LINK REF="STD-Zhou-2002" TYPE="STUDY">Zhou 2002</LINK>). We excluded one trial in which investigators looked at pre-term infants with hypotension (<LINK REF="STD-Roz_x00e9_-1993" TYPE="STUDY">Rozé 1993</LINK>), as this topic is covered in another Cochrane review (<LINK REF="REF-Subhedar-2003" TYPE="REFERENCE">Subhedar 2003</LINK>). One study was a non-randomized multi-centre prospective cohort study and therefore was excluded (<LINK REF="STD-Sperry-2008" TYPE="STUDY">Sperry 2008</LINK>). Another study compared low-dose dopamine versus dopexamine and versus placebo added to norepinephrine with the intention of improving renal and splanchnic blood flow. Low-dose dopamine at 3 µg/kg/min is not considered to have relevant vasopressor properties; therefore we also excluded this study (<LINK REF="STD-Schmoelz-2006" TYPE="STUDY">Schmoelz 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies waiting to be assessed</HEADING>
<P>We have not yet been able to retrieve two particular studies. One, which was published in 1966 (<LINK REF="STD-Singh-1966" TYPE="STUDY">Singh 1966</LINK>), is a 'comparative study of angiotensin and norepinephrine in hypotensive states', according to the title. As no abstract is available, we do not know how many participants were enrolled. The second study, published in the journal <I>Critical Care Shock </I>in 2002 (<LINK REF="STD-Hai-Bo-2002" TYPE="STUDY">Hai Bo 2002</LINK>), also could not be retrieved. This paper is on the 'renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine-dobutamine in septic shock'. We do not know whether this study contained original data from human experiments, whether it was randomized and, if so, whether researchers reported relevant outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Our search resulted in 52 potentially relevant ongoing studies. We considered five ongoing studies (<LINK REF="STD-Choudhary-2013" TYPE="STUDY">Choudhary 2013</LINK>; <LINK REF="STD-Cohn-2007" TYPE="STUDY">Cohn 2007</LINK>a; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>; <LINK REF="STD-Gordon-2014" TYPE="STUDY">Gordon 2014</LINK>; <LINK REF="STD-Lienhart-2007" TYPE="STUDY">Lienhart 2007</LINK>) as relevant (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<SUBSECTION>
<HEADING LEVEL="3">Methodological quality of included studies</HEADING>
<P>We have presented risk of bias in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<P>GRADE evidence quality varied considerably between comparisons and ranged from high to very low.</P>
<P>Generally, risk of bias in the included studies was moderate. For the comparison of norepinephrine versus dopamine, risk of bias was low, but for the other comparisons, risk of bias was moderate to high. We classified 11 studies as having low risk of bias for the primary outcome of mortality (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>); only four studies fulfilled all trial quality items (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>).</P>
</SUBSECTION>
<ALLOCATION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Random sequence generation was reported in all but four studies (<LINK REF="STD-Levy-2011" TYPE="STUDY">Levy 2011</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>). Allocation concealment was appropriate in 11 studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>) and was not appropriate in three studies (<LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>).</P>
<P>All but eight studies presented intention-to-treat analyses; for six studies this item was unclear (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>), and for four studies this was not fulfilled (<LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>From the available information, identical care for the intervention group and the control group could be assumed for 12 studies (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>). An appropriate outcome description was present in 20 studies; for the remaining eight studies, this was unclear (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>). Treating personnel were blinded in nine studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>). In the same nine studies, outcome assessors were blinded too. In one study, only outcome assessors were blinded (<LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Generally, studies included critically ill participants, for whom follow-up usually is not of major concern.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Given the large number of comparisons, each with a few studies only, proper assessment of between-study reporting bias was not possible. However, when looking at the funnel plot in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, we could not spot major asymmetry. Within-study reporting bias: Many of the included studies were performed several years ago, when it was not standard to publish trial protocols. Accordingly, we could not systematically assess selective outcome data reporting because protocols were not available. However, for the primary outcome of 'mortality', we assumed that selective omission of this outcome was unlikely in the ICU setting because this is one of the standard clinical outcomes. Choice of outcome usually is determined by the design (short-term haemodynamic studies vs longer-term studies with clinical outcomes).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>All but two studies explicitly described inclusion and exclusion criteria (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>). Participants were adequately described in all but three studies (<LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>In total, six vasopressors were compared in several combinations and directions (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Therefore, we have organized our comparisons to present each vasopressor against all comparators in a separate analysis per outcome. Vasopressors that were used in both study arms were considered as constant between groups and generally were not explicitly described in analyses. For studies with more than two study arms, we used each comparison separately. We refrained from including overall summary effects within analyses to address considerable clinical heterogeneity due to major differences in comparators and,when applicable, to avoid a unit of analysis error.</P>
<SUBSECTION>
<HEADING LEVEL="3">Main analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Total mortality</HEADING>
<P>Total mortality was assessed in all included studies. If mortality was assessed at several time points in a study we used data from the latest follow-up time. Mortality was assessed at an undetermined time point in seven studies (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003,</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997,</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994,</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007,</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>,; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>).</P>
<P>
<I>Norepinephrine was compared with dopamine, epinephrine, terlipressin, vasopressin, phenylephrine and norepinephrine + terlipressin + dobutamine</I>
 (14 studies; 2607 participants) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). In addition, <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK> compared norepinephrine versus norepinephrine + vasopressin and norepinephrine versus norepinephrine + terlipressin and found no differences in both comparisons (risk ratio (RR) 1.25, 95% confidence interval (CI) 0.69 to 2.26; and RR 1.43, 95% CI 0.75 to 2.70 - data from the single study not presented in analyses). Studies were performed in participants with septic shock (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>), in critically ill participants (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>), in participants with refractory hypotension after anaesthesia (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>) and in adult post-operative participants (<LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>). None of the comparisons revealed significant differences. <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK> compared NPVD (including norepinephrine) versus norepinephrine + terlipressin + dobutamine and found no differences in mortality (14/20 vs 14/20; RR 1.00, 95% CI 0.67 to 1.50). The funnel plot, which is presented in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> shows no indication of relevant asymmetry.</P>
<P>
<I>Epinephrine was compared with norepinephrine, norepinephrine + dobutamine and norepinephrine + dopexamine</I> (six studies; 703 participants) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Overall 298 deaths were observed among the 703 participants. Studies were performed in participants with septic shock (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>; <LINK REF="STD-Seguin-2002" TYPE="STUDY">Seguin 2002</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>), participants with cardiogenic shock (<LINK REF="STD-Levy-2011" TYPE="STUDY">Levy 2011</LINK>) and critically ill participants (<LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>). In no comparisons was a significant difference found.</P>
<P>
<I>Vasopressin was compared with placebo (non-protocol vasoactive drugs), terlipressin and norepinephrine/dopamine</I> (eight studies; 1138 participants) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). In the comparisons 'versus placebo/non-protocol vasoactive drugs', two studies actually used a placebo (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>), two studies (<LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>) compared fixed-dose vasopressin + variable-dose norepinephrine versus variable-dose norepinephrine and one study compared vasopressin versus norepinephrine or dopamine (<LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>). Overall 503 deaths were observed among 1138 participants. Studies were performed in participants with septic shock (<LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>), in adult post-operative participants (<LINK REF="STD-Luckner-2006" TYPE="STUDY">Luckner 2006</LINK>) and in paediatric participants with vasodilatory shock (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>). In no comparisons was a significant difference found.</P>
<P>
<I>Terlipressin was compared with placebo (non-protocol vasoactive drugs), norepinephrine and vasopressin</I> (seven studies; 259 participants) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). In the comparisons 'versus placebo/non-protocol vasoactive drugs', one study actually used a placebo (<LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>), and three studies (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>) compared fixed-dose terlipressin + variable-dose norepinephrine versus variable-dose norepinephrine. In the same study (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>), investigators compared norepinephrine + terlipressin + dobutamine versus non-protocol vasoactive drugs and found no difference (14/20 vs 14/20; RR 1.00, 95% CI 0.67 to 1.50). In another study, terlipressin was compared with dopamine (<LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>). Overall 150 deaths were observed among 259 participants. Studies were performed in participants with septic shock (<LINK REF="STD-Albanese-2005" TYPE="STUDY">Albanese 2005</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>), in children with catecholamine-resistant shock (<LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>) and in participants with refractory hypotension after anaesthesia (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>). No comparisons revealed a significant difference.</P>
<P>
<I>Dopamine was compared with norepinephrine and with terlipressin</I> (seven studies; 1432 participants) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Overall 869 deaths were observed among 1432 participants. Studies were performed in participants with septic shock (<LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>; <LINK REF="STD-Marik-1994" TYPE="STUDY">Marik 1994</LINK>; <LINK REF="STD-Martin-1993" TYPE="STUDY">Martin 1993</LINK>; <LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Ruokonen-1993" TYPE="STUDY">Ruokonen 1993</LINK>) and in participants with several causes of shock (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>). In no comparisons was a significant difference found.</P>
<P>
<I>Phenylephrine was compared with norepinephrine in participants with septic shock</I> (two studies; 86 participants) (<LINK REF="STD-Jain-2010" TYPE="STUDY">Jain 2010</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Overall 50 deaths were observed among 86 participants (RR 0.92, 95% CI 0.64 to 1.32).</P>
<P>In a network that included vasopressors only (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>), we found no differences in effects of any vasopressor versus non-protocol vasoactive drugs on mortality, as shown in the network forest plot comparing seven vasopressor regimens versus norepinephrine (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) from 22 studies with 24 pair-wise comparisons. Heterogeneity/inconsistency: tau<SUP>2</SUP> &lt; 0.0001; I<SUP>2</SUP> statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.39 (d.f. 17), P value = 0.96. Likewise, no hotspots are evident in the heatplot indicating the absence of specific sources of important inconsistency in the network (see <A HREF="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</A>). For the full network assessment, including measures for characterizing a network meta-analysis (direct evidence proportion, mean path length, minimal parallelism of mixed treatment comparisons and evidence flow per design) (see <A HREF="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</A>).</P>
<P>In a network that included vasopressors and combinations with beta-agonist action (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>), we found no differences in the effects of any vasopressor versus norepinephrine on mortality, as shown in the network forest plot comparing four vasopressor regimens with a beta-agonist component versus norepinephrine (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>) from six studies with six pair-wise comparisons. Heterogeneity/inconsistency: tau<SUP>2</SUP> &lt; 0.0001; I<SUP>2</SUP> statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42 (d.f. 3), P value = 0.94 (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). No indication of severe heterogeneity/inconsistency was found, although several analyses were not possible with available data. For the full network assessment, see the Appendix (<A HREF="http://www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf">www.meduniwien.ac.at/user/harald.herkner/AppendixCARG029_2015.pdf</A>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Morbidity</HEADING>
<P>Morbidity was assessed as (1a) ICU LOS; (1b) hospital LOS; (1c) duration of vasopressor treatment; (1d) duration of mechanical ventilation; (1e) renal failure (as defined by study authors as oliguria or renal replacement therapy) and (1f) other. Renal outcomes are presented separately in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<I>Norepinephrine was compared with dopamine, vasopressin, phenylephrine and norepinephrine + terlipressin + dobutamine </I>in terms of (1a) ICU LOS (five studies; 2781 participants) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). All studies included participants with septic shock. Investigators reported no differences in (1a) ICU LOS and (1b) hospital LOS (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Additionally, <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK> compared norepinephrine versus vasopressin and found no significant differences in (1b) hospital LOS (difference 1.00 day, 95% CI -3.01 to 5.01). Further, they reported no significant differences in (1c) vasopressor use (17, interquartile range (IQR) 0 to 24 vs 19, IQR 0 to 24; P value = 0.61) and (1d) days alive free of mechanical ventilation (six, IQR 0 to 20 vs 9, IQR 0 to 20; P value = 0.24). <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK> compared norepinephrine with epinephrine and found no differences in the number of (1c) vasopressor-free days (25 days, IQR 14 to 27 vs 26 days, IQR 19 to 27; P value = 0.31). <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> compared norepinephrine with dopamine and found no differences in days free of mechanical ventilation within 28 days (9.5 ± 11.4 days vs 8.5 ± 11.2 days; P value = 0.13). They noted a small difference in (1c) days free of any vasopressor therapy within 28 days (14.2 ± 12.3 days vs 12.6 ± 12.5 days; P value = 0.007). The largest study by <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> and a smaller study by <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK> compared dopamine versus norepinephrine and found significant differences in (1f) arrhythmia (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), including mostly sinus tachycardia (<LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>): 25% versus 6%; atrial fibrillation: 21% versus 11% (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>), 13% versus 3% (<LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>); ventricular tachycardia (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>): 2.4% versus 1.0%; and ventricular fibrillation (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>): 1.2% versus 0.5%. <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK> compared noradrenaline with terlipressin and found no differences in (1b) hospital LOS (5 days, IQR 4 to 7 vs 5 days, IQR 4 to 7).</P>
<P>
<I>Epinephrine was compared with norepinephrine + dobutamine </I>in terms of (1a) ICU LOS in participants with septic shock (one study; 330 participants) (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>). Researchers reported no significant differences in ICU LOS (difference 1.00 day, 95% CI -3.01 to 5.01). In the same study (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>), the number of (1c) vasopressor-free days until day 90 was reported as a median 53 days (IQR 0 to 86) in the epinephrine group and 66 days (IQR 6 to 86) in the norepinephrine + dobutamine group (P value = 0.18). In the same study, duration of (1c) vasopressor support was presented as a Kaplan-Meier plot (log-rank test P value = 0.09). <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK> compared epinephrine with norepinephrine and found no differences in the number of (1c) vasopressor-free days (26 days, IQR 19 to 27 vs 25 days, IQR 14 to 27; P value = 0.31).</P>
<P>
<I>Vasopressin was compared with placebo (non-protocol vasoactive drugs), terlipressin and norepinephrine</I>
 in terms of (1a) ICU LOS (four studies; 1046 participants) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Studies were performed in participants with septic shock (<LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>) and paediatric vasodilatory shock (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>). In no comparison was a significant difference found. Vasopressin was compared with norepinephrine in terms of (1b) hospital LOS in one study (<LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>), and no significant difference was found (difference 1.00 day, 95% CI -3.01 to 5.01). Further, researchers noted no significant differences in (1c) vasopressor use (19, IQR 0 to 24 vs 17, IQR 0 to 24; P value = 0.61) and (1d) days alive free of mechanical ventilation (9, IQR 0 to 20 vs 6, IQR 0 to 20; P value = 0.24). <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK> compared vasopressin with placebo/non-protocol vasoactive drugs in paediatric participants and found no differences in (1c) time to vasopressor discontinuation (50 hours, IQR 30 to 219 vs 47, IQR 26 to 87; P value = 0.85) and (1d) mechanical ventilation-free days until day 30 (17 days, IQR 0 to 24 vs 23 days, IQR 13 to 26; P value = 0.15). <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK> compared vasopressin with non-protocol vasoactive drugs and found no differences in (1a) LOS (five days (IQR 3 to 8) vs five days (IQR 3 to 8) and (1d) duration of mechanical ventilation (4 days (IQR 3 to 6) vs 4 days (IQR 2 to 5); P value &gt; 0.05),</P>
<P>
<I>Terlipressin was compared with placebo (non-protocol vasoactive drugs)</I>
 (six studies; 185 participants) (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>), dopamine (<LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>), norepinephrine (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>) and vasopressin (<LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>) in terms of (1a) ICU LOS (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), (1b) hospital LOS (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>), (1c) pressor-free days until day 28 (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>), (1d) duration of mechanical ventilation (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>) and (1f) serious adverse events (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). In comparisons summarized as 'versus placebo/non-protocol vasoactive drugs', one study actually used placebo (<LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>); in two studies (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>), fixed-dose terlipressin + variable dose norepinephrine was compared with variable-dose norepinephrine. Studies were performed in participants with septic shock (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>) and in children with catecholamine-resistant shock (<LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>), peri-operative refractory hypotension (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>) and acute respiratory distress syndrome (<LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>). In no comparison was a significant difference found.</P>
<P>
<I>Dopamine was compared with norepinephrine</I>
 (two studies; 1931 participants; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>) <I>and terlipressin</I> (one study; 32 participants) <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>) in terms of (1a) ICU LOS (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), (1b) hospital LOS (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>), (1c) pressor-free days until day 28 (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>) and (1f) arrhythmia (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> and <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK> compared dopamine with norepinephrine and found no differences in (1a) ICU LOS and (1b) hospital LOS (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). Further, <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> assessed (1d) days free of mechanical ventilation within 28 days (8.5 ± 11.2 days vs 9.5 ± 11.4 days; P value = 0.13). <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK> compared dopamine with noradrenaline for duration of mechanical ventilation (5.3 ± 3.6 days vs 4.3 ± 2.5 days; difference 1.00, 95% CI -1.15 to 3.15).</P>
<P>
<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> reported a small difference in (1c) days free of any vasopressor therapy within 28 days (12.6 ± 12.5 days vs 14.2 ± 12.3 days; P value = 0.007; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). The largest study by <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> and a smaller study by <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK> compared dopamine versus norepinephrine and found significant differences in (1f) arrhythmias (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>), including mostly sinus tachycardia (<LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>): 25% versus 6%; atrial fibrillation: 21% versus 11% (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>), 13% versus 3% (<LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>); ventricular tachycardia (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>): 2.4% versus 1.0%; and ventricular fibrillation (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>): 1.2% versus 0.5%.</P>
<P>
<I>Phenylephrine was compared with norepinephrine in participants with septic shock</I>
 (one study; 32 participants) (<LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>). Mean (1a) ICU LOS was 16 ± 13 versus 16 ± 10 days (difference 0.00 days, 95% CI -8.27 to 8.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Measures of health-related quality of life and measures of anxiety and depression</HEADING>
<P>In no studies were measures of health-related quality of life assessed. In no studies were measures of anxiety and depression assessed.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Among the network of vasopressors versus combinations of vasopressors, 18 studies provided data on participants with septic shock. In 17 studies, septic shock was an eligibility criterion; in one study, data on a subgroup of participants with septic shock were available for day 28 (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>). Overall 20 study arms included 2706 participants with 1370 mortality outcomes. The network forest plot is presented as <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>. In this subgroup analysis, dopamine was inferior to norepinephrine (dopamine vs norepinephrine RR 1.11, 95% CI 1.005 to 1.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We classified 11 studies (1148 participants) as having low risk of bias for the primary outcome of mortality (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Seguin-2006" TYPE="STUDY">Seguin 2006</LINK>; <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK>); for the remaining studies, at least some risk of bias could not be excluded because information was lacking, or because high risk of bias was indicated by the study design.</P>
<P>In no comparisons did within-study risk of bias seem to affect overall estimates (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>).</P>
<P>In all comparisons, heterogeneous mortality outcomes were included (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>For the comparison of norepinephrine versus dopamine (six studies; 1400 participants) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), effects of using the latest mortality outcome yielded an RR of 0.93 (95% CI 0.86 to 1.01) as compared with an RR of 0.92 (95% CI 0.85 to 1.01; analysis not shown) if 28-day mortality, hospital mortality and undetermined periods were acknowledged.</P>
<P>For the comparison of epinephrine versus norepinephrine + dobutamine (four studies; 412 participants) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), effects of using the latest mortality outcome included an RR of 1.04 (95% CI 0.86 to 1.26) as compared with an RR of 1.19 (95% CI 0.92 to 1.54; analysis not shown) if 28-day mortality and undetermined periods were acknowledged.</P>
<P>For the comparison of vasopressin versus non-protocol vasoactive drugs (five studies; 296 participants) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), effects of using the latest mortality outcome included an RR of 0.92 (95% CI 0.69 to 1.22) as compared with an RR of 0.90 (95% CI 0.06 to 12.64; analysis not shown) if restricted to studies reporting 24-hour mortality (<LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>), and an RR of 1.05 (95% CI 0.63 to 1.75; analysis not shown) if restricted to studies reporting 30-day or ICU mortality (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>).</P>
<P>For the comparison of norepinephrine versus vasopressin (three studies; 812 participants) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), effects of using the latest mortality outcome included an RR of 1.12 (95% CI 0.98 to 1.29) as compared with an RR of 1.10 (95% CI 0.94 to 1.30; analysis not shown) if 28-day mortality and ICU mortality were acknowledged. In the comparison of terlipressin and non-protocol vasoactive drugs, ICU mortality and 90-day mortality were combined. Choosing time points other than 90 days had no significant impact on the estimates (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>In summary, estimates remained virtually unchanged if definitions of mortality were changed, or if studies with different mortality definitions were compared.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting bias</HEADING>
<P>Funnel plots of the primary outcome of all comparisons did not suggest major asymmetry. We present the funnel plot for comparison 1.1 (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We identified too few studies per comparison to sensibly perform a formal test for funnel plot asymmetry. Overall, however, reporting bias does not seem to be a major problem in this review and in particular does not explain the results.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-02-05 12:29:13 +0000" MODIFIED_BY="Jane Cracknell">
<SUMMARY_OF_RESULTS MODIFIED="2016-02-05 12:29:13 +0000" MODIFIED_BY="Jane Cracknell">
<P>We found 28 studies that fulfilled our inclusion criteria. Overall 3497 participants with 1773 mortality outcomes were analysed. Information was derived mainly from six studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Myburgh-2008" TYPE="STUDY">Myburgh 2008</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>) that reported on 2797 participants (80% of total) and 1463 mortality outcomes (83% of total mortality outcomes) across all comparisons. Six different vasopressors, given alone or in combination with dobutamine or dopexamine, were compared in 12 different combinations.</P>
<P>All 28 studies reported mortality outcomes. Length of stay (LOS) was reported in 12 studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK>; <LINK REF="STD-Hua-2013" TYPE="STUDY">Hua 2013</LINK>; <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>; <LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>; <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>; <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>; <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK>). Other morbidity outcomes were reported in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes.</P>
<P>In summary, investigators reported no differences in mortality outcomes in any of the studies comparing different vasopressors or combinations. In particular, for the comparison between dopamine and norepinephrine, which included most participants, researchers observed no differences in mortality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The same results were obtained by our network meta-analysis (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</P>
<P>
<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> and <LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK> when comparing dopamine versus norepinephrine found higher risk of arrhythmia in the dopamine group (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). In total, 347 arrhythmia episodes were documented in 1891 participants (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Other adverse events such as new infectious episodes, skin ischaemias and arterial occlusion did not differ between intervention groups.</P>
<P>We found no differences in other relevant morbidity outcomes within any comparisons. This finding was consistent among the few large studies identified, as well as in studies with different levels of within-study bias risk. Overall the quality of the evidence ranged from high to very low across comparisons.</P>
<P>Our review included no pre-defined subgroup analyses; therefore, we cannot make strong inferences about whether effects of vasopressors differ across populations with different causes of shock. However, in one of the large trials comparing norepinephrine versus dopamine (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>), a pre-defined subgroup analysis according to shock type revealed a beneficial effect on 28-day mortality among participants with cardiogenic shock treated with norepinephrine. However, although subgroups were pre-defined, randomization was not stratified; moreover the test for subgroup differences (P value = 0.87) suggests that this subgroup effect can be explained by chance alone.</P>
<P>No evidence suggests that any of the investigated vasopressors are clearly superior over others.</P>
<P>Nine studies can be regarded as placebo/non-protocol vasoactive drug controlled add-on studies. <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK> and <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK> compared norepinephrine versus norepinephrine + terlipressin and dobutamine, which might be seen as add-on therapy of terlipressin + dobutamine versus no extra vasopressor in participants receiving norepinephrine. Investigators reported no differences in mortality or in LOS. Likewise <LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK> compared a vasopressin + norepinephrine arm versus a norepinephrine alone arm. This add-on vasopressin therapy did not have an effect. <LINK REF="STD-Yildizdas-2008" TYPE="STUDY">Yildizdas 2008</LINK> compared terlipressin versus placebo in paediatric patients with septic shock who did not respond to fluid resuscitation and high-dose catecholamines, and found no differences in mortality but significant reduction of LOS. This effect was no longer found when data were combined with those from <LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>. <LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK> and <LINK REF="STD-Han-2012" TYPE="STUDY">Han 2012</LINK> studied vasopressin versus non-protocol vasoactive drugs in participants with septic shock who were already taking catecholamines; <LINK REF="STD-D_x00fc_nser-2003" TYPE="STUDY">Dünser 2003</LINK> and <LINK REF="STD-Svoboda-2012" TYPE="STUDY">Svoboda 2012</LINK> compared norepinephrine versus norepinephrine + vasopressin; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK> compared vasopressin versus placebo in paediatric patients with vasodilatory shock after volume resuscitation under catecholamines. In none of these comparisons could a significant effect on mortality or morbidity be found. This result must not be interpreted as showing no effects of vasopressors versus placebo at all. Moreover, these results indicate that in participants requiring massive vasoactive support, additional vasopressors have no major effect. It is noteworthy that this evidence on placebo/non-protocol vasoactive drug comparisons comes from a few small studies only and therefore must be interpreted with additional caution.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Even though 28 studies met our inclusion criteria, numerous comparisons were necessary. Accordingly, the actual number of studies per comparison, as well as the number of participants in most studies, was small. Therefore, some comparisons resulted in under-powered effects. Also only limited subgroup analyses could be performed to investigate potential sources of heterogeneity.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Overall quality of the evidence ranged from high to very low. Only four studies (<LINK REF="STD-Annane-2007" TYPE="STUDY">Annane 2007</LINK>; <LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>; <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>; <LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>) fulfilled all criteria for the risk of bias assessment (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). However, when only bias items that were assumed to strongly influence the effects were considered, 11 studies were classified as having low risk of bias. Small-study bias usually tends to overestimate a true effect, but on the other hand, in the case of a null effect, limited power to exclude the absence of an effect may matter more. Many comparisons must be interpreted with caution. In summary, however, within-study bias does not seem to explain our findings.</P>
<P>Studies were too few for review authors to examine reporting bias in detail. However, as no obvious asymmetry in funnel plots was considered, and given that the comprehensive search strategy used several electronic databases without restrictions, as well as trial registers and experts in the field, reporting bias may not be a major source of distortion.</P>
<P>For the network meta-analysis, we considered at least two possible clinical elements of concern, including type of shock (septic shock vs other shock) and variability of the set point (mean arterial pressure) for titration of vasopressors. Allowing placebo to be real placebo or an active drug in a network meta-analysis adds another source of inconsistency, although we considered all such trials as add-on vasopressor trials. We acknowledge the clinical heterogeneity included in our analyses, but we assume that heterogeneity comes mainly from within the single studies, and that the extra heterogeneity introduced by the network meta-analysis is less important than the between-single study heterogeneity.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Data show no relevant departures from protocol (<LINK REF="REF-M_x00fc_llner-2002" TYPE="REFERENCE">Müllner 2002</LINK>) as potential sources of bias and no relevant decisions about analyses. The decision to include a network meta-analysis was made at the time of publication of the last update (<LINK REF="REF-Havel-2011" TYPE="REFERENCE">Havel 2011</LINK> ).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Several cohort studies have presented different conclusions about the effects of different vasopressors.</P>
<P>In a university hospital-based cohort study, <LINK REF="REF-Martin-2000" TYPE="REFERENCE">Martin 2000</LINK> studied 97 participants with septic shock. Participants were treated with a mix of catecholamines, mainly to compare high-dose dopamine versus norepinephrine in a non-randomized design. Norepinephrine in comparison with other vasopressors was significantly associated with better outcomes. This effect was adjusted for many potential confounders, but treatment allocation may have been poorly controlled.</P>
<P>In a multi-centre cohort study in 198 European ICUs (<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>) (occurrence of sepsis in acutely ill patients (SOAP study)), the effects of norepinephrine, dopamine, dobutamine and epinephrine were assessed in 1058 participants with shock. Epinephrine and in particular dopamine were found to worsen outcomes. In a smaller subset of participants with septic shock, epinephrine was associated with poor outcomes and dopamine showed a trend towards poor outcomes. These data were derived from a very heterogeneous sample and, despite extensive multi-variable adjustments, residual confounding may explain the effects.</P>
<P>
<LINK REF="REF-Povoa-2009" TYPE="REFERENCE">Povoa 2009</LINK> reported a multi-centre cohort study from 17 Portuguese ICUs, in which 897 participants with community-acquired sepsis were studied. In this population, norepinephrine and dobutamine were associated with worse outcomes, whereas dopamine was a predictor for better outcomes. In particular, when participants who received dopamine only were compared with participants who received norepinephrine only, the latter showed significantly worse outcomes. This effect was adjusted for age, sex, admission diagnosis, SAPS II, sequential organ failure assessment score (SOFA score) and inotropic support, but residual confounding cannot reasonably be excluded. Specifically, concern was expressed that the choice of vasopressors was driven by disease severity - simply that sicker participants were more likely to receive norepinephrine than dopamine.</P>
<P>In contrast to the observational evidence, recent reviews (<LINK REF="REF-Beale-2004" TYPE="REFERENCE">Beale 2004</LINK>; <LINK REF="REF-Holmes-2009" TYPE="REFERENCE">Holmes 2009</LINK>; <LINK REF="REF-Leone-2008" TYPE="REFERENCE">Leone 2008</LINK>) have been conservative in stating differences between several vasopressors, and have indicated that norepinephrine and dopamine are most often considered to be the vasopressors of choice for participants with shock.</P>
<P>In the meta-analysis comparing norepinephrine versus dopamine in the setting of septic shock, DeBacker reported significantly increased mortality among participants undergoing therapy with dopamine. This finding is true when only 28-day mortality is considered, but the effect is attenuated when the latest reported mortality is taken into account (<LINK REF="REF-DeBacker-2012" TYPE="REFERENCE">DeBacker 2012</LINK>). Recently, two additional concordant systematic reviews on vasopressors in septic shock were published; both included mixed treatment comparisons (<LINK REF="REF-Avni-2015" TYPE="REFERENCE">Avni 2015</LINK>; <LINK REF="REF-Zhou-2015" TYPE="REFERENCE">Zhou 2015</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<IMPLICATIONS_PRACTICE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressor therapy is an important part of haemodynamic support for patients with shock (<LINK REF="REF-Dellinger-2013" TYPE="REFERENCE">Dellinger 2013</LINK>). Several different vasopressors are available, and for six vasopressors, the effect was assessed in randomized controlled trials. The quality of evidence differs greatly between several comparisons, but, in summary, evidence is insufficient to prove that any of the vasopressors at assessed doses are superior over others in terms of mortality. Dopamine increases the risk for arrhythmia and might confer a mortality disadvantage versus norepinephrine. Most available data involve norepinephrine. The choice of the specific vasopressor may therefore be individualized and left to the discretion of the treating physician. Factors such as experience, physiological effects (e.g. heart rate, intrinsic inotropic effects, splanchnic perfusion), drug interaction with other therapeutics (especially vasopressin and concomitant use of corticosteroids) (<LINK REF="REF-Russell-2009" TYPE="REFERENCE">Russell 2009</LINK>), availability and cost should be considered.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>A large number of randomized trials have been conducted, but the sample population for specific comparisons is small. We hope that our review encourages the scientific community to design future studies in a way that outcomes that matter to patients, such as survival, but also long-term health-related quality of life, can be evaluated. Such studies ideally would be large, multi-centre trials based on simple and pragmatic study protocols. Such studies are also needed to evaluate whether surrogate endpoints, such as filling pressures, are of clinical use and, if so, how they should be used. In this context, special concern arises about use of target blood pressure as an endpoint of resuscitation, as achievement of specific blood pressure values may not reflect reversal of the underlying condition, as is shown in the group of participants with persisting "cryptogenic" shock despite normalization of blood pressure (<LINK REF="REF-Rivers-2001" TYPE="REFERENCE">Rivers 2001</LINK>). A single universally valid blood pressure goal appropriate for all patients with shock probably does not exist at all (<LINK REF="REF-Asfar-2014" TYPE="REFERENCE">Asfar 2014</LINK>). Furthermore, it is known that blood pressure targets often are not reached in controlled clinical trials (<LINK REF="REF-Takala-2010" TYPE="REFERENCE">Takala 2010</LINK>). Moreover, increasing evidence does not support superiority of strict goal-directed therapy protocols (<LINK REF="REF-ARISE-2014" TYPE="REFERENCE">ARISE 2014</LINK>; <LINK REF="REF-ProCESS-2014" TYPE="REFERENCE">ProCESS 2014</LINK>).</P>
<P>In the light of currently available evidence, additional well-designed studies with individualized goals of resuscitation including clinical parameters of end-organ perfusion and appropriate patient-relevant outcomes endpoints are urgently needed.</P>
<P>As with all Cochrane reviews, this review will be updated regularly. It is hoped that answers to the questions under study will be found over the next few years.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>For the update review, we would like to thank Andrea Morelli for providing information on two potentially eligible studies, and we'd like to extend special thanks to Dr Jinglan Mu for providing us with a translation of a newly included paper. We would like to thank Anna Lee (Content Editor), Cathal Walsh (Statistical Editor), Djillali Annane and Anthony Gordon (Peer Reviewers) and Roy Buffery (Consumer Referee) for help and editorial advice provided during preparation of this systematic review, and of course, Jane Cracknell (Managing Editor) for help and editorial advice provided during preparation of the review at all stages.</P>
<P>We would like to thank people who contributed to earlier versions of the review, namely, Jane Ballantyne, Anna Lee, Nathan Pace, Mike Grocott, Lance Richard, Ann Møller, Karen Hovhannisyan, Janet Wale, Nete Villebro and Kathie Godfrey. We are also grateful to experts in the field for sharing their knowledge with us: Daniel DeBacker, Djillali Annane, Claude Martin and Jean Louis Vincent. We'd like to extend particular thanks to Djillali Annane for providing a list of potentially relevant articles on vasopressors and inotropic drugs for septic shock.</P>
<P>We would also like to acknowledge Bernhard Urbanek, an author of the original version of this review (<LINK REF="REF-M_x00fc_llner-2004" TYPE="REFERENCE">Müllner 2004</LINK>), who did not participate as a review author for updated reviews.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Gunnar Gamper: no conflict of interest.</P>
<P>Christof Havel: no conflict of interest.</P>
<P>Jasmin Arrich: no conflict of interest.</P>
<P>Heidrun Losert: no conflict of interest.</P>
<P>Nathan Leon Pace: no conflict of interest.</P>
<P>Marcus Müllner: no conflict of interest.</P>
<P>Harald Herkner: no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>GG: selecting, reading, and comparing titles, abstracts and papers; drafting a data extraction sheet; extracting data from studies; drafting the update review.</P>
<P>CH: revising the protocol for content and clarity; building a database for data extraction; selecting, reading and comparing titles, abstracts and papers; extracting data from studies; drafting a data extraction sheet; reading and correcting the full review.</P>
<P>HL: selecting, reading and comparing titles, abstracts and papers; reading and correcting the full review.</P>
<P>JA: performing the literature search; selecting, reading and comparing titles, abstracts and papers; drafting a data extraction sheet; extracting data from studies; preparing the SoF table; reading and correcting the full review.</P>
<P>NLP: planning and performing network meta-analyses; reading and correcting the full review.</P>
<P>MM: conceiving of the initial review; drafting the protocol; performing the literature search; selecting, reading and comparing titles, abstracts and papers; drafting a data extraction sheet; extracting data from studies; drafting the first review; reading and correcting the full review.</P>
<P>HH: conceiving of the update review; overseeing the search process; serving as arbiter for trial selection in case of discrepancies and arbiter for data extraction in case of discrepancies; performing statistical analyses; drafting the update review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>In keeping with the decision made after the last update (<LINK REF="REF-Havel-2011" TYPE="REFERENCE">Havel 2011</LINK>), we now include a network meta-analysis to simultaneously model effects from direct and indirect comparisons, given the 10 treatment nodes currently available.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<INCLUDED_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Albanese-2005" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Albanese 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanese J, Leone M, Delmas A, Martin C</AU>
<TI>Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1897-902</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:31:53 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:31:53 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16148457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Annane-2007" MODIFIED="2010-06-22 08:57:32 +0100" MODIFIED_BY="[Empty name]" NAME="Annane 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-22 08:56:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, et al</AU>
<TI>Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9588</NO>
<PG>676-84</PG>
<IDENTIFIERS MODIFIED="2010-06-22 08:56:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17720019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boccara-2003" MODIFIED="2011-03-22 06:55:14 +0000" MODIFIED_BY="[Empty name]" NAME="Boccara 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-03-22 06:55:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boccara G, Ouattara A, Godet G, Dufresne E, Bertrand M, Riou B, et al</AU>
<TI>Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors</TI>
<SO>Anesthesiology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>1338-44</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:32:15 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:32:15 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 12766641"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choong-2009" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Choong 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choong K, Bohn D, Fraser DD, Gaboury I, Hutchison JS, Joffe AR, et al</AU>
<TI>Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2009</YR>
<VL>180</VL>
<NO>7</NO>
<PG>632-9</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:34:38 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:34:38 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19608718"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Backer-2010" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="De Backer 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al</AU>
<TI>Comparison of dopamine and norepinephrine in the treatment of shock</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>9</NO>
<PG>779-89</PG>
<IDENTIFIERS MODIFIED="2010-06-22 09:14:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20200382"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x00fc_nser-2003" MODIFIED="2010-06-30 16:36:10 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dünser 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-30 16:36:10 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al</AU>
<TI>Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>107</VL>
<PG>2313-9</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:36:10 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:36:10 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12732600"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2012" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Han 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han X-D, Sun H, Huang X-Y, Zhang S-Y, Wang Y-D, Ren K, et al</AU>
<TI>[A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]</TI>
<SO>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue</SO>
<YR>2012</YR>
<VL>24</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hua-2013" MODIFIED="2014-05-05 18:13:33 +0100" MODIFIED_BY="[Empty name]" NAME="Hua 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-05 18:13:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hua F, Wang X, Zhu L</AU>
<TI>Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2013</YR>
<VL>44</VL>
<NO>2</NO>
<PG>434-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2010" MODIFIED="2015-05-15 01:35:54 +0100" MODIFIED_BY="Jane Cracknell" NAME="Jain 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-15 01:35:54 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain G, Singh DK</AU>
<TI>Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock</TI>
<SO>Indian Journal of Critical Care Medicine</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>1</NO>
<PG>29-34</PG>
<IDENTIFIERS MODIFIED="2014-05-05 18:27:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-05 18:27:04 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="    20606906"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-05 18:21:09 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauzier-2006" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Lauzier 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauzier F, Levy B, Lamarre P, Lesur O</AU>
<TI>Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>11</NO>
<PG>1782-9</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:47:11 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:47:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17019548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1997" MODIFIED="2010-06-30 16:47:19 +0100" MODIFIED_BY="Jane Cracknell" NAME="Levy 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-06-30 16:47:19 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, et al</AU>
<TI>Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>282-7</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:47:19 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:47:19 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9083230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-2011" MODIFIED="2014-05-14 14:35:19 +0100" MODIFIED_BY="Harald Herkner" NAME="Levy 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-05-14 14:35:19 +0100" MODIFIED_BY="Harald Herkner" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy B, Perez P, Perny J, Thivilier C, Gerard A</AU>
<TI>Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study</TI>
<SO>Critical Care Medicine</SO>
<YR>2011</YR>
<VL>39</VL>
<NO>3</NO>
<PG>450-5</PG>
<IDENTIFIERS MODIFIED="2014-05-14 14:34:48 +0100" MODIFIED_BY="Harald Herkner">
<IDENTIFIER MODIFIED="2014-05-14 14:34:48 +0100" MODIFIED_BY="Harald Herkner" TYPE="PUBMED" VALUE="21037469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luckner-2006" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Luckner 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luckner G, Dunser MW, Stadlbauer KH, Mayr VD, Jochberger S, Wenzel V, et al</AU>
<TI>Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>R40</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:41:11 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:41:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16542484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malay-1999" MODIFIED="2011-02-17 11:38:53 +0000" MODIFIED_BY="Harald Herkner" NAME="Malay 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-06-30 16:52:11 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malay MB, Ashton RC Jr, Landry DW, Townsend RN</AU>
<TI>Low-dose vasopressin in the treatment of vasodilatory septic shock</TI>
<SO>Journal of Trauma</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>699-703</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:52:11 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:52:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10528604"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marik-1994" MODIFIED="2010-06-30 16:52:16 +0100" MODIFIED_BY="Jane Cracknell" NAME="Marik 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-30 16:52:16 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marik PE, Mohedin M</AU>
<TI>The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<PG>1354-7</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:52:16 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:52:16 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7933396"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1993" MODIFIED="2011-02-17 11:39:04 +0000" MODIFIED_BY="Harald Herkner" NAME="Martin 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-30 16:52:22 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martin C, Papazian L, Perrin G, Saux P, Gouin F</AU>
<TI>Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>103</VL>
<PG>1826-31</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:52:22 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:52:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8404107"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathur-2007" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Mathur 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathur S, Dhunna R, Chakraborty A</AU>
<TI>Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography</TI>
<SO>Indian Journal of Critical Care Medicine</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>4</NO>
<PG>186-91</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:54:49 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:54:49 +0100" MODIFIED_BY="Jane Cracknell" TYPE="EMBASE" VALUE="2008016347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-2008a" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2008a" YEAR="2008">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Ertmer C, Lange M, Duenser M, Rehberg S, Van Aken H, et al</AU>
<TI>Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>4</NO>
<PG>494-503</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:55:22 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:55:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18308741"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-2008b" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2008b" YEAR="2008">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Laderchi A, et al</AU>
<TI>Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial</TI>
<SO>Critical Care</SO>
<YR>2008</YR>
<VL>12(6)</VL>
<NO>R143</NO>
<PG>1-11</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:59:05 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:59:05 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19017409 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-2009" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, et al</AU>
<TI>Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study</TI>
<SO>Critical Care</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>4</NO>
<PG>R130</PG>
<IDENTIFIERS MODIFIED="2010-06-30 16:59:42 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 16:59:42 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19664253"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myburgh-2008" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Myburgh 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, et al</AU>
<TI>A comparison of epinephrine and norepinephrine in critically ill patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>12</NO>
<PG>2226-34</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:00:28 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:00:28 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18654759"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2010" MODIFIED="2016-01-18 13:33:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Patel 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-18 13:33:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel GP, Grahe JS, Sperry M, Singla S, Elpern E, Lateef O, et al</AU>
<TI>Efficacy and safety of dopamine versus norepinephrine in the management of septic shock</TI>
<SO>Shock</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>4</NO>
<PG>375-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19851126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruokonen-1993" MODIFIED="2011-02-17 11:39:41 +0000" MODIFIED_BY="Harald Herkner" NAME="Ruokonen 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-30 17:00:42 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ</AU>
<TI>Regional blood flow and oxygen transport in septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>1296-303</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:00:42 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:00:42 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8370292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-2008" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Russell 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-01-18 13:33:32 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, et al</AU>
<TI>The effects of vasopressin on acute kidney injury in septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Wang N, Walley KR, Ashby D, Russell JA</AU>
<TI>The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock</TI>
<SO>Chest</SO>
<YR>2012</YR>
<VL>142</VL>
<NO>3</NO>
<PG>593-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S, et al</AU>
<TI>Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2013</YR>
<VL>188</VL>
<PG>356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, et al</AU>
<TI>Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>3</NO>
<PG>811-8</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:02:42 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:02:42 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19237882"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al</AU>
<TI>Vasopressin versus norepinephrine infusion in patients with septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>9</NO>
<PG>877-87</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:03:18 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:03:18 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18305265"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seguin-2002" MODIFIED="2011-02-17 11:40:07 +0000" MODIFIED_BY="Harald Herkner" NAME="Seguin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-30 17:04:37 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seguin P, Bellissant E, Le-Tulzo Y, Laviolle B, Lessard Y, Thomas R, et al</AU>
<TI>Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>71</VL>
<PG>381-8</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:04:36 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:04:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="12011824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seguin-2006" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Seguin 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seguin P, Laviolle B, Guinet P, Morel I, Malledant Y, Bellissant E</AU>
<TI>Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10(1)</VL>
<NO>R32</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svoboda-2012" MODIFIED="2014-05-05 18:13:53 +0100" MODIFIED_BY="[Empty name]" NAME="Svoboda 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 18:13:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svoboda P, Scheer P, Kantorova I, Doubek J, Dudra J, Radvan M, et al</AU>
<TI>Terlipressin in the treatment of late phase catecholamine-resistant septic shock</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2012</YR>
<VL>59</VL>
<NO>116</NO>
<PG>1043-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildizdas-2008" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Yildizdas 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildizdas D, Yapicioglu H, Celik U, Sertdemir Y, Alhan E</AU>
<TI>Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>3</NO>
<PG>511-7</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:05:42 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:05:42 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18092150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Argenziano-1997" MODIFIED="2011-03-22 06:57:07 +0000" MODIFIED_BY="[Empty name]" NAME="Argenziano 1997" YEAR="">
<REFERENCE MODIFIED="2011-03-22 06:57:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW</AU>
<TI>A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96 Suppl II</VL>
<PG>286-90</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:16:49 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:16:49 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9386112"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hentschel-1995" MODIFIED="2010-06-30 17:24:07 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hentschel 1995" YEAR="">
<REFERENCE MODIFIED="2010-06-30 17:24:07 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hentschel R, Hensel D, Brune T, Rabe H, Jorch G</AU>
<TI>Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants</TI>
<SO>Biology of the Neonate</SO>
<YR>1995</YR>
<VL>68</VL>
<PG>318-24</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:24:07 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:24:07 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8835086"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinstner-2002" MODIFIED="2011-03-22 06:59:26 +0000" MODIFIED_BY="[Empty name]" NAME="Kinstner 2002" YEAR="">
<REFERENCE MODIFIED="2011-03-22 06:59:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinstner C, Germann P, Ullrich R, Landry D, Sladen R</AU>
<TI>Infusion of arginine-vasopressin (AVP) enhances blood pressure and renal function while preserving cerebral and splanchnic perfusion in patients in septic shock</TI>
<SO>Anesthesiology Abstracts of Scientific Papers, Annual Meeting</SO>
<YR>2002</YR>
<PG>Abstract No A-439</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1999" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Levy 1999" YEAR="">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy B, Nace L, Bollaert PE, Dousset B, Mallie JP, Larcan A</AU>
<TI>Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>1999</YR>
<VL>25</VL>
<PG>942-8</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:24:21 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:24:21 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10501749"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majerus-1984" MODIFIED="2011-03-22 07:00:26 +0000" MODIFIED_BY="[Empty name]" NAME="Majerus 1984" YEAR="">
<REFERENCE MODIFIED="2011-03-22 07:00:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majerus TC, Chodoff P, Borel CO</AU>
<TI>Dopamine and dobutamine in septic shock. A comparison</TI>
<SO>Archives Internationales de Physiologie et de Biochimie</SO>
<YR>1984</YR>
<VL>92</VL>
<PG>S65-7</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:24:26 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:24:26 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="6085242"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-2011" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A</AU>
<TI>Effect of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock</TI>
<SO>Critical Care</SO>
<YR>2011</YR>
<VL>15</VL>
<PG>R217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-2011a" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2011a" YEAR="2011">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A</AU>
<TI>Short term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<PG>963-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2002" MODIFIED="2010-06-30 17:24:33 +0100" MODIFIED_BY="Jane Cracknell" NAME="Patel 2002" YEAR="">
<REFERENCE MODIFIED="2010-06-30 17:24:33 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel BM, Chittock DR, Russell JA, Walley KR</AU>
<TI>Beneficial effects of short-term vasopressin infusion during severe septic shock</TI>
<SO>Anesthesiology</SO>
<YR>2002</YR>
<VL>96</VL>
<PG>576-82</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:24:33 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:24:33 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="11873030"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roz_x00e9_-1993" MODIFIED="2010-06-30 17:24:38 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rozé 1993" YEAR="">
<REFERENCE MODIFIED="2010-06-30 17:24:38 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roze JC, Tohier C, Maingueneau C, Lefevre M, Mouzard A</AU>
<TI>Response to dobutamine and dopamine in the hypotensive very preterm infant</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>59-63</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:24:38 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:24:38 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8346957"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmoelz-2006" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Schmoelz 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmoelz M, Schelling G, Dunker M, Irlbeck M</AU>
<TI>Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine-treated septic shock</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>2</NO>
<PG>173-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16616656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sperry-2008" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sperry 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sperry JL, Minei JP, Frankel HL, West MA, Harbrecht B G, Moore EE, et al</AU>
<TI>Early use of vasopressors after injury: caution before constriction</TI>
<SO>Journal of Trauma</SO>
<YR>2008</YR>
<VL>64</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:27:02 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:27:02 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18188092"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Totaro-1997" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Totaro 1997" YEAR="">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Totaro RJ, Raper RF</AU>
<TI>Epinephrine-induced lactic acidosis following cardiopulmonary bypass</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>1693-9</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:27:08 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:27:08 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9377884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2002" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Zhou 2002" YEAR="">
<REFERENCE MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SX, Qiu HB, Huang YZ, Yang Y, Zheng RQ</AU>
<TI>Effects of norepinephrine, epinephrine, and norepinephrine-dobutamine on systemic and gastric mucosal oxygenation in septic shock</TI>
<SO>Acta Pharmacologica Sinica</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>654-8</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:27:56 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:27:56 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12100762 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Agrawal-2011" MODIFIED="2016-01-18 13:36:59 +0000" MODIFIED_BY="Jane Cracknell" NAME="Agrawal 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-18 13:36:59 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agrawal A, Gupta A, Consul S, Shastri P</AU>
<TI>Comparative study of dopamine and norepinephrine in the management of septic shock</TI>
<SO>Saudi Journal of Anaesthesia</SO>
<YR>2011</YR>
<VL>5</VL>
<PG>162-6</PG>
<IDENTIFIERS MODIFIED="2015-11-13 17:08:06 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER MODIFIED="2015-11-13 17:08:06 +0000" MODIFIED_BY="Harald Herkner" TYPE="PUBMED" VALUE="21804796"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-13 17:09:46 +0000" MODIFIED_BY="Harald Herkner"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chawla-2014" MODIFIED="2016-01-18 13:37:11 +0000" MODIFIED_BY="Jane Cracknell" NAME="Chawla 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-18 13:37:11 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chawla L. Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al</AU>
<TI>Intravenous angiotensin II for the treatment of high output shock (ATHOS trial): a pilot study</TI>
<SO>Critical Care</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>5</NO>
<PG>534-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2012" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Chen 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen H, Zeng Z</AU>
<TI>Comparison of the effect and complications between dopamine and norepinephrine on treatment of septic shock</TI>
<SO>Jiangxi Medical Journal</SO>
<YR>2012</YR>
<VL>47</VL>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-13 17:09:25 +0000" MODIFIED_BY="Harald Herkner"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-2007" MODIFIED="2016-01-18 13:38:36 +0000" MODIFIED_BY="Jane Cracknell" NAME="Cohn 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-01-18 13:38:36 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohn SM, McCarthy J, Stewart RM, Jonas RB, Dent DL, Michalek JE</AU>
<TI>Impact of low-dose vasopressin on trauma outcome: prospective randomized study</TI>
<SO>World Journal of Surgery</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>2</NO>
<PG>430-9</PG>
<IDENTIFIERS MODIFIED="2015-11-16 11:36:51 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER MODIFIED="2015-11-16 11:36:51 +0000" MODIFIED_BY="Harald Herkner" TYPE="DOI" VALUE="10.1007/s00268-010-0875-8"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hai-Bo-2002" MODIFIED="2010-06-24 10:12:10 +0100" MODIFIED_BY="[Empty name]" NAME="Hai Bo 2002" YEAR="">
<REFERENCE MODIFIED="2010-06-24 10:12:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hai Bo Q, Yi Y, Shao Xia Z, Ying Zi H, Rui Qiang Z</AU>
<TI>Renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine-dobutamine in septic shock</TI>
<SO>Critical Care and Shock</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>9-14</PG>
<IDENTIFIERS MODIFIED="2010-06-24 10:12:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-24 10:12:10 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hajjar-2013" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hajjar 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hajjar L, Vincent JL, Rhodes A, Annane D, Galas F, Almeida J, et al</AU>
<TI>Vasopressin versus norepinephrine for the management of shock</TI>
<SO>Critical Care</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>Suppl 2</NO>
<PG>S83-P222</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-13 17:09:03 +0000" MODIFIED_BY="Harald Herkner"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-High-2008" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="High 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>High K</AU>
<TI>Impact of dopamine and norepinephrine on renal perfusion in patients with septic shock</TI>
<SO>Journal of Herbal Medicine</SO>
<YR>2008</YR>
<VL>30</VL>
<PG>1188</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hussain-2014" MODIFIED="2016-01-18 13:41:42 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hussain 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-18 13:41:42 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hussain T, Zahir J, Akbar A, Qureshi QA, Rehman HR</AU>
<TI>Efficacy of phenylephrine versus noradrenaline in management of patients presenting with septic shock in the intensive care unit</TI>
<SO>Rawal Medical Journal</SO>
<YR>2014</YR>
<VL>2</VL>
<PG>136-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2010" MODIFIED="2016-01-04 15:47:43 +0000" MODIFIED_BY="Jane Cracknell" NAME="Liu 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-01-04 15:47:43 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu P, Chen T, Zhang Y</AU>
<TI>Comparison evaluation of resuscitation effect of norepinephrine and dopamine on the treatment of septic shock</TI>
<SO>Clinical Education of General Practice</SO>
<YR>2010</YR>
<VL>8</VL>
<PG>265-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveira-2014" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Oliveira 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliveira S, Dessa F, Rocha C, Oliveira F</AU>
<TI>Early vasopressin application in shock study</TI>
<SO>Critical Care</SO>
<YR>2014</YR>
<VL>Suppl</VL>
<PG>S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plotkin-2007" MODIFIED="2016-01-18 14:06:36 +0000" MODIFIED_BY="Jane Cracknell" NAME="Plotkin 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-01-18 14:06:36 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plotkin LL</AU>
<TI>Use of vasopressin to correct hemodynamic disorders in patients with abdominal sepsis</TI>
<SO>Anesteziologiia i Reanimatologiia</SO>
<YR>2007</YR>
<VL>2</VL>
<PG>47-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1966" MODIFIED="2010-06-30 17:31:05 +0100" MODIFIED_BY="Jane Cracknell" NAME="Singh 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-06-30 17:31:05 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh S, Malhotra RP</AU>
<TI>Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock)</TI>
<SO>The Journal of the Association of Physicians of India</SO>
<YR>1966</YR>
<VL>14</VL>
<PG>639-45</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:31:05 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:31:05 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="4292372"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ventura-2014" MODIFIED="2016-01-18 13:46:06 +0000" MODIFIED_BY="Jane Cracknell" NAME="Ventura 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-18 13:46:06 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ventura AMc, Goes PF, Fernandes I de COF, Hsin SH, Souza de C, Gaiga L, et al</AU>
<TI>Randomized double-blind trial of dopamine or epinephrine as first-line vasoactive drugs in fluid refractory pediatric septic shock</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>1</NO>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Wu 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu J, Chen J, Ou Y, Yang C, Chen M, Hwuang SW, et al</AU>
<TI>Effect of dopamine and norepinephrine on hemodynamics and oxygen metabolism of tissue in patients with septic shock</TI>
<SO>Chinese Archives of General Surgery</SO>
<YR>2010</YR>
<VL>4</VL>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zambolim-2014" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Zambolim 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zambolim C, Nagaoka D, Fukushima J, Park C, Carneiro J, Osawa E, et al</AU>
<TI>Vasopressin versus norepinephrine for the management of septic shock in cancer patients</TI>
<SO>Critical Care</SO>
<YR>2014</YR>
<VL>Suppl</VL>
<PG>S57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhuangyu-2011" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Zhuangyu 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhuangyu Y</AU>
<TI>Effect of norepinephrine and dopamine on infectious tissue oxygen metabolismand hemodynamics in patients with shock</TI>
<SO>Shandong Medicine Journal</SO>
<YR>2011</YR>
<VL>51</VL>
<PG>93-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Choudhary-2013" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Choudhary 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="OTHER">
<AU>Choudhary A</AU>
<TI>Efficacy and safety of monotherapy with noradrenaline and terlipressin in patients of cirrhosis with septic shock admitted to intensive care unit</TI>
<SO>NCT01836224</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2006" MODIFIED="2009-11-18 14:16:28 +0000" MODIFIED_BY="[Empty name]" NAME="Fernandez 2006" YEAR="2006">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2014" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gordon 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ</AU>
<TI>Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH)</TI>
<SO>BMJ open</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>7</NO>
<PG>e005866</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lienhart-2007" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Lienhart 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lienhart H G, Wenzel V, Braun J, Dorges V, Dunser M, Gries A, et al</AU>
<TI>Vasopressin for therapy of persistent traumatic hemorrhagic shock. The VITRIS.at study. [German]</TI>
<SO>Anaesthetist</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NOVEL-2015" MODIFIED="2015-12-04 09:34:32 +0000" MODIFIED_BY="Harald Herkner" NAME="NOVEL 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-12-04 09:34:32 +0000" MODIFIED_BY="Harald Herkner" PRIMARY="NO" TYPE="OTHER">
<TI>NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock (NOVEL)</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS MODIFIED="2015-11-16 11:13:23 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER MODIFIED="2015-11-16 11:13:23 +0000" MODIFIED_BY="Harald Herkner" TYPE="OTHER" VALUE="NCT02454348"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasoactive-Drugs-in-Intensive-Care-Unit--2015" MODIFIED="2015-12-04 09:34:50 +0000" MODIFIED_BY="Harald Herkner" NAME="Vasoactive Drugs in Intensive Care Unit  2015" YEAR="2015">
<REFERENCE MODIFIED="2015-12-04 09:34:50 +0000" MODIFIED_BY="Harald Herkner" PRIMARY="NO" TYPE="OTHER">
<TI>Vasoactive Drugs in Intensive Care Unit</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS MODIFIED="2015-11-16 11:14:26 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER MODIFIED="2015-11-16 11:14:26 +0000" MODIFIED_BY="Harald Herkner" TYPE="OTHER" VALUE="NCT02118467"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-ACCP_x002f_SCCM-1992" MODIFIED="2010-06-30 17:31:39 +0100" MODIFIED_BY="Jane Cracknell" NAME="ACCP/SCCM 1992" TYPE="JOURNAL_ARTICLE">
<AU>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference</AU>
<TI>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>864-74</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:31:39 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:31:39 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1597042"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alberti-2005" MODIFIED="2016-01-18 13:57:12 +0000" MODIFIED_BY="Jane Cracknell" NAME="Alberti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, et al</AU>
<TI>Systemic inflammatory response and progression to severe sepsis in critically ill infected patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<NO>5</NO>
<PG>461-8</PG>
<IDENTIFIERS MODIFIED="2010-12-03 14:39:45 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="15531752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Angus-2001" MODIFIED="2011-03-22 07:01:41 +0000" MODIFIED_BY="[Empty name]" NAME="Angus 2001" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR</AU>
<TI>Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2010-12-03 13:45:06 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="11445675"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2008" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Annane 2008" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Sébille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, et al</AU>
<TI>Incidence and prognosis of sustained arrhythmias in critically ill patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>178</VL>
<PG>20-5</PG>
<IDENTIFIERS MODIFIED="2015-05-05 10:15:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-05 10:15:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18388358"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ARISE-2014" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="ARISE 2014" TYPE="JOURNAL_ARTICLE">
<AU>The ARISE Investigators and the ANZICS Clinical Trials Group</AU>
<TI>Goal-directed resuscitation for patients with early septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>371</VL>
<PG>1496-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Asfar-2014" MODIFIED="2016-01-18 13:59:46 +0000" MODIFIED_BY="Jane Cracknell" NAME="Asfar 2014" TYPE="JOURNAL_ARTICLE">
<AU>Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, et al</AU>
<TI>High versus low blood-pressure target in patients with septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>370</VL>
<NO>17</NO>
<PG>1583-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Avni-2015" MODIFIED="2016-01-18 14:00:08 +0000" MODIFIED_BY="Jane Cracknell" NAME="Avni 2015" TYPE="JOURNAL_ARTICLE">
<AU>Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A</AU>
<TI>Vasopressors for the treatment of septic shock: systematic review and meta-analysis</TI>
<SO>PLoS One</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>8</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babaev-2005" MODIFIED="2011-03-22 07:02:05 +0000" MODIFIED_BY="[Empty name]" NAME="Babaev 2005" TYPE="JOURNAL_ARTICLE">
<AU>Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS</AU>
<TI>Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>4</NO>
<PG>448-54</PG>
<IDENTIFIERS MODIFIED="2010-12-02 09:54:13 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="16046651"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beale-2004" MODIFIED="2011-03-22 07:02:41 +0000" MODIFIED_BY="[Empty name]" NAME="Beale 2004" TYPE="JOURNAL_ARTICLE">
<AU>Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE</AU>
<TI>Vasopressor and inotropic support in septic shock: an evidence-based review</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32 Suppl</VL>
<NO>11</NO>
<PG>455-65</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:57:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15542956"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blanco-2008" MODIFIED="2011-03-22 07:03:03 +0000" MODIFIED_BY="[Empty name]" NAME="Blanco 2008" TYPE="JOURNAL_ARTICLE">
<AU>Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, et al</AU>
<TI>Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study</TI>
<SO>Critical Care (London, England)</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>6</NO>
<PG>R158</PG>
<IDENTIFIERS MODIFIED="2010-12-03 13:58:22 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="19091069"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cannon-2009" MODIFIED="2011-03-22 07:03:25 +0000" MODIFIED_BY="[Empty name]" NAME="Cannon 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cannon CM, Braxton CC, Kling-Smith M, Mahnken JD, Carlton E, Moncure M</AU>
<TI>Utility of the shock index in predicting mortality in traumatically injured patients</TI>
<SO>The Journal of Trauma</SO>
<YR>2009</YR>
<VL>67</VL>
<NO>6</NO>
<PG>1426-30</PG>
<IDENTIFIERS MODIFIED="2010-12-03 13:04:51 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="20009697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DeBacker-2012" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="DeBacker 2012" TYPE="JOURNAL_ARTICLE">
<AU>DeBacker D, Aldecoa C, Njimi H, Vincent JL</AU>
<TI>Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis</TI>
<SO>Critical Care Medicine</SO>
<YR>2012</YR>
<VL>40</VL>
<NO>3</NO>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2008" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dellinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>1</NO>
<PG>296-327</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:32:07 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:32:07 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18158437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2013" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Dellinger 2013" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012</TI>
<SO>Critical Care Medicine</SO>
<YR>2013</YR>
<VL>41</VL>
<NO>2</NO>
<PG>580-637</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esteban-2007" MODIFIED="2011-03-22 07:03:54 +0000" MODIFIED_BY="[Empty name]" NAME="Esteban 2007" TYPE="JOURNAL_ARTICLE">
<AU>Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, et al</AU>
<TI>Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>5</NO>
<PG>1284-9</PG>
<IDENTIFIERS MODIFIED="2010-12-03 13:18:50 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="17414725"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Geiling-1926" MODIFIED="2011-03-22 07:04:43 +0000" MODIFIED_BY="[Empty name]" NAME="Geiling 1926" TYPE="JOURNAL_ARTICLE">
<AU>Geiling EMK, Campbell DJ</AU>
<TI>Variations in blood pressure induced by repeated injections of extracts of the posterior lobe of the pituitary gland</TI>
<SO>Journal of Pharmacological and Experimental Therapeutics</SO>
<YR>1926</YR>
<VL>29</VL>
<PG>449&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-04-24 15:28:18 +0100" MODIFIED_BY="Harald Herkner" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ</AU>
<TI>What is "quality of evidence" and why is it important to clinicians?</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7651</NO>
<PG>995-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18456631"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hayden-1994" MODIFIED="2011-03-22 07:04:57 +0000" MODIFIED_BY="[Empty name]" NAME="Hayden 1994" TYPE="OTHER">
<AU>Hayden WR</AU>
<TI>Sepsis terminology in pediatrics</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>4</NO>
<PG>657-8</PG>
<IDENTIFIERS MODIFIED="2009-11-19 12:51:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8151490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Higgins 2011" TYPE="OTHER">
<TI>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hinshaw-1972" MODIFIED="2011-03-22 07:05:38 +0000" MODIFIED_BY="[Empty name]" NAME="Hinshaw 1972" TYPE="BOOK">
<AU>Hinshaw LB, Cox BG</AU>
<SO>The Fundamental Mechanisms of Shock</SO>
<YR>1972</YR>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffman-1992" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Hoffman 1992" TYPE="BOOK_SECTION">
<AU>Hoffman B, Lefkowitz RJ</AU>
<TI>Catecholamines and sympathomimetic drugs</TI>
<SO>The Pharmacological Basis of Therapeutics</SO>
<YR>1992</YR>
<PG>187-220</PG>
<EN>8th</EN>
<ED>A Goodman Gilman</ED>
<PB>McGraw-Hill</PB>
<CY>Singapore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmes-2009" MODIFIED="2011-03-22 07:06:07 +0000" MODIFIED_BY="[Empty name]" NAME="Holmes 2009" TYPE="JOURNAL_ARTICLE">
<AU>Holmes CL, Walley KR</AU>
<TI>Vasoactive drugs for vasodilatory shock in ICU</TI>
<SO>Current Opinion in Critical Care</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>5</NO>
<PG>398-402</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:51:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19542884"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krahn-2013" MODIFIED="2014-12-18 11:14:24 +0000" MODIFIED_BY="Harald Herkner" NAME="Krahn 2013" TYPE="JOURNAL_ARTICLE">
<AU>Krahn U, Binder H, König J</AU>
<TI>A graphical tool for locating inconsistency in network meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>35</NO>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-K_x00f6_nig-2012" MODIFIED="2016-01-18 14:01:02 +0000" MODIFIED_BY="Jane Cracknell" NAME="König 2012" TYPE="JOURNAL_ARTICLE">
<AU>König J, Krahn U, Binder H</AU>
<TI>Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons</TI>
<SO>Statistics in Medicine</SO>
<YR>2012</YR>
<VL>32</VL>
<PG>5414-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leone-2004" MODIFIED="2011-03-22 07:06:30 +0000" MODIFIED_BY="[Empty name]" NAME="Leone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Leone M, Vallet B, Teboul JL, Mateo J, Bastien O, Martin C</AU>
<TI>Survey of the use of catecholamines by French physicians</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>5</NO>
<PG>984-8</PG>
<IDENTIFIERS MODIFIED="2010-12-03 15:53:00 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="14997293"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leone-2008" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Leone 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leone M, Martin C</AU>
<TI>Vasopressor use in septic shock: an update</TI>
<SO>Current Opinion in Anaesthesiology</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:51:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18443479"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-2003" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Levy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al</AU>
<TI>2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>4</NO>
<PG>1250-6</PG>
<IDENTIFIERS MODIFIED="2009-11-19 09:28:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12682500"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-2010" MODIFIED="2011-03-22 07:06:51 +0000" MODIFIED_BY="[Empty name]" NAME="Levy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al</AU>
<TI>Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>12</NO>
<PG>2019-29</PG>
<IDENTIFIERS MODIFIED="2010-12-03 16:14:49 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="20862451"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martin-2000" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Martin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Martin C, Viviand X, Leone M, Thirion X</AU>
<TI>Effect of norepinephrine on the outcome of septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>8</NO>
<PG>2758-65</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:53:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10966247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Povoa-2009" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Povoa 2009" TYPE="JOURNAL_ARTICLE">
<AU>Povoa PR, Carneiro AH, Ribeiro OS, Pereira AC</AU>
<TI>Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study)</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>2</NO>
<PG>410-6</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:52:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19114885"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ProCESS-2014" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="ProCESS 2014" TYPE="JOURNAL_ARTICLE">
<AU>The ProCESS Investigators</AU>
<TI>A randomized trial of protocol-based care for early septic shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>370</VL>
<PG>1683-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quenot--2013" MODIFIED="2016-01-18 14:02:48 +0000" MODIFIED_BY="Jane Cracknell" NAME="Quenot  2013" TYPE="JOURNAL_ARTICLE">
<AU>Quenot J-P, Binquet C, Kara F, Martinet O, Ganster F, Navellou J-C, et al</AU>
<TI>The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study</TI>
<SO>Critical Care</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>R65</NO>
<PG>1-10</PG>
<IDENTIFIERS MODIFIED="2015-11-27 10:19:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-27 10:19:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi:10.1186/cc12598"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-R-Core-Team-2014" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="R Core Team 2014" TYPE="COMPUTER_PROGRAM">
<AU>R Core Team</AU>
<TI>R: A language and environment for statistical computing.</TI>
<YR>2014</YR>
<PB>R Foundation for Statistical Computing</PB>
<CY>Vienna, Austria</CY>
<MD>http://www.R-project.org/</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reinelt-2001" MODIFIED="2016-01-18 14:03:11 +0000" MODIFIED_BY="Jane Cracknell" NAME="Reinelt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Reinelt P Karth DG, Geppert A, Heinz G</AU>
<TI>Incidence and type of cardiac arrhythmias in critically ill patients: a single center experience in a medical-cardiological ICU</TI>
<SO>Intensive Care Medicine</SO>
<YR>2001</YR>
<VL>27</VL>
<PG>1466-73</PG>
<IDENTIFIERS MODIFIED="2015-05-05 10:11:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-05 10:11:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11685339"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.3" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="RevMan 5.3" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rivers-2001" MODIFIED="2011-03-22 07:07:50 +0000" MODIFIED_BY="[Empty name]" NAME="Rivers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al</AU>
<TI>Early goal-directed therapy in the treatment of severe sepsis and septic shock</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>1368-77</PG>
<IDENTIFIERS MODIFIED="2010-06-30 17:33:24 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 17:33:24 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="11794169"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Russell-2009" MODIFIED="2016-01-18 14:04:18 +0000" MODIFIED_BY="Jane Cracknell" NAME="Russell 2009" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, et al</AU>
<TI>Interaction of vasopressin infusion, corticosteroid treatment, and the mortality of septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>3</NO>
<PG>811-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2014-10-14 16:00:44 +0100" MODIFIED_BY="Harald Herkner" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rucker G, Schwarzer G, Carpenter J</AU>
<TI>Arcsine test for publication bias in meta-analyses with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>5</NO>
<PG>746-63</PG>
<IDENTIFIERS MODIFIED="2010-06-14 15:42:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17592831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2012" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Rücker 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G</AU>
<TI>Network meta-analysis, electrical networks and graph theory</TI>
<SO>Research Synthesis Methods</SO>
<YR>2012</YR>
<VL>3</VL>
<PG>312-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sakr-2006" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Sakr 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, et al</AU>
<TI>Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>3</NO>
<PG>589-97</PG>
<IDENTIFIERS MODIFIED="2010-06-16 15:54:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16505643"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salanti-2014" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Salanti 2014" TYPE="JOURNAL_ARTICLE">
<AU>Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT</AU>
<TI>Evaluating the quality of evidence from a network meta-analysis</TI>
<SO>PLOS ONE</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>7</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subhedar-2003" MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell" NAME="Subhedar 2003" TYPE="COCHRANE_REVIEW">
<AU>Subhedar NV, Shaw NJ</AU>
<TI>Dopamine versus dobutamine for hypotensive preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-07 17:12:02 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2008-08-07 17:12:02 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD001242"/>
<IDENTIFIER MODIFIED="2008-08-07 17:11:58 +0100" MODIFIED_BY="Jane Cracknell" TYPE="OTHER" VALUE="CD001242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sundararajan-2005" MODIFIED="2011-03-22 07:08:38 +0000" MODIFIED_BY="[Empty name]" NAME="Sundararajan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K</AU>
<TI>Epidemiology of sepsis in Victoria, Australia</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>1</NO>
<PG>71-80</PG>
<IDENTIFIERS MODIFIED="2010-12-03 13:47:36 +0000" MODIFIED_BY="Harald Herkner">
<IDENTIFIER TYPE="PUBMED" VALUE="15644651"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Takala-2010" MODIFIED="2016-01-18 14:04:51 +0000" MODIFIED_BY="Jane Cracknell" NAME="Takala 2010" TYPE="JOURNAL_ARTICLE">
<AU>Takala J</AU>
<TI>Should we target blood pressures in Sepsis?</TI>
<SO>Critical Care Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<PG>S609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2008" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Young 2008" TYPE="BOOK_SECTION">
<AU>Young WF</AU>
<TI>SHOCK</TI>
<SO>CURRENT Diagnosis and Treatment Emergency Medicine</SO>
<YR>2008</YR>
<PG>160</PG>
<EN>6th</EN>
<ED>Stone CK, Humphries R</ED>
<PB>LANGE CURRENT Series/McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zaritsky-1994" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Zaritsky 1994" TYPE="BOOK_SECTION">
<AU>Zaritsky AL</AU>
<TI>Catecholamines, inotropic medications, and vasopressor agents</TI>
<SO>Essentials of Critical Care Pharmacology</SO>
<YR>1994</YR>
<PG>255-72</PG>
<EN>2nd</EN>
<ED>Chernow B</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2015" MODIFIED="2016-01-18 14:05:42 +0000" MODIFIED_BY="Jane Cracknell" NAME="Zhou 2015" TYPE="JOURNAL_ARTICLE">
<AU>Zhou F, Mao Z, Zeng X, Kang H, Liu H, Pan L, et al</AU>
<TI>Vasopressors in septic shock: a systematic review and network meta-analysis</TI>
<SO>Therapeutics and Clinical Risk Management</SO>
<YR>2015</YR>
<VL>11</VL>
<PG>1047-59</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Havel-2011" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Havel 2011" TYPE="COCHRANE_REVIEW">
<AU>Havel C, Arrich J, Losert H, Gamper G, Müllner M, Herkner H</AU>
<TI>Vasopressors for hypotensive shock</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-03-18 14:35:19 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-03-18 14:35:17 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD003709.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00fc_llner-2002" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Müllner 2002" TYPE="COCHRANE_PROTOCOL">
<AU>Müllner M, Urbanek B, Havel C, Losert H, Gamper G</AU>
<TI>Vasopressors for shock</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-03-18 14:39:07 +0000" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2015-03-18 14:39:05 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD003709"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00fc_llner-2004" MODIFIED="2010-06-30 14:51:31 +0100" MODIFIED_BY="Jane Cracknell" NAME="Müllner 2004" TYPE="COCHRANE_REVIEW">
<AU>Müllner M, Urbanek B, Havel C, Losert H, Gamper G, Herkner H</AU>
<TI>Vasopressors for shock</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-06-30 14:51:31 +0100" MODIFIED_BY="Jane Cracknell">
<IDENTIFIER MODIFIED="2010-06-30 14:51:31 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD003709"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Arutyunov-2010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Arutyunov 2010" TYPE="JOURNAL_ARTICLE">
<AU>Arutyunov GP, Arutyunov AG, Volkova AL, Task G</AU>
<TI>Study evaluating the impact of a combination of inotropic support and heart rate monitoring on prognosis and stabilization rate in patients with decompensated chronic heart failure (LEGION)</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>3</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bahloul-2012" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Bahloul 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bahloul M, Chaari A, Ben Mbarek MN, Kallel H, Bouaziz M</AU>
<TI>Use of heptaminol hydrochloride for catecholamine weaning in septic shock</TI>
<SO>American Journal of Therapeutics</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>1</NO>
<PG>e8-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chi-2013" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Chi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chi C-Y, Khanh TH, Kim, Tseng F-C, Wang S-M, Thinh LQ, et al</AU>
<TI>Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2013</YR>
<VL>41</VL>
<NO>7</NO>
<PG>1754-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comparison-2011" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Comparison 2011" TYPE="JOURNAL_ARTICLE">
<AU>Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock</AU>
<TI>A prospective, randomized pilot study</TI>
<SO>Critical Care Medicine</SO>
<YR>2011</YR>
<VL>39</VL>
<NO>3</NO>
<PG>450-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daley-2013" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Daley 2013" TYPE="JOURNAL_ARTICLE">
<AU>Daley MJ, Lat I, Mieure KD, Jennings HR, Hall JB, Kress JP</AU>
<TI>A comparison of initial monotherapy with norepinephrine versus vasopressin for resuscitation in septic shock</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2013</YR>
<VL>47</VL>
<NO>3</NO>
<PG>301-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Backer-2012" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="De Backer 2012" TYPE="JOURNAL_ARTICLE">
<AU>De Backer D, Aldecoa C, Njimi H, Vincent J-L</AU>
<TI>Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*</TI>
<SO>Critical Care Medicine</SO>
<YR>2012</YR>
<VL>40</VL>
<NO>3</NO>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fayed-2013" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Fayed 2013" TYPE="JOURNAL_ARTICLE">
<AU>Fayed N, Refaat EK, Yassein TE, Alwaraqy M</AU>
<TI>Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation</TI>
<SO>Journal of Critical Care</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>5</NO>
<PG>775-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Gordon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, et al</AU>
<TI>The effects of vasopressin on acute kidney injury in septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2012" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Gordon 2012" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AC, Wang N, Walley KR, Ashby D, Russell JA</AU>
<TI>The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock</TI>
<SO>Chest</SO>
<YR>2012</YR>
<VL>142</VL>
<NO>3</NO>
<PG>593-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasija-2010" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hasija 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hasija S, Makhija N, Choudhury M, Hote M, Chauhan S, Kiran U</AU>
<TI>Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>2</NO>
<PG>230-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Memis-2012" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Memis 2012" TYPE="JOURNAL_ARTICLE">
<AU>Memis D, Inal MT, Sut N</AU>
<TI>The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock</TI>
<SO>Journal of Critical Care</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>3</NO>
<PG>318</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohta-2010" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Mohta 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A</AU>
<TI>Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension</TI>
<SO>Anaesthesia</SO>
<YR>2010</YR>
<VL>65</VL>
<NO>12</NO>
<PG>1200-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morelli-2010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2010" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, et al</AU>
<TI>Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study</TI>
<SO>Critical Care (London, England)</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>6</NO>
<PG>R232</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morelli-2011" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2011" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, et al</AU>
<TI>Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock</TI>
<SO>Critical Care (London, England)</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>5</NO>
<PG>R217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morelli-2011a" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Morelli 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Morelli A, Donati A, Ertmer C, Rehberg S, Orecchioni A, Di Russo A, et al</AU>
<TI>Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>6</NO>
<PG>963-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redfors-2011" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Redfors 2011" TYPE="JOURNAL_ARTICLE">
<AU>Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten S-E</AU>
<TI>Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>1</NO>
<PG>60-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russell-2013" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Russell 2013" TYPE="JOURNAL_ARTICLE">
<AU>Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S, et al</AU>
<TI>Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2013</YR>
<VL>188</VL>
<NO>3</NO>
<PG>356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torgersen-2010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NAME="Torgersen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, et al</AU>
<TI>Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>1</NO>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vasu-2012" MODIFIED="2014-05-05 18:12:22 +0100" MODIFIED_BY="[Empty name]" NAME="Vasu 2012" TYPE="JOURNAL_ARTICLE">
<AU>Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE</AU>
<TI>Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials</TI>
<SO>Journal of Intensive Care Medicine</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>3</NO>
<PG>172-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Albanese-2005">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre open-label randomized controlled study at a tertiary care University hospital; France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with hyperdynamic septic shock after fluid resuscitation</P>
<P>Mean age = 66 years, 35% female</P>
<P>APACHE II score = 28.5 (N = 20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Norepinephrine started with 0.3 mcg/kg and increased by 0.3 mcg/kg every 4 minutes until MAP 65 to 75 mm Hg</P>
<P>vs</P>
<P>Terlipressin 1 mg bolus, followed by second bolus of 1 mg if MAP &lt; 65 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>In-hospital mortality, renal function (urine flow, creatinine clearance up to 8 hours - presented on a graph only, no numbers provided), haemodynamic parameters, blood gas, lactate at 6 hours</P>
<P>For the mortality analysis, we used data on in-hospital mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 00:59:42 +0100" MODIFIED_BY="Jane Cracknell">
<P>No explicit primary outcome defined</P>
<P>No funding source </P>
<P>Declarations of interest: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Annane-2007">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre double-blind randomized controlled trial in 19 ICUs (CATS study); France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (study authors' definition)</P>
<P>Mean age = 63 years, 39% female</P>
<P>SAPS II score = 53, SOFA score = 11 (N = 330)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Epinephrine infusion 0.2 mcg/kg/min (N = 161)</P>
<P>vs</P>
<P>Norepinephrine infusion 0.2 mcg/kg/min and dobutamine 5 mcg/kg/min (N = 169)</P>
<P>Both adjusted according to MAP, pulmonary arterial wedge pressure, cardiac index and response to fluid challenge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>28-Day mortality (primary); 7-, 14-, 90-day ICU; hospital mortality; duration of vasopressor therapy; time to haemodynamic success; adverse events</P>
<P>For the mortality analysis, we used data on 90-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:00:34 +0100" MODIFIED_BY="Jane Cracknell">
<P>The French Ministry of Health provided financial support (1997 Clinical Research Hospital Programme PHRC 1997, AOM 97123)</P>
<P>Conflict of interest: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Boccara-2003">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants scheduled for carotid endarterectomy and refractory peri-operative hypotension<BR/>(N = 20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed (terlipressin infused in 1 mg intravenous boluses up to 3 mg vs norepinephrine (50 mcg/mL) at initial rate of 10 mL/h, incrementally by 2 mL/h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Death, stroke, myocardial ischaemias; renal failure; hospital stay</P>
<P>For the mortality analysis, we used data on undetermined mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:02:21 +0100" MODIFIED_BY="Jane Cracknell">
<P>It is unclear when participants died (peri-operative or in-hospital)</P>
<P>Conflict of interest not declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Choong-2009">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre double-blind randomized controlled trial, University hospital PCCUs (Paediatric Critical Care Unit); Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Paediatric participants with vasodilatory shock (study authors' definition)</P>
<P>Mean age = 10 years, 48% female</P>
<P>PRISM III score = 13, MODS score = 3; PELOD score = 10.5 (N = 69)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressin infusion 0.0005 U/kg/min, increased every 5 minutes up to 0.002 U/kg/min (max dose 0.05 U/min) to maintain target MAP for age</P>
<P>vs</P>
<P>Saline placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Time to vasopressor discontinuation (primary), 30-day mortality, organ dysfunction, urine output, haemodynamics, vasopressor dose, vasopressin serum levels, vasopressor-free days until day 30, organ failure-free days until day 30, mechanical ventilation-free days until day 30, PCCU LOS, adverse events</P>
<P>For the mortality analysis, we used data on 30-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>All other vasopressors were open-label and were used at the treating physician's discretion</P>
<P>Supported by grants from the Canadian Institutes of Health Research (200511MCT-154713), Heart and Stroke Foundation (NA 5937), Physician Services Incorporated (02&#8211;65), Hospital for Sick Children Foundation (XG 02&#8211; 071R), Canadian Intensive Care Foundation, Laerdal Foundation and Ferring Inc</P>
<P>Conflicts of interest: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-De-Backer-2010">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre randomized controlled trial, 8 University hospitals (SOAP II study); Belgium, Austria, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with shock (study authors' definition)</P>
<P>Mean age = 68 years, 57%female</P>
<P>APACHE II score = 20, SOFA score = 9 (N = 1679)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dopamine incrementally increased dose by 2 mcg/kg/min (max 20 mcg)</P>
<P>vs</P>
<P>Norepinephrine incrementally increased dose by 0.02 mcg/kg/min (max 0.19 mcg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>28-Day mortality (primary); 6-month-12-month-, ICU- and hospital mortality; ICU LOS, hospital LOS, number of days without need for organ support (vasopressors, ventilators, renal replacement therapy), time to reach MAP &gt; 65 mm Hg, adverse events (arrhythmias, myocardial necrosis, skin necrosis, ischaemias in limbs or distal extremities, secondary infections)</P>
<P>For the mortality analysis, we used data on 12-month mortality (main analysis)</P>
<P>For the subgroup analysis in septic shock patients, we used 28-day data available in the meta-analysis by DeBacker (<LINK REF="REF-DeBacker-2012" TYPE="REFERENCE">DeBacker 2012</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>If patients hypotensive after max dosage, open-label norepinephrine</P>
<P>Supported in part by the European Society of Intensive Care through support from the European Critical Care Research Network</P>
<P>Dr Aldecoa reports receiving consulting fees from Covidien. No other potential conflict of interest relevant to this article was reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-D_x00fc_nser-2003">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; Austria<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult surgical and medical participants with vasodilatory shock<BR/>(N = 48)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Fixed dose of vasopressin (4 U/h) + goal-directed norepinephrine (MAP &#8805; 70 mm Hg) vs goal-directed norepinephrine (MAP &#8805; 70 mm Hg)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>24-Hour mortality; 48-hour mortality; ICU mortality; ICU LOS</P>
<P>For the mortality analysis, we used data on ICU mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:06:42 +0100" MODIFIED_BY="Jane Cracknell">
<P>Participants were allowed to receive vasopressin in the norepinephrine group if "failed"</P>
<P>This study was supported in part by the Lorenz Bo&#776;hler Fund </P>
<P>Conflict of interest: not declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Han-2012">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre RCT in community hospitals; China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Patients with septic shock who were older than 16 years with dopamine requirements exceeding 5 µg/kg/min; 29% female, mean 72 years old, average APACHE I score 27.4, SOFA score 9.3 (N = 139)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Pituitrin (vasopressin 0.017 to 0.042 U/min) vs standard vasopressors (dopamine or norepinephrine 2 to 20 µg/kg/min)</P>
<P>norepinephrine added to both groups to keep haemodynamics stable</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>28-Day survival, LOS hospital, duration mechanical ventilation; MAP, heart rate, serum creatinine, lactate, norepinephrine dose, heparin, glucocorticoids</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Published in Chinese; funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hua-2013">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with ARDS and septic shock. Mean age 54 years, 44% female, APACHE II score 18.6, lung injury score 2.9. SAPS 45.5 (N = 32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Terlipressin (1.3 &#956;g/kg/h) vs dopamine (up to 20 &#956;g/kg/min) to reach MAP 70 ± 5 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>28-Day mortality, LOS ICU, LOS hospital, pressor-free days, duration of mechanical ventilation; VEGF, TNFa, haemodynamics, oxygenation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:08:10 +0100" MODIFIED_BY="Jane Cracknell">
<P>Funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Jain-2010">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock. Mean age 44 years, 48% female, APACHE II score 18.4</P>
<P>Dopamine infusion rate 25 µg/kg/min (N = 32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Norepinephrine (0.5 to 3.5 µg/kg/min with increments of 0.5 µg/kg/min every 30 minutes) vs phenylephrine (0.5 to 8.5 µg/kg/min with increments of 1 µg/kg/min every 30 minutes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Survival (time point not reported), main outcomes were haemodynamic parameters within 6 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Source of support: nil</P>
<P>Conflict of interest: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Lauzier-2006">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre open-label randomized controlled trial at University hospitals; Canada, France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (ACCP/SCCM definition <LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>) mean age = 55 years, 39% female</P>
<P>Mean APACHE II score = 23.15, moderate SOFA score = 8.9 (N = 23)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Arginine-vasopression (AVP) infusion 0.04 to 0.2 U/min (N = 13), at doses &gt; 0.2 U/min rescue therapy with norepinephrine or additional AVP allowed</P>
<P>vs</P>
<P>Norepinephrine 0.1 to 2.8 mcg/kg/min (N = 10), at doses &gt; 2.8 mcg/kg/min rescue therapy with norepinephrine or additional AVP allowed,</P>
<P>both for 48 hours to achieve MAP &gt; 70 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Haemodynamic parameters, organ dysfunction, creatinine clearance based on 2-hour collection 24 hours after randomization, ICU mortality</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dobutamine allowed if cardiac index &lt; 3 L/min/m<SUP>2</SUP>
</P>
<P>Funding: not reported</P>
<P>Conflicts of interest: not declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Levy-1997">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult surgical and medical participants with septic shock<BR/>(N = 30)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed epinephrine vs norepinephrine + fixed dobutamine (5 mcg/kg/min)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Survival (not further clarified); haemodynamics, tonometry</P>
<P>For the mortality analysis, we used data on undetermined mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:10:31 +0100" MODIFIED_BY="Jane Cracknell">
<P>It is unclear when participants died</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Levy-2011">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with cardiogenic shock. Mean age 65 years, 30% female, SAP II score 51, SOFA score 8.5</P>
<P>acute or chronic heart failure with EF &lt; 30% or CI &lt; 2.2 L/min/m<SUP>2 </SUP>and systolic blood pressure: &lt; 90 mm Hg; MAP &lt; 60 mm Hg or drop in MAP &gt; 30 mm Hg despite dobutamine up to 10 µg/kg/min and dopamine up to 20 µg/kg/min (N = 30)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Epinephrine (mean dose 0.15 µg/kg/min at 24 hours for 5 days) vs</P>
<P>norepinephrine (mean dose 0.13 µg/kg/min at 24 hours) + dobutamine (8 ± 2 µg/kg/min for 5 days)</P>
<P>Target MAP between 65 and 70 mm Hg and stable CI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Mortality 28 days. Vasopressor titration, haemodynamic, metabolic, splanchnic and renal parameters at baseline, 1, 6, 12 and 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Before study: Start with dobutamine up to 10 µg/kg/min, then dopamine up to 2 to 20 µg/kg/min, then start study drug and concomitantly stop dopamine. Dobutamine stopped in the epinephrine group</P>
<P>Funding: not reported</P>
<P>Conflits of interest: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Luckner-2006">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; Austria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult post-operative participants (major surgery or cardiac surgery) with MAP &lt; 65 mm Hg and norepinephrine support &gt; 0.5 mcg/kg/min</P>
<P>Mean age = 69 years, 39% female</P>
<P>Modified Goris score = 12.3 (N = 18)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Arginine-vasopressin infusion 4 U/h and norepinephrine infusion to achieve and maintain MAP &gt; 65 mm Hg</P>
<P>vs</P>
<P>Norepinephrine infusion to achieve and maintain MAP &gt; 65 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Cutaneous vascular reactivity and flow motion at 1 hour (primary), haemodynamics, metabolic variables, ICU mortality</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>One study author has received a grant from Aguettant Laboratories, Lyon, France - a company that has applied for registration of vasopressin with European authorities No personal conflict of interest</P>
<P>Funding: not declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Malay-1999">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, general hospital; USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult surgical and trauma participants with septic shock<BR/>(N = 10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Fixed dose of vasopressin (0.04 U/min) vs placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>24-Hour mortality</P>
<P>For the mortality analysis, we used data on 24-hour mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:12:18 +0100" MODIFIED_BY="Jane Cracknell">
<P>Funding: not reported</P>
<P>Conflict of interest. not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Marik-1994">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock; unclear whether medical or surgical<BR/>(N = 20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed norepinephrine (to achieve MAP &gt; 75 mm Hg) vs dopamine ("... and in case of dopamine &#8230; to keep pulse rate &lt; 150/min")<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Death</P>
<P>For the mortality analysis, we used data on undetermined mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:12:54 +0100" MODIFIED_BY="Jane Cracknell">
<P>It is unclear when participants died</P>
<P>Funding: not reported</P>
<P>Confict of interest: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Martin-1993">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock; unclear whether medical or surgical<BR/>(N = 32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed dopamine (max 25 mcg/kg/min; if goal not reached, addition of norepinephrine) vs norepinephrine (max 5 mcg/kg/min; if goal not reached, addition of dopamine)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Hospital mortality</P>
<P>For the mortality analysis, we used data on hospital mortality.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:13:27 +0100" MODIFIED_BY="Jane Cracknell">
<P>Funding: not reported</P>
<P>Conflict of interest: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Mathur-2007">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (study authors' definition)</P>
<P>Mean age = 54 years, 36% female</P>
<P>APACHE II score = 25 (N = 50)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dopamine infusion 10 mcg/kg/min, increased by 2.5 mcg/kg/min every 15 minutes (up to 25 mcg/kg/min) to achieve goal</P>
<P>vs</P>
<P>Norepinephrine infusion 0.5 mcg/kg/min, increased by 0.25 mcg/kg/min every 15 minutes (up to 2.5 mcg/kg/min) to achieve goal</P>
<P>Goal (to be achieved and maintained for 6 hours): SBP &gt; 90 mm Hg and SVRI &gt; 1100 dynes*s/cm<SUP>5</SUP>*m<SUP>2</SUP> and CI &gt; 4 L/min/m<SUP>2</SUP> and IDO<SUB>2</SUB> &gt; 550 mL/min/m<SUP>2</SUP> and IVO<SUB>2</SUB> &gt; 150 mL/min/m<SUP>2</SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Haemodynamic parameters, haemodynamic response (goal achieved), urine output, mortality</P>
<P>For the mortality analysis, we used data on undetermined mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:14:07 +0100" MODIFIED_BY="Jane Cracknell">
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Morelli-2008a">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre open-label randomized controlled pilot study, University hospital; Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (<LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK> <LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>) and norepinephrine support &gt; 0.9 mcg/kg/min</P>
<P>Mean age = 66 years, 27% female</P>
<P>SAPS score = 60 (N = 59)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<UL>
<LI>Norepinephrine infusion incrementally to achieve MAP 65 to 75</LI>
</UL>
<P>vs</P>
<UL>
<LI>Terlipressin 1 mg (bolus) and norepinephrine infusion to achieve MAP 65 to 75</LI>
</UL>
<P>vs</P>
<UL>
<LI>Terlipressin 1 mg (bolus) and dobutamine infusion 3 mcg/kg/min (increasing by 1 to 3 mcg/kg/min up to 20 mcg/kg/min to maintain mixed venous oxygen saturation at baseline) and norepinephrine infusion to achieve MAP 65 to 75</LI>
</UL>
<P>We used comparisons 1 vs 2 and 1 vs 3, but not 2 vs 3, because this is virtually a comparison of dobutamine vs control. Dobutamine is not considered a vasopressor</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Organ dysfunction, urine output 2 and 4 hours after study start, haemodynamics, vasopressor requirements, ICU LOS, ICU mortality</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:15:17 +0100" MODIFIED_BY="Jane Cracknell">
<P>This study was funded by an independent research grant from the Department of Anesthesiology and Intensive Care of the University of Rome, &#8216;La Sapienza&#8217; </P>
<P>Conflict of interest: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Morelli-2008b">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre double-blind randomized controlled study, University hospital; Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (Surviving Sepsis Campaign 2008 criteria; <LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>)</P>
<P>Mean age = 70 years, 34% female</P>
<P>Simplifies APACHE II score = 56 (N = 32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Norepinephrine infusion to achieve MAP 65 to 75 mm Hg</P>
<P>vs</P>
<P>Phenylephrine infusion to achieve MAP 65 to 75 mm Hg</P>
<P>For both arms, explicit dosing schemes are not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Plasma disappearance rate of indocyanine green (PDR) and blood clearance of indocyanine green (CBI) (primary), haemodynamics, organ function, ICU LOS, ICU mortality Creatinine clearance and urine output presented only graphically, P values reported</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Noradrenaline dose at baseline was 0.8 ± 0.7 mcg/kg/min</P>
<P>Dobutamine was added to achieve mixed venous oxygen saturation &gt; 64% if necessary</P>
<P>Funding: The present study was funded by an independent research grant from the Department of Anesthesiology and Intensive Care of the University of Rome 'La Sapienza'</P>
<P>Conflict of interest: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Morelli-2009">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (Surviving Sepsis Campaign criteria 2008; <LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>)</P>
<P>Mean age 66 years, 27% female</P>
<P>SAPS II score = 60 (N = 45)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Terlipressin infusion 1.3 mcg/kg/h</P>
<P>vs</P>
<P>Arginine-vasopressin infusion 0.03 U/min</P>
<P>vs</P>
<P>Norepinephrine infusion 15 mcg/min</P>
<P>For all groups, open-label norepinephrine was added to achieve MAP 65 to 75 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Norepinephrine requirements (primary), haemodynamics, metabolic parameters, blood gas, cytokine levels, ICU mortality, ICU LOS, adverse events, renal replacement therapy, creatinine clearance and urine output at 48 hours (data presented in a graph only, with intragroup comparisons)</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Funding: This study was funded by an independent research grant from the Department of Anesthesiology and Intensive Care of the University of Rome 'La Sapienza'</P>
<P>Conflict of interest: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Myburgh-2008">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre double-blind randomized controlled trial, 4 multi-disciplinary university hospital ICUs; Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult ICU participants requiring vasopressors for any reason</P>
<P>Mean age = 60 years, 39% female</P>
<P>APACHE II score = 22 (N = 280)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Switch from the vasopressor at inclusion to</P>
<UL>
<LI>Epinephrine (no dosing scheme reported)</LI>
</UL>
<P>or</P>
<UL>
<LI>Norepinephrine (no dosing scheme reported)</LI>
</UL>
<P>To achieve MAP &gt; 70 mm Hg (or individualized by treating physicians), no restriction on other vasopressors except study drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Time to achieve MAP goal, drug-free days from randomization (primary); mortality at days 28, 90</P>
<P>For the mortality analysis, we used data on 90-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Subgroup analysis: septic shock, circulatory failure</P>
<P>22 patients withdrawn by treating physicians for adverse events</P>
<P>Funding for statistical analysis of this study from the Australian and New Zealand College of Anaesthetists (Project grant: 06/024). Financial contribution from participating institutions that provided substantial support from internal funds</P>
<P>Conflict of interest: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Patel-2010">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre prospective quasi-randomized open-label clinical trial in a medical intensive care unit, University hospital; USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult fluid-resuscitated participants with septic shock</P>
<P>Age not stated, 54% female</P>
<P>APACHE II score = 28</P>
<P>SOFA score = 12, (N = 252)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dopamine 5 to 20 mcg/kg/min to pre-determined max of 20 mcg/kg/min</P>
<P>vs</P>
<P>Norepinephrine 5 to 20 mcg/min, to pre-determined max of 20 mcg/kg/min</P>
<P>as the initial vasopressor</P>
<P>If haemodynamic goal was not achieved (MAP &gt; 60 mm Hg and/or SBP &gt; 90 mm Hg): add (1) vasopressin 0.04 U/min and (2) phenylephrine (25 to 200 mcg/min)</P>
<P>If ScvO<SUB>2</SUB> &lt; 70%: add dobutamine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Primary: all-cause 28 day mortality. Secondary: organ dysfunction, hospital and ICU LOS and safety (primarily occurrence of arrhythmias)</P>
<P>For the mortality analysis, we used data on 28-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>SOFA score as secondary outcome not explicitly presented</P>
<P>Funding: The dopamine vs norepinephrine trial was not funded</P>
<P>Conflict of interest: None of the authors has any financial involvement nor commercial association that might pose a real or perceived conflict of interest in connection with this study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Ruokonen-1993">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomised controlled trial, University hospital; Finland<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult, medical participants with septic shock<BR/>(N = 10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed norepinephrine vs dopamine</P>
<P>Participants in the norepinephrine group received additional low-dose dopamine (not considered a vasopressor)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Death</P>
<P>For the mortality analysis, we used data on undetermined mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:22:05 +0100" MODIFIED_BY="Jane Cracknell">
<P>It is unclear when participants died; duration of the intervention is unclear</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Russell-2008">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Multi-centre double-blind randomized controlled trial, University hospitals (VASST study); Canada, Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock defined by <LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK> criteria (<LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>)</P>
<P>Mean age 61 years, 39% female</P>
<P>APACHE score = 27 (N = 778)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressine infusion 0.01 U/min, increased by 0.005 U/min every 10 minutes (max 0.03 U/min) until MAP 65 to 75 mm Hg</P>
<P>vs</P>
<P>Norepinephrine infusion 5 mcg/min, increased by 2.5 mcg/min every 10 minutes (max 15 mcg/min) until MAP 65 to 75 mm Hg</P>
<P>Additional open-label vasopressors allowed if MAP not reached at maximum doses of study drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>28-Day mortality (primary), 90-day mortality, days alive and organ dysfunction free (renal replacement therapy, mechanical ventilation) until day 28, days alive and free of SIRS until day 28, days alive and free of corticosteroids until day 28, ICU LOS and hospital, serious adverse events</P>
<P>For the mortality analysis, we used data on 90-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Funding: supported by a grant (MCT 44152) from the Canadian Institutes of Health Research</P>
<P>Drs Russell, Walley and Gordon report serving as officers and</P>
<P>holding stock in Sirius Genomics, which has submitted a patent, owned by the University of British Columbia and licenced to Sirius Genomics that is related to the genetics of vasopressin. The University of British Columbia has also submitted a patent related to use of vasopressin in septic shock. Drs Russell, Walley and Gordon report that they are inventors on this patent. Drs Russell and Walley report that they received consulting fees from Ferring, which manufactures vasopressin. Dr Russell reported that he received grant support from Sirius Genomics, Novartis and Eli Lilly; and Dr Wally, from Sirius Genomics. No other potential conflict of interest relevant to this article was reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Seguin-2002">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock; unclear whether medical or surgical<BR/>(N = 22)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Goal-directed epinephrine vs norepinephrine + fixed dobutamine (5 mcg/kg/min)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Death</P>
<P>For the mortality analysis, we used data on undetermined mortality<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>It is unclear when participants died</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Seguin-2006">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital; France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult participants with septic shock (study authors' definition)</P>
<P>Mean age = 66 years, 23% female</P>
<P>SAPS II score = 54, SOFA score = 10 (N = 22)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Dopexamine (DX) infusion 0.5 mcg/kg/min and norepinephrine (NE) infusion 0.2 mcg/kg/min</P>
<P>If cardiac index &gt; 3 L/kg/min, NE increased by 0.2 mcg/kg/min every 3 minutes until MAP 70 to 80 mm Hg</P>
<P>If cardiac index &lt; 3 L/kg/min, DX increased by 0.5 mcg/kg/min every 3 minutes until MAP 70 to 80 mm Hg</P>
<P>vs</P>
<P>Epinephrine infusion 0.2 mcg/kg/min. Increased by 0.2 mcg/kg/min every 3 minutes until MAP 70 to 80 mm Hg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Gastromucosal blood flow (primary), haemodynamics, 28-day mortality, 90-day mortality</P>
<P>For the mortality analysis, we used data on 90-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Funding: This study was supported by Grant from Rennes University Hospital and Rennes 1 University, 2001 Clinical Research Program, Rennes, France</P>
<P>Conflict of interest: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Svoboda-2012">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, community hospital; Czech Republic</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult patients with late advanced refractory septic shock, with blood pressure &lt; 90 mm Hg systolic or &lt; 70 mm Hg mean, who need norepinephrine &gt; 0,6 µg/kg/min for longer than 24 hours after adequate volume resuscitation unless CVP &gt; 12 mm Hg. Mean age = 73 years, 40% female. SOFA score 18, MODS 14 (N = 30)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Terlipressin (4 mg/24 h) vs 'no terlipressin'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Mortality at day 3, day 7, day 14, day 28, day 90; haemodynamic response, norepinephrine requirement, changes in MODS and SOFA score, differences in laboratory variables and safety of treatment (serious adverse events)</P>
<UL>
<LI>Arrhythmias</LI>
<LI>CV events</LI>
<LI>Limb/skin ischaemia</LI>
<LI>Hepatosplanchnic ischaemia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 01:24:40 +0100" MODIFIED_BY="Jane Cracknell">
<P>Both groups received &#8220;conventional open label norepinephrine&#8221;</P>
<P>Grant of IGA MZ CR NR 9284-3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Yildizdas-2008">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Single-centre randomized controlled trial, University hospital PICU (Paediatric Intensive Care Unit); Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Paediatric participants with septic shock (<LINK REF="REF-Hayden-1994" TYPE="REFERENCE">Hayden 1994</LINK>; <LINK REF="REF-ACCP_x002f_SCCM-1992" TYPE="REFERENCE">ACCP/SCCM 1992</LINK>) and non-response to fluid resuscitation and high-dose catecholamines</P>
<P>Mean age = 28 months, 47% female</P>
<P>PRISM score = 29 (N = 58)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Terlipressin bolus 20 mcg/kg every 6 hours up to 96 hours (if MAP &lt; 2 SD for age and at discretion of treating physicians)</P>
<P>vs</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>ICU mortality, ICU LOS, biochemical markers, mechanical ventilation, haemodynamics, adverse events (digital ischaemias). Urine output narratively described as unchanged within the intervention group, but no numbers or between-group comparisons presented)</P>
<P>For the mortality analysis, we used data on ICU mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Placebo administration not described in sufficient detail</P>
<P>Funding: not reported</P>
<P>Conflict of interest: not declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACCP/SCCM = American College of Chest Physicians/Society of Critical Care Medicine; APACHE´= Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; AVP = arginine-vasopressin; CBI = blood clearance of indocyanine green; CI = cardiac index; CV = cardiovascular; EF = ejection fraction; h = hour; ICU = intensive care unit; IDO<SUB>2</SUB> = index of oxygen delivery; IVO<SUB>2 </SUB>= oxygen consumption, indexed; LOS = length of stay; MAP = mean arterial pressure; MODS = multiple organ dysfunction score; NE = norepinephrine; PCCU = Paediatric Critical Care Unit; PELOD = paediatric logistic organ dysfunction score; PICU = paediatric intensive care unit; PRISM = Paediatric Risk of Mortality score; RCT = randomized controlled trial; SAPS = simplified acute physiology score; SBP = systolic blood pressure; ScvO<SUB>2</SUB> = central venous oxygen saturation; SIRS = systemic Inflammatory response syndrome; SOFA = sequential organ failure assessment; SOAP = sepsis occurrence in acutely ill patients; SVRI = systemic vascular resistance index; TNFa = tumour necrosis factor alpha; U = units; VASST (study) = Vasopressin And Septic Shock Trial; VEGF = vascular endothelial growth factor; 2SD = standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Argenziano-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: vasodilatory shock after left ventricular assist device placement)</P>
<P>Intervention: vasopressin or saline placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hentschel-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints and other population</P>
<P>(study population: hypotensive pre-term infants)</P>
<P>Intervention: dobutamine or dopamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Kinstner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adult patients with septic shock)</P>
<P>Intervention: arginine-vasopressin or placebo</P>
<P>Study population: adults with septic shock</P>
<P>NB: published only as abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Levy-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adult patients with septic shock)</P>
<P>Intervention: dobutamine or dopexamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Majerus-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adult patients after abdominal surgery with septic shock)</P>
<P>Intervention: dopamine or dobutamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 11:16:53 +0000" MODIFIED_BY="Harald Herkner" STUDY_ID="STD-Morelli-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 11:16:53 +0000" MODIFIED_BY="Harald Herkner">
<P>No relevant endpoints</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-16 11:16:47 +0000" MODIFIED_BY="Harald Herkner" STUDY_ID="STD-Morelli-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-16 11:16:47 +0000" MODIFIED_BY="Harald Herkner">
<P>No relevant endpoints</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Patel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adult patients with severe septic shock)</P>
<P>Intervention: norepinephrine or vasopressin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Roz_x00e9_-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Other population</P>
<P>(study population: pre-term infants with refractory shock)</P>
<P>Intervention: dopamine vs dobutamine<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Schmoelz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Participants with septic shock treated with norepinephrine received dopexamine (2 mcg/kg/min), dopamine (3 mcg/kg/min) or saline placebo</P>
<P>Comparison between dopamine and saline placebo as add-on therapy was initially considered relevant. However, the dopamine dose (3 mcg/kg/min) is not considered to have vasopressor properties and accordingly does not fulfil our inclusion criteria for vasopressor vs placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Sperry-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Data from a multi-centre prospective cohort study in patients with blunt injury and haemorrhagic shock, not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Totaro-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adult patients with hypotension after cardiopulmonary bypass)</P>
<P>Intervention: epinephrine or norepinephrine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Zhou-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>No relevant endpoints</P>
<P>(study population: adults with septic shock)</P>
<P>Intervention: norepinephrine, epinephrine and norepinephrine-dobutamine in a cross-over fashion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Agrawal-2011">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Chawla-2014">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Chen-2012">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Cohn-2007">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Randomized placebo-controlled parallel-group efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Age 18+, systolic blood pressure &lt; 90 mm Hg, clinical evidence of acute traumatic injury, infusion of study drug within 1 hour after shock onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressin bolus 4 U, followed by continuous infusion 2.4 U/h for 5 hours</P>
<P>vs</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-16 11:33:40 +0000" MODIFIED_BY="Harald Herkner">
<P>Organ dysfunction, 28-day mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Estimated enrolment: 333 participants</P>
<P>NCT00420407</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-29 14:51:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hai-Bo-2002">
<CHAR_METHODS MODIFIED="2010-06-29 14:50:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 14:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 14:50:58 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 14:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 14:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hajjar-2013">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-High-2008">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Hussain-2014">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Liu-2010">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Oliveira-2014">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Plotkin-2007">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-29 14:51:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1966">
<CHAR_METHODS MODIFIED="2010-06-29 14:51:02 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 14:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 14:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 14:51:05 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 14:51:06 +0100" MODIFIED_BY="[Empty name]">
<P>Not available</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Ventura-2014">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Wu-2010">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Zambolim-2014">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Zhuangyu-2011">
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Study report under retrieval</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Choudhary-2013">
<CHAR_STUDY_NAME MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>A Prospective Open Label Randomized Non Inferiority Trial to Compare the Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Prospective open-label randomized non-inferiority trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Patients of cirrhosis with septic shock admitted to intensive care unit</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>Terlipressin versus noradrenaline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>Mortality, organ failure, LOS, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>April 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>drashokdm@hotmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>NCT01836224</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Fernandez-2006">
<CHAR_STUDY_NAME MODIFIED="2009-11-18 14:21:17 +0000" MODIFIED_BY="[Empty name]">
<P>Terlipressin in Septic Shock in Cirrhosis; Effects on Survival of Terlipressin Administration in Cirrhotic Patients With Severe Sepsis or Septic Shock. A Randomized, Open Labelled Controlled Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Treatment, randomized, open-label, uncontrolled, single group assignment, safety/efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-18 14:25:37 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with liver cirrhosis and septic shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Terlipressin 1, 1.5 and 2 mg/4 h intravenously in patients with body weight &lt; 50 kg, between 50 and 70 kg and &gt; 70 kg, respectively, until 24 hours after shock resolution + dopamine (1 to 20 µg/kg/min) and/or norepinephrine (0.05 to 4 µg/kg/min) until shock resolution</P>
<P>vs</P>
<P>Dopamine (1 to 20 µg/kg/min) and/or norepinephrine (0.05 to 4 µg/kg/min) until shock resolution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Hospital survival (primary), refractory shock, variceal bleeding, hepatorenal syndrome</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-11-18 14:23:08 +0000" MODIFIED_BY="[Empty name]">
<P>October 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Javier Fernandez, MD; <A HREF="mailto:Jfdez%40clinic.ub.es?subject=NCT00628160,%2005-SS-JFDEZ-1,%20Terlipressin%20in%20Septic%20Shock%20in%20Cirrhosis">Jfdez@clinic.ub.es</A>; Hospital Clinic Barcelona, Catalonia, Spain</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-01-29 08:15:39 +0000" MODIFIED_BY="[Empty name]">
<P>NCT00628160</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Gordon-2014">
<CHAR_STUDY_NAME MODIFIED="2015-03-16 11:10:09 +0000" MODIFIED_BY="Harald Herkner">
<P>VAsopressin vs Noradrenaline as Initial therapy in Septic sHock</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Double-blind factorial (2 × 2) randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult patients with septic shock, being treated in 19 intensive care units (ICUs) in the UK<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressin or noradrenaline (Study Drug 1) by continuous infusion to stabilize blood pressure. If maximum limit of Study Drug 1 is reached, then Study Drug 2 (hydrocortisone or placebo) will be administered</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Renal failure-free days at day 28 post randomization, renal outcomes, survival, other organ failure, biomarkers</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-15 01:31:22 +0100" MODIFIED_BY="Jane Cracknell">
<P>01/10/2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-16 11:10:08 +0000" MODIFIED_BY="Harald Herkner">
<P>http://www.vanishtrial.co.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>ISRCTN20769191; EudraCT number <A HREF="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005363-24">2011-005363-24</A>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Lienhart-2007">
<CHAR_STUDY_NAME MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressin for the Therapy of Persistent Traumatic Hemorrhagic Shock. The VITRIS.at Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>European multi-centre randomized controlled study in the pre-hospital emergency medical helicopter setting</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Adult pre-hospital traumatic haemorrhagic shock despite standard treatment within 60 minutes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Vasopressin (10IU IV) vs saline placebo up to 3 injections at least 5 minutes apart</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-29 08:17:30 +0000" MODIFIED_BY="[Empty name]">
<P>Hospital admission rate (primary), haemodynamics, fluid requirements, hospital discharge rate</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>January 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-11-18 10:43:03 +0000" MODIFIED_BY="[Empty name]">
<P>www.vitris.at</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-16 11:10:08 +0000" MODIFIED_BY="Harald Herkner">
<P>NCT 00379522</P>
<P>EudraCT-number 2006-004252-20</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-NOVEL-2015">
<CHAR_STUDY_NAME MODIFIED="2015-12-04 09:20:06 +0000" MODIFIED_BY="Harald Herkner">
<P>NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock (NOVEL)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Open-label, non-randomized</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-04 09:20:06 +0000" MODIFIED_BY="Harald Herkner">
<P>Individuals with septic shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain target mean arterial pressure (65 to 75 mm Hg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-04 09:20:06 +0000" MODIFIED_BY="Harald Herkner">
<P>Time to goal MAP</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-04 09:20:06 +0000" MODIFIED_BY="Harald Herkner">
<P>November 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Drayton Hammond, PharmD</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-12-04 09:20:06 +0000" MODIFIED_BY="Harald Herkner"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" STUDY_ID="STD-Vasoactive-Drugs-in-Intensive-Care-Unit--2015">
<CHAR_STUDY_NAME MODIFIED="2015-12-04 09:21:23 +0000" MODIFIED_BY="Harald Herkner">
<P>Vasoactive Drugs in Intensive Care Unit</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Randomized parallel-group double-blind controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-04 09:22:55 +0000" MODIFIED_BY="Harald Herkner">
<P>ICU patients with shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>Phenylephrine and vasopressin vs norepinephrine and epinephrine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-04 09:24:55 +0000" MODIFIED_BY="Harald Herkner">
<P>Hospital mortality (primary), haemodynamics, length of stay, ICU complications, functional status</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-04 09:25:04 +0000" MODIFIED_BY="Harald Herkner">
<P>May 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<P>John P. Kress, MD, University of Chicago</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-12-04 09:19:26 +0000" MODIFIED_BY="Harald Herkner"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ICU = intensive care unit</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Computer-generated randomization schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:37:09 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Computer randomization sequence, stratified by centre, 1:1, blocks of 6</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-29 03:14:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Implicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:38:14 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Computer randomization sequence, 1:1, stratified by centre, permuted blocks within strata</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Computer-generated permuted blocks of 6 to 10, stratified to centres</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>'patients were randomly assigned into an AVP group and an NE group'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Computer-generated random list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Adaequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Computer-generated block randomization list, stratified by centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>'According to a randomization code'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Randomization code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Random number-generating computer programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:56:11 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>'according to the randomization code'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>'were randomly allocated into two groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Computer-based procedure reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Computer-based procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Computer-based procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:05:21 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Random number generator (StatMate, GraphPad), stratified by centre in invariable blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 06:48:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Even and odd calender day enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>'patients received in random order ...'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Computer-generated procedure, stratified by centre and severity of shock, variable permutated blocks (size 2 to 6)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Appropriately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Computer-generated random treatment list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:25:37 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Open random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Unclear whether allocation was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Double-blind, double-dummy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:35:51 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 06:39:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Central telephone-based randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:44:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:16:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-15 01:07:30 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>No details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 15:47:04 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-15 01:09:19 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:45:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Sequentially numbered opaque sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:09:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-15 01:11:10 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Consecutive patients, &#8230;according to the randomization code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>No sufficient detail reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:53:31 +0000" MODIFIED_BY="Harald Herkner" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Pharmacy controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:12:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 14:59:44 +0000" MODIFIED_BY="Harald Herkner" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Not reported in sufficient detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>No means to conceal the allocation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Double-blind study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-01 15:03:31 +0000" MODIFIED_BY="Harald Herkner" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>No concealment procedure reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Independently prepared double-blind study drugs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 06:49:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Central telephone-based allocation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Appropriately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Opaque sealed numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:52:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Open random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-18 10:05:35 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" NO="14">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" NO="15">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>All participants were followed to day 28; data on outcomes during stay in hospital were available for 1656 participants (98.6%), along with data on 6-month outcomes for 1443 participants (85.9%) and data on 12-month outcomes for 1036 participants (61.7%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Complete follow-up during study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-15 01:09:19 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Three participants in each group excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-15 01:10:02 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Three participants died during study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-15 01:10:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Complete follow-up for study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Complete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-15 01:13:01 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Complete outcome data</P>
<P>One participant in each group did not respond to therapy and died during the study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Complete data not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Complete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Completely reported, open-label therapy after 12h</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Complete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Reported explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Completely reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Complete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Midway through the trial, the executive committee, unaware of all data and in conference with the data and safety monitoring committee, determined that participants who had undergone randomization but had never received an infusion would not be included in the primary analysis, as their omission would be equally distributed between groups, would be unrelated to treatment assignment and would not bias outcome ascertainment. We increased the total number of participants enrolled to maintain target sample size after removal of such participants from the analysis</P>
<P>3 participants withdrew consent after receiving study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Appropriately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Outcome data complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Implicitly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7">
<NAME>Explicit in-/exclusion criteria</NAME>
<DESCRIPTION>
<P>Are explicit inclusion and exclusion criteria for study patient described?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:07:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Implicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Only high-level information given </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 10:08:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Explicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:46:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>No sufficient detail reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="8">
<NAME>ITT-analysis</NAME>
<DESCRIPTION>
<P>Was the effect of the intervention assessed in an intention-to-treat analysis?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Appropriately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:14:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Post-randomization exclusions in 6 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:10:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Analysis was performed 'as treated'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:12:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>One participant with inappropriate noradrenaline dosing excluded from the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Excluded from analysis were participants who did not survive 3 hours after start of study drug infusion (also for mortality estimates)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="9">
<NAME>Adequate patient description</NAME>
<DESCRIPTION>
<P>Was sufficient detail given to allow for adequate judgement of the study population?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Appropriately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Only high-level information on aetiology given </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-15 01:10:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>No sufficient detail reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Described adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Described adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:49:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>But age not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="10">
<NAME>Identical care</NAME>
<DESCRIPTION>
<P>Was patient care identical for the study groups except for the described study intervention?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>For only 6 hours</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:14:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:16:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Open-label intervention; no treatment protocol presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 15:47:05 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Open-label intervention, no treatment protocol presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 08:06:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Groups differ in steroid therapy and baseline vasopressor support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:11:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Open-label intervention, no treatment protocol presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:46:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>No sufficient detail reported, in particular on catecholamine therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:12:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:13:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 15:36:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Not reported in sufficient detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:49:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Sufficient detail not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>Described adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Open-label intervention. Open-label norepinephrine to maintain goal MAP. Target blood pressure determined by the doctor in charge for each individual participant, usually 70 ± 5 mm Hg</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:52:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Catecholamine therapy not described in sufficient detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="11">
<NAME>Outcome description</NAME>
<DESCRIPTION>
<P>Were study outcomes described in sufficient detail?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Implicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:09:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Implicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Time to survival not reported, several post-randomization exclusions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 09:18:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Only implicitly described, no primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:11:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Implicit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:13:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Implicit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 11:47:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Implicitly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 15:36:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Not reported in sufficient detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Only primary outcome described in the Methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>Adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="12">
<NAME>Physicians blinded</NAME>
<DESCRIPTION>
<P>Was treating staff sufficiently blinded to the intervention?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:14:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:44:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Identical syringes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:44:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Identical syringes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:09:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-29 04:52:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Not reported, but from indirect information high risk was assumed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:11:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Not reported/not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:13:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:48:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Not explicitly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="13">
<NAME>Outcome assessors blinded?</NAME>
<DESCRIPTION>
<P>Were the outcome assessors blinded to the study group allocation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Albanese-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Annane-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:14:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boccara-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Choong-2009">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-De-Backer-2010">
<DESCRIPTION>
<P>Appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:09:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x00fc_nser-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Han-2012">
<DESCRIPTION>
<P>Low risk for mortality outcomes, high risk for other outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 15:47:06 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Hua-2013">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Jain-2010">
<DESCRIPTION>
<P>Outcomes were assessed by another physician blinded to the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="NO" STUDY_ID="STD-Lauzier-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:11:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2011">
<DESCRIPTION>
<P>Low risk for mortality, unclear risk for other outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luckner-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Malay-1999">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:13:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marik-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Martin-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Mathur-2007">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 15:36:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2008a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Morelli-2008b">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-2009">
<DESCRIPTION>
<P>Not explicitly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Myburgh-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-2010">
<DESCRIPTION>
<P>But not explicitly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-18 10:15:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ruokonen-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-Russell-2008">
<DESCRIPTION>
<P>Performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2002">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Seguin-2006">
<DESCRIPTION>
<P>No sufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" RESULT="UNKNOWN" STUDY_ID="STD-Svoboda-2012">
<DESCRIPTION>
<P>Low risk for mortality, high risk for adverse outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-24 10:52:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yildizdas-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2015-04-28 16:00:33 +0100" MODIFIED_BY="Harald Herkner" NO="16">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Dopamine compared with norepinephrine for hypotensive shock</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Dopamine compared with norepinephrine for hypotensive shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>hypotensive shock<BR/>
<B>Settings: </B>critical care units<BR/>
<B>Intervention: </B>dopamine<BR/>
<B>Comparison: </B>norepinephrine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Norepinephrine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Dopamine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Total mortality<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.07<BR/>(0.99 to 1.16)<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1400<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH<SUP>d,e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>380 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>407 per 1000<BR/>(376 to 441)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Arrhythmia &lt; BR/&gt; follow-up: <BR/>range 28 days</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>f,g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 2.33<BR/>(1.45 to 3.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1931<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH<SUP>h</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>76 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>177 per 1000<BR/>(110 to 293)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>The largest study reported 12-month mortality, one study reported 28-day mortality and one hospital mortality. For the remaining 3 studies, the time point of mortality assessment was undetermined. A sensitivity analysis indicates no influence on effects by differences in mortality definition<BR/>
<SUP>b</SUP>
<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>
</P>
<P>
<SUP>c</SUP>Estimate from the network meta-analysis integrating direct and indirect comparisons<BR/>
<SUP>d</SUP>Four smaller studies included up to 50 participants, each of whom did not fulfil some of the quality criteria and one high risk of bias study that contributed 252 participants. However, the summary result is mainly made up by the largest study of more than 1000 participants that fulfils all low risk of bias criteria<BR/>
<SUP>e</SUP>The main outcomes of the four smaller studies are haemodynamics and metabolic measures. Mortality is reported only at the end of the results and often is unclear timepoint-wise. However, the study by <LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK> (which contributes mainly to the summary result) clearly defines mortality endpoints<BR/>
<SUP>f</SUP>
<LINK REF="REF-Reinelt-2001" TYPE="REFERENCE">Reinelt 2001</LINK>
<BR/>
<SUP>g</SUP>
<LINK REF="REF-Annane-2008" TYPE="REFERENCE">Annane 2008</LINK>
<BR/>
<SUP>h</SUP>Information was obtained from 992 participants, 86% of whom were studied in a low risk of bias study (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>); remaining participants were included in a high risk of bias study (<LINK REF="STD-Patel-2010" TYPE="STUDY">Patel 2010</LINK>). Effects show into the same direction</P>
<P>

</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Terlipressin compared with norepinephrine for hypotensive shock</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Terlipressin compared with norepinephrine for hypotensive shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>hypotensive shock<BR/>
<B>Settings: </B>critical care units<BR/>
<B>Intervention: </B>terlipressin<BR/>
<B>Comparison: </B>norepinephrine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Norepinephrine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Terlipressin</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Total mortality<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.93<BR/>(0.69 to 1.26)<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>231<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>380 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>353 per 1000<BR/>(262 to 479)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI: </B>Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Direct comparisons based on in-hospital mortality and mortality at an undetermined point in time. A sensitivity analysis indicates no influence on effects by differences in mortality definition.<BR/>
<SUP>b</SUP>
<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>
</P>
<P>
<SUP>c</SUP>Estimate from the network meta-analysis integrating direct and indirect comparisons</P>
<P>
<SUP>d</SUP>Risk of bias was serious with adequate allocation concealment in one small study that contributed to the estimates only; imprecision of the estimates was very serious, as direct comparisons are based on two small studies only, whereas only one contributed to the estimates</P>
<P>

</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Vasopressin compared with norepinephrine for hypotensive shock</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Vasopressin compared with norepinephrine for hypotensive shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>hypotensive shock<BR/>
<B>Settings: </B>critical care units<BR/>
<B>Intervention: </B>vasopressin<BR/>
<B>Comparison: </B>norepinephrine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Norepinephrine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vasopressin</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Total mortality<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.90<BR/>(0.78 to 1.03)<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1108<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>380 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>342 per 1000<BR/>(296 to 391)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI: </B>Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>For the direct comparison, the largest study reported 90-day mortality, and 2 studies contributed ICU mortality. A sensitivity analysis indicates no influence on effects by differences in mortality definition<BR/>
<SUP>b</SUP>
<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>
</P>
<P>
<SUP>c</SUP>Estimate from the network meta-analysis integrating direct and indirect comparisons</P>
<P>
<SUP>d</SUP>The effect is based mainly on 1 moderately large RCT, and direct evidence comes from 3 RCTS including 812 individuals overall</P>
<P>

</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" READONLY="YES">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Phenylephrine compared with norepinephrine for hypotensive shock</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Phenylephrine compared with norepinephrine for hypotensive shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>hypotensive shock<BR/>
<B>Settings: </B>critical care units<BR/>
<B>Intervention: </B>phenylephrine<BR/>
<B>Comparison: </B>norepinephrine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Norepinephrine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Phenylephrine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Total mortality<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.08<BR/>(0.76 to 1.55)<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>86<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>VERY LOW<SUP>d,e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>380 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>410 per 1000<BR/>(289 to 589)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI: </B>Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>For the direct comparison, one study measured ICU mortality; for the other study, the time point of mortality assessment was undetermined<BR/>
<SUP>b</SUP>
<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>
</P>
<P>
<SUP>c</SUP>Estimate from the network meta-analysis integrating direct and indirect comparisons</P>
<P>
<SUP>d</SUP>Two small studies, with 1 having unclear allocation concealment and an open intervention</P>
<P>
<SUP>e</SUP>Two small studies with 86 individuals overall for the direct comparison</P>
<P>

</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" READONLY="YES">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Epinephrine compared with norepinephrine for hypotensive shock</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Epinephrine compared with norepinephrine for hypotensive shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>hypotensive shock<BR/>
<B>Settings: </B>critical care units<BR/>
<B>Intervention: </B>epinephrine<BR/>
<B>Comparison: </B>norepinephrine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Norepinephrine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Epinephrine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Total mortality<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.88<BR/>(0.63 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>269<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>380 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>334 per 1000<BR/>(239 to 475)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI: </B>Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>90-Day mortality<BR/>
<SUP>b</SUP>
<LINK REF="REF-Sakr-2006" TYPE="REFERENCE">Sakr 2006</LINK>
</P>
<P>
<SUP>c</SUP>Effect from only 1 moderately large single RCT</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Morbidity outcomes - measures of renal function comparing several vasopressor regimens (each single vasopressor is compared with other available vasopressor regimens)</TITLE>
<TABLE COLS="4" ROWS="14">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vasopressor</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Comparator (Reference)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Effect*</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>Norepinephrine</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Vasopressin (<LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P>Vasopressin (<LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Creatinine clearance</P>
<P>  </P>
<P> </P>
<P/>
<P>Days alive free of renal replacement therapy</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54 mL min<SUP>-1</SUP>1.73 m<SUP>-2 </SUP>± 38 vs 122 mL min<SUP>-1</SUP>1.73m<SUP>-2 </SUP>± 66 , P value &lt; 0.001</P>
<P> </P>
<P>(23 (IQR 5 to 28) vs 25 (IQR 6 to 28), P value = 0.64)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norepinephrine + terlipressin + dobutamine</P>
<P>(<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urine output 4 hours after study start</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96 mL/h ± 48 vs 130 mL/h ± 76 (P value &lt; 0.05)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norepinephrine + terlipressin</P>
<P>(<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urine output 4 hours after study start</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>96 mL/h ± 48 vs 147 mL/h ± 119 (P value = 0.08)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dopamine (<LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P>Dopamine (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Post-treatment urine output</P>
<P> </P>
<P> </P>
<P> </P>
<P>Days free of renal support within 28 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.17 mL/kg/h ± 0.47 vs 0.81 mL/kg/h ± 0.75, P value &lt; 0.05</P>
<P> </P>
<P/>
<P>14.0 ± 12.3 days vs 12.8 ± 12.4 days, P value = 0.07 </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Phenylephrine (<LINK REF="STD-Morelli-2008b" TYPE="STUDY">Morelli 2008b</LINK>)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Creatinine clearance</P>
<P>Urine output</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No difference (P value = 0.61)</P>
<P>No difference (P value = 0.17)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Terlipressin (<LINK REF="STD-Boccara-2003" TYPE="STUDY">Boccara 2003</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Renal failure post-operatively</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(0/10 vs 0/10)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Terlipressin + norepinephrine and vasopressin + norepinephrine</P>
<P>(<LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Need for renal replacement therapy</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(8/15 vs 4/15 vs 5/15, P value = 0.29)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Epinephrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> Norepinephrine + dobutamine (<LINK REF="STD-Levy-1997" TYPE="STUDY">Levy 1997</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Oliguria reversal</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9/12 vs 10/11</P>
<P>RR 0.36 (95% CI 0.04 to 3.00)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Vasopressin</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norepinephrine (<LINK REF="STD-Lauzier-2006" TYPE="STUDY">Lauzier 2006</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P>Norepinephrine (<LINK REF="STD-Russell-2008" TYPE="STUDY">Russell 2008</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P>Norepinephrine vs terlipressin (<LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Creatinine clearance</P>
<P> </P>
<P> </P>
<P> </P>
<P>Days alive free of renal replacement therapy</P>
<P> </P>
<P> </P>
<P>Need for renal replacement therapy</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>122 mL min<SUP>-1</SUP>1.73m<SUP>-2 </SUP>± 66 vs 54 mL min<SUP>-1</SUP>1.73m<SUP>-2 </SUP>± 38, P value &lt; 0.001</P>
<P> </P>
<P>25 (IQR 6 to 28) vs 23 (IQR 5 to 28), P value = 0.64</P>
<P> </P>
<P> </P>
<P> </P>
<P>8/15 vs 4/15 vs 5/15, P value = 0.29</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo/non-protocol vasoactive drugs (<LINK REF="STD-Choong-2009" TYPE="STUDY">Choong 2009</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P>Placebo/non-protocol vasoactive drugs (<LINK REF="STD-Malay-1999" TYPE="STUDY">Malay 1999</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urine output</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P>Creatinine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.7 mL/kg/h (IQR 0.7 to 3.5) vs 1.5 mL/kg/h (IQR 0.7 to 3.7), P value = 0.65</P>
<P> </P>
<P/>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Terlipressin</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norepinephrine vs vasopressin (<LINK REF="STD-Morelli-2009" TYPE="STUDY">Morelli 2009</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Need for renal replacement therapy</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/15 vs 4/15 vs 5/15, P value = 0.29</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo/non-protocol vasoactive drugs in patients taking norepinephrine (<LINK REF="STD-Morelli-2008a" TYPE="STUDY">Morelli 2008a</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urine output 4 hours after study start</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>147 mL/h ± 119 vs 96 mL/h ± 48 (P value = 0.08)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dopamine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Norepinephrine (<LINK REF="STD-Mathur-2007" TYPE="STUDY">Mathur 2007</LINK>)</P>
<P> </P>
<P> </P>
<P> </P>
<P>Norepinephrine (<LINK REF="STD-De-Backer-2010" TYPE="STUDY">De Backer 2010</LINK>)</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Post-treatment urine output</P>
<P> </P>
<P> </P>
<P>Days free of renal support within 28 days</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.81 mL/kg/h ± 0.75 vs 1.17 mL/kg/h ± 0.47, P value &lt; 0.05</P>
<P> </P>
<P>12.8 ± 12.4 days vs 14.0 ± 12.3 days, P value = 0.07</P>
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*All effects are presented as outcomes in the vasopressor group (left hand column) versus comparator (second column) with risk ratio or P value for differences between groups</P>
<P>CI = confidence interval</P>
<P>IQR = 25% to 75% interquartile range</P>
<P>N/A = not applicable</P>
<P>RR = risk ratio</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<COMPARISON ID="CMP-001" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<NAME>Norepinephrine</NAME>
<DICH_OUTCOME CHI2="9.514380607451685" CI_END="1.0495184319430053" CI_START="0.9154300725819935" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9801840308481491" ESTIMABLE="YES" EVENTS_1="670" EVENTS_2="708" I2="0.0" I2_Q="32.39765060290981" ID="CMP-001.01" LOG_CI_END="0.020990070189353456" LOG_CI_START="-0.038374824766603664" LOG_EFFECT_SIZE="-0.008692377288625118" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6584803273744362" P_Q="0.20543672738387497" P_Z="0.565990110376204" Q="5.91695412315385" RANDOM="YES" SCALE="3.23" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1275" TOTAL_2="1332" WEIGHT="500.0" Z="0.5739670368617267">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Norepinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours norepinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2950075033085504" CI_END="1.0125934863357613" CI_START="0.858555530241147" DF="5" EFFECT_SIZE="0.9323989154754155" ESTIMABLE="YES" EVENTS_1="400" EVENTS_2="454" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.005435129393371685" LOG_CI_START="-0.06623160999941756" LOG_EFFECT_SIZE="-0.030398240303022947" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6546061832464369" P_Z="0.09637634530831175" STUDIES="6" TAU2="0.0" TOTAL_1="681" TOTAL_2="719" WEIGHT="100.0" Z="1.6626808109903648">
<NAME>Norepinephrine vs dopamine</NAME>
<DICH_DATA CI_END="3.0860393758160356" CI_START="0.5760709962774482" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.48940146307208326" LOG_CI_START="-0.23952398985548332" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2010-02-12 14:11:00 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-Ruokonen-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="0.9666495677467114"/>
<DICH_DATA CI_END="1.3718869430927787" CI_START="0.35717228920871935" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.13731832273075364" LOG_CI_START="-0.4471222427022401" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-02-12 14:11:20 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.34330328116279757" STUDY_ID="STD-Martin-1993" TOTAL_1="16" TOTAL_2="16" VAR="0.11785714285714285" WEIGHT="1.5036771053837723"/>
<DICH_DATA CI_END="1.8548992636322397" CI_START="0.3743839129487778" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.26832032881004214" LOG_CI_START="-0.4266828209052918" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-02-12 14:11:00 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Marik-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="1.0633145245213815"/>
<DICH_DATA CI_END="1.111849431883921" CI_START="0.48831817737109395" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.04604597849655581" LOG_CI_START="-0.31129710904573776" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2014-05-21 08:19:49 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.2099050984991547" STUDY_ID="STD-Mathur-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.044060150375939834" WEIGHT="4.022207956807277"/>
<DICH_DATA CI_END="1.0441563991574272" CI_START="0.8710846949021381" EFFECT_SIZE="0.9537026047936341" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="349" LOG_CI_END="0.01876555441704762" LOG_CI_START="-0.0599396168173456" LOG_EFFECT_SIZE="-0.020587031200148983" MODIFIED="2010-03-24 14:23:18 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.046231807179963544" STUDY_ID="STD-De-Backer-2010" TOTAL_1="507" TOTAL_2="529" VAR="0.0021373799951253285" WEIGHT="82.9141696022278"/>
<DICH_DATA CI_END="1.1292600099150885" CI_START="0.6616714256800023" EFFECT_SIZE="0.864406779661017" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="67" LOG_CI_END="0.05279394889614589" LOG_CI_START="-0.17935761998456146" LOG_EFFECT_SIZE="-0.06328183554420781" MODIFIED="2015-04-27 15:26:41 +0100" MODIFIED_BY="Harald Herkner" ORDER="94" O_E="0.0" SE="0.13636698072932701" STUDY_ID="STD-Patel-2010" TOTAL_1="118" TOTAL_2="134" VAR="0.018595953433232643" WEIGHT="9.529981243313067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5984456803496063" CI_START="0.7992966777913383" DF="0" EFFECT_SIZE="1.1303239898070623" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.20369788231852334" LOG_CI_START="-0.0972919921344492" LOG_EFFECT_SIZE="0.05320294509203708" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.4883810126587207" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="135" WEIGHT="100.0" Z="0.6928861407139929">
<NAME>Norepinephrine vs epinephrine</NAME>
<DICH_DATA CI_END="1.5984456803496063" CI_START="0.7992966777913383" EFFECT_SIZE="1.1303239898070623" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" LOG_CI_END="0.20369788231852334" LOG_CI_START="-0.0972919921344492" LOG_EFFECT_SIZE="0.05320294509203708" MODIFIED="2010-02-12 14:24:17 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.17680294217758383" STUDY_ID="STD-Myburgh-2008" TOTAL_1="134" TOTAL_2="135" VAR="0.03125928036265005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1315266092423184" CI_START="0.3002542859305412" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="0.6553898727617942" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4462871026284195">
<NAME>Norepinephrine vs terlipressin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-12 14:13:54 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.0" STUDY_ID="STD-Boccara-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-02-12 14:14:07 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Albanese-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24975974353766633" CI_END="1.2940944709572186" CI_START="0.9754696877825001" DF="2" EFFECT_SIZE="1.123543470251907" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="182" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.1119659816787567" LOG_CI_START="-0.010786221536845247" LOG_EFFECT_SIZE="0.05058988007095572" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.8826029264778886" P_Z="0.10619805079921388" STUDIES="3" TAU2="0.0" TOTAL_1="397" TOTAL_2="415" WEIGHT="100.0" Z="1.6155203788419048">
<NAME>Norepinephrine vs vasopressin</NAME>
<DICH_DATA CI_END="1.6410942610357304" CI_START="0.7289581658429516" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.21513352673986003" LOG_CI_START="-0.13729739467912067" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2010-06-22 09:46:06 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Luckner-2006" TOTAL_1="8" TOTAL_2="10" VAR="0.042857142857142844" WEIGHT="12.13139045401984"/>
<DICH_DATA CI_END="6.1945337025816185" CI_START="0.06820529523052236" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7920086201523427" LOG_CI_START="-1.1661819068666315" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2010-02-12 14:27:17 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Lauzier-2006" TOTAL_1="10" TOTAL_2="13" VAR="1.323076923076923" WEIGHT="0.3929603220155927"/>
<DICH_DATA CI_END="1.3149196148494726" CI_START="0.971971016948821" EFFECT_SIZE="1.1305148186782843" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="172" LOG_CI_END="0.11889920385666389" LOG_CI_START="-0.01234668503963225" LOG_EFFECT_SIZE="0.053276259408515825" MODIFIED="2010-02-12 14:26:24 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.07709448481531224" STUDY_ID="STD-Russell-2008" TOTAL_1="379" TOTAL_2="392" VAR="0.0059435595889384095" WEIGHT="87.47564922396457"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.011806967482214962" CI_END="1.3215270287718375" CI_START="0.6442171049420025" DF="1" EFFECT_SIZE="0.922686467104617" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.12107605004542077" LOG_CI_START="-0.1909677481855233" LOG_EFFECT_SIZE="-0.034945849070051285" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.9134722732912802" P_Z="0.6606662194889216" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.43899353856590073">
<NAME>Norepinephrine vs phenylephrine</NAME>
<DICH_DATA CI_END="1.5996501245803938" CI_START="0.5063607269823907" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.20402500416841649" LOG_CI_START="-0.29553998528976677" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2010-02-17 11:50:28 +0000" MODIFIED_BY="[Empty name]" ORDER="502" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Morelli-2008b" TOTAL_1="16" TOTAL_2="16" VAR="0.08611111111111111" WEIGHT="39.01639344262295"/>
<DICH_DATA CI_END="1.485127351190087" CI_START="0.5918053083432206" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.1717636964462921" LOG_CI_START="-0.2278211436467792" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-05-14 13:02:50 +0100" MODIFIED_BY="Harald Herkner" ORDER="231" O_E="0.0" SE="0.23471811304752896" STUDY_ID="STD-Jain-2010" TOTAL_1="27" TOTAL_2="27" VAR="0.05509259259259258" WEIGHT="60.98360655737706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1276453505031834" CI_END="0.7732358529306079" CI_START="-0.4911681356374765" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1410338586465657" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.8898615342965565" P_Q="0.8857867141630088" P_Z="0.6619404206679237" Q="0.6461675479523187" RANDOM="YES" SCALE="15.82" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1357" TOTAL_2="1424" UNITS="" WEIGHT="400.0" Z="0.4372357032201773">
<NAME>LOS ICU</NAME>
<GROUP_LABEL_1>Norepinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours norepinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4007426172718898" CI_START="-1.4007426172718898" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="1.0" P_Z="0.4142719492223581" STUDIES="1" TAU2="0.0" TOTAL_1="382" TOTAL_2="396" WEIGHT="99.99999999999999" Z="0.8163990468779535">
<NAME>Norepinephrine vs vasopressin</NAME>
<CONT_DATA CI_END="3.4007426172718898" CI_START="-1.4007426172718898" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="15.0" MODIFIED="2010-02-17 11:05:59 +0000" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="17.8" SD_2="16.3" SE="1.2248911899446322" STUDY_ID="STD-Russell-2008" TOTAL_1="382" TOTAL_2="396" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.1979503230456165" CI_START="-7.1979503230456165" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.7518296345285751" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.31622776601683794">
<NAME>Norepinephrine vs norepinephrine + terlipressin + dobutamine</NAME>
<CONT_DATA CI_END="5.1979503230456165" CI_START="-7.1979503230456165" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="15.0" MODIFIED="2010-02-17 11:11:54 +0000" MODIFIED_BY="[Empty name]" ORDER="497" SD_1="10.0" SD_2="10.0" SE="3.1622776601683795" STUDY_ID="STD-Morelli-2008a" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.272725657389394" CI_START="-8.272725657389394" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Norepinephrine vs phenylephrine</NAME>
<CONT_DATA CI_END="8.272725657389394" CI_START="-8.272725657389394" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="16.0" MODIFIED="2010-02-17 11:49:50 +0000" MODIFIED_BY="[Empty name]" ORDER="501" SD_1="10.4" SD_2="13.3" SE="4.220855955845923" STUDY_ID="STD-Morelli-2008b" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4814778025508647" CI_END="0.7509041699641471" CI_START="-0.5713514799369851" DF="1" EFFECT_SIZE="0.08977634501358102" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.4877537357060481" P_Z="0.7901245833263106" STUDIES="2" TAU2="0.0" TOTAL_1="939" TOTAL_2="992" WEIGHT="100.0" Z="0.266148838771712">
<NAME>Norepinephrine vs dopamine</NAME>
<CONT_DATA CI_END="0.7080924052731382" CI_START="-0.7080924052731382" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" MODIFIED="2011-01-25 15:38:55 +0000" MODIFIED_BY="Harald Herkner" ORDER="51" SD_1="7.4" SD_2="7.4" SE="0.36127827391650086" STUDY_ID="STD-De-Backer-2010" TOTAL_1="821" TOTAL_2="858" WEIGHT="87.17480785520272"/>
<CONT_DATA CI_END="2.546092659997978" CI_START="-1.1460926599979775" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="6.8" MODIFIED="2010-06-23 14:27:44 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="7.6" SD_2="7.3" SE="0.9419013178607979" STUDY_ID="STD-Patel-2010" TOTAL_1="118" TOTAL_2="134" WEIGHT="12.825192144797287"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6655485780712052" CI_END="2.2911409874793804" CI_START="-0.9648747124116541" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6631331375338632" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2015-12-21 09:30:34 +0000" MODIFIED_BY="Harald Herkner" NO="3" P_CHI2="0.414608207694271" P_Q="1.0" P_Z="0.42466848649057154" Q="0.0" RANDOM="YES" SCALE="95.79" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="939" TOTAL_2="992" UNITS="" WEIGHT="100.0" Z="0.7983481569606157">
<NAME>LOS hospital</NAME>
<GROUP_LABEL_1>Norepinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Dopamine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours norepinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8180750946202195" CI_START="-0.8180750946202195" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="11.0" MODIFIED="2010-06-24 08:59:15 +0100" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="19.0" SD_2="19.0" SE="0.9276063789747995" STUDY_ID="STD-De-Backer-2010" TOTAL_1="821" TOTAL_2="858" WEIGHT="80.1843022078743"/>
<CONT_DATA CI_END="2.957226092032408" CI_START="-4.357226092032406" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="14.2" MODIFIED="2010-06-24 08:57:55 +0100" MODIFIED_BY="[Empty name]" ORDER="193" SD_1="13.3" SD_2="16.3" SE="1.8659659671708968" STUDY_ID="STD-Patel-2010" TOTAL_1="118" TOTAL_2="134" WEIGHT="19.815697792125707"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8903425999577737" CI_END="0.6871132374875855" CI_START="0.26472270314450513" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42649088336573615" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="258" I2="65.40202535109127" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.1629716845366141" LOG_CI_START="-0.5772088111445597" LOG_EFFECT_SIZE="-0.37009024784058686" METHOD="MH" MODIFIED="2015-12-21 09:31:00 +0000" MODIFIED_BY="Harald Herkner" NO="4" P_CHI2="0.08911210834012906" P_Q="1.0" P_Z="4.614922740836978E-4" Q="0.0" RANDOM="YES" SCALE="14.96" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08256115086444953" TOTALS="YES" TOTAL_1="939" TOTAL_2="992" WEIGHT="100.0" Z="3.5021658378949336">
<NAME>Arrhythmia</NAME>
<GROUP_LABEL_1>Norepinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Dopamine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours norepinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6397197323050865" CI_START="0.4145321006748881" EFFECT_SIZE="0.5149605465233279" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="207" LOG_CI_END="-0.1940102531607447" LOG_CI_START="-0.38244183277072624" LOG_EFFECT_SIZE="-0.2882260429657355" MODIFIED="2010-06-24 09:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.11068564261426546" STUDY_ID="STD-De-Backer-2010" TOTAL_1="821" TOTAL_2="858" VAR="0.012251311480932897" WEIGHT="62.44645937595462"/>
<DICH_DATA CI_END="0.5333911823941261" CI_START="0.1821861965451398" EFFECT_SIZE="0.31173147224991693" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="51" LOG_CI_END="-0.2729541680035238" LOG_CI_START="-0.7394845307185082" LOG_EFFECT_SIZE="-0.5062193493610161" MODIFIED="2010-06-24 09:43:01 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.2740422444213222" STUDY_ID="STD-Patel-2010" TOTAL_1="118" TOTAL_2="134" VAR="0.07509915172747571" WEIGHT="37.553540624045375"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2">
<NAME>Epinephrine</NAME>
<DICH_OUTCOME CHI2="1.619747571016569" CI_END="1.1942595185980485" CI_START="0.855167086593847" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0105896462741262" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="151" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.0770987114233703" LOG_CI_START="-0.06794902246923047" LOG_EFFECT_SIZE="0.00457484447706994" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.898851078039826" P_Q="0.5522560106640438" P_Z="0.9016038192450977" Q="1.1874879254178428" RANDOM="YES" SCALE="8.27" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="347" TOTAL_2="356" WEIGHT="300.0" Z="0.12363558077464623">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2510999079381344" CI_START="0.625607746508648" DF="0" EFFECT_SIZE="0.8847020933977455" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.0972919921344492" LOG_CI_START="-0.20369788231852334" LOG_EFFECT_SIZE="-0.05320294509203709" MODIFIED="2010-06-29 09:35:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4883810126587206" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="134" WEIGHT="100.0" Z="0.6928861407139931">
<NAME>Epinephrine vs norepinephrine</NAME>
<DICH_DATA CI_END="1.2510999079381344" CI_START="0.625607746508648" EFFECT_SIZE="0.8847020933977455" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.0972919921344492" LOG_CI_START="-0.20369788231852334" LOG_EFFECT_SIZE="-0.05320294509203709" MODIFIED="2010-02-15 08:39:09 +0000" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.1768029421775838" STUDY_ID="STD-Myburgh-2008" TOTAL_1="135" TOTAL_2="134" VAR="0.03125928036265004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.42393456099015037" CI_END="1.2630125382394612" CI_START="0.858773660646273" DF="3" EFFECT_SIZE="1.0414614255487542" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="102" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.10140766192602144" LOG_CI_START="-0.0661212842304343" LOG_EFFECT_SIZE="0.017643188847793624" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.9352550000586629" P_Z="0.6797353059802329" STUDIES="4" TAU2="0.0" TOTAL_1="202" TOTAL_2="210" WEIGHT="100.0" Z="0.41282435671528417">
<NAME>Epinephrine vs norepinephrine + dobutamine</NAME>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-02-16 10:42:11 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Levy-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="9.422273229413147"/>
<DICH_DATA CI_END="2.2074737659003936" CI_START="0.2899241702829271" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.34389555102994734" LOG_CI_START="-0.5377155770460601" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-02-16 10:42:20 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.5178627406773132" STUDY_ID="STD-Seguin-2002" TOTAL_1="11" TOTAL_2="11" VAR="0.2681818181818182" WEIGHT="3.610984184906922"/>
<DICH_DATA CI_END="1.2804583768591487" CI_START="0.8403823298065782" EFFECT_SIZE="1.0373401534526854" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="85" LOG_CI_END="0.10736546566724224" LOG_CI_START="-0.07552308780841675" LOG_EFFECT_SIZE="0.015921188929412734" MODIFIED="2010-02-16 10:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.10742964162454251" STUDY_ID="STD-Annane-2007" TOTAL_1="161" TOTAL_2="169" VAR="0.011541127899577636" WEIGHT="83.90863636209848"/>
<DICH_DATA CI_END="3.766239014647583" CI_START="0.4148701115152691" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-05-14 14:53:00 +0100" MODIFIED_BY="Harald Herkner" ORDER="349" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Levy-2011" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="3.05810622358146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.526715482911022" CI_START="0.4632045937439141" DF="0" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.7424671075377625" LOG_CI_START="-0.3342271422259129" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="0.45739633205779673" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0" Z="0.7431409884809256">
<NAME>Epinephrine vs norepinephrine + dopexamine</NAME>
<DICH_DATA CI_END="5.5267154829110225" CI_START="0.46320459374391415" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7424671075377625" LOG_CI_START="-0.3342271422259128" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2010-02-15 08:42:48 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Seguin-2006" TOTAL_1="10" TOTAL_2="12" VAR="0.39999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3">
<NAME>Vasopressin</NAME>
<DICH_OUTCOME CHI2="4.468582190329238" CI_END="1.0223734234783264" CI_START="0.7966214867327971" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9024658645108988" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="261" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.009609551508058381" LOG_CI_START="-0.09874798383726108" LOG_EFFECT_SIZE="-0.04456921616460133" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.8125681820201252" P_Q="0.7909008722399098" P_Z="0.10689012425391246" Q="0.46916575609180977" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="575" TOTAL_2="563" WEIGHT="300.0" Z="1.6123301111162145">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Vasopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vasopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.773122740762109" CI_END="1.2243746452255027" CI_START="0.6914471499337631" DF="4" EFFECT_SIZE="0.9201034501034848" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="58" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.08791432749776709" LOG_CI_START="-0.1602410091472778" LOG_EFFECT_SIZE="-0.03616334082475539" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.43758024724217637" P_Z="0.5678330460949942" STUDIES="5" TAU2="0.0" TOTAL_1="145" TOTAL_2="151" WEIGHT="100.00000000000001" Z="0.5712457893142219">
<NAME>Vasopressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="3.3474131138717054" CI_START="0.01194952598896136" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5247093131953876" LOG_CI_START="-1.922649321867425" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-02-15 10:24:29 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.4375905768565218" STUDY_ID="STD-Malay-1999" TOTAL_1="5" TOTAL_2="5" VAR="2.066666666666667" WEIGHT="1.0281394127858963"/>
<DICH_DATA CI_END="2.4150608909565046" CI_START="0.41406823477810606" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38292808509706755" LOG_CI_START="-0.38292808509706755" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-22 12:07:21 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.4498677054212187" STUDY_ID="STD-D_x00fc_nser-2003" TOTAL_1="24" TOTAL_2="24" VAR="0.20238095238095238" WEIGHT="10.499117768213623"/>
<DICH_DATA CI_END="5.095551572170946" CI_START="0.7407821948395711" EFFECT_SIZE="1.9428571428571428" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7071912014503718" LOG_CI_START="-0.13030946473845045" LOG_EFFECT_SIZE="0.28844086835596067" MODIFIED="2010-02-15 10:27:22 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.4919520370144727" STUDY_ID="STD-Choong-2009" TOTAL_1="35" TOTAL_2="34" VAR="0.2420168067226891" WEIGHT="8.779644198535117"/>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-06-25 14:49:07 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="23.179870397354755"/>
<DICH_DATA CI_END="1.2844432648108726" CI_START="0.600637741055175" EFFECT_SIZE="0.8783422459893048" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.10871492578901966" LOG_CI_START="-0.22138738239838085" LOG_EFFECT_SIZE="-0.0563362283046806" MODIFIED="2014-10-29 11:43:11 +0000" MODIFIED_BY="Harald Herkner" ORDER="102" O_E="0.0" SE="0.19390372986205795" STUDY_ID="STD-Han-2012" TOTAL_1="66" TOTAL_2="73" VAR="0.03759865645441794" WEIGHT="56.51322822311062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3452615705961373" CI_START="0.5569197335406775" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.7158064239433396" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.36406908278664474">
<NAME>Vasopressin vs terlipressin</NAME>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-02-16 10:55:46 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24975974353766653" CI_END="1.0251471804042047" CI_START="0.7727411115977629" DF="2" EFFECT_SIZE="0.8900412191223828" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="196" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.010786221536845192" LOG_CI_START="-0.11196598167875667" LOG_EFFECT_SIZE="-0.05058988007095579" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.8826029264778885" P_Z="0.10619805079921349" STUDIES="3" TAU2="0.0" TOTAL_1="415" TOTAL_2="397" WEIGHT="100.00000000000001" Z="1.6155203788419066">
<NAME>Vasopressin vs norepinephrine</NAME>
<DICH_DATA CI_END="14.661618230962407" CI_START="0.16143265143318902" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1661819068666315" LOG_CI_START="-0.7920086201523426" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2010-02-15 10:24:55 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Lauzier-2006" TOTAL_1="13" TOTAL_2="10" VAR="1.323076923076923" WEIGHT="0.3929603220155927"/>
<DICH_DATA CI_END="1.3718208353474188" CI_START="0.6093495198556591" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.13729739467912072" LOG_CI_START="-0.21513352673986" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2010-02-15 10:26:52 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Luckner-2006" TOTAL_1="10" TOTAL_2="8" VAR="0.042857142857142844" WEIGHT="12.13139045401984"/>
<DICH_DATA CI_END="1.0288372621841817" CI_START="0.7605027628357924" EFFECT_SIZE="0.884552757273122" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="188" LOG_CI_END="0.01234668503963221" LOG_CI_START="-0.11889920385666389" LOG_EFFECT_SIZE="-0.05327625940851585" MODIFIED="2010-02-15 10:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.07709448481531224" STUDY_ID="STD-Russell-2008" TOTAL_1="392" TOTAL_2="379" VAR="0.005943559588938409" WEIGHT="87.47564922396458"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="16.11" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="527" TOTAL_2="519" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>LOS ICU</NAME>
<GROUP_LABEL_1>vasopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vasopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Vasopressin vs terlipressin</NAME>
<CONT_DATA CI_END="13.213148968098976" CI_START="-7.2131489680989755" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="14.0" MODIFIED="2010-02-16 10:57:26 +0000" MODIFIED_BY="[Empty name]" ORDER="173" SD_1="16.3" SD_2="11.9" SE="5.21088604110024" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="396" TOTAL_2="382" WEIGHT="0.0" Z="0.0">
<NAME>Vasopressin vs norepinephrine</NAME>
<CONT_DATA CI_END="1.4007426172718898" CI_START="-3.4007426172718898" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="16.0" MODIFIED="2010-02-15 10:31:58 +0000" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="16.3" SD_2="17.8" SE="1.2248911899446322" STUDY_ID="STD-Russell-2008" TOTAL_1="396" TOTAL_2="382" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Vasopressin vs placebo/non-protocol vasoactive drugs</NAME>
<CONT_DATA CI_END="3.574657384996016" CI_START="-4.174657384996017" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="8.3" MODIFIED="2010-02-15 10:32:26 +0000" MODIFIED_BY="[Empty name]" ORDER="176" SD_1="7.9" SD_2="8.5" SE="1.9769023387974574" STUDY_ID="STD-Choong-2009" TOTAL_1="35" TOTAL_2="34" WEIGHT="0.0"/>
<CONT_DATA CI_END="10.213148968098976" CI_START="-10.213148968098976" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="17.0" MODIFIED="2010-02-15 10:33:01 +0000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="16.3" SD_2="11.9" SE="5.21088604110024" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.2317535351585072" CI_START="-1.2317535351585072" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" MODIFIED="2014-10-14 14:49:26 +0100" MODIFIED_BY="Harald Herkner" ORDER="103" SD_1="3.7" SD_2="3.7" SE="0.6284572292523851" STUDY_ID="STD-Han-2012" TOTAL_1="66" TOTAL_2="73" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4">
<NAME>Terlipressin</NAME>
<DICH_OUTCOME CHI2="1.6216142975260734" CI_END="1.092379073348962" CI_START="0.8144090126504878" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9432090768043865" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.03837337178981005" LOG_CI_START="-0.08915742886449209" LOG_EFFECT_SIZE="-0.025392028537341" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.9510109430791648" P_Q="0.9405401799530352" P_Z="0.43510986192469436" Q="0.39855824036398974" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" WEIGHT="400.0" Z="0.7804775187212439">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3987223318264401" CI_END="1.1011203669170282" CI_START="0.8075090249754433" DF="3" EFFECT_SIZE="0.9429552661021475" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="60" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.041834795657137776" LOG_CI_START="-0.09285261515768738" LOG_EFFECT_SIZE="-0.02550890975027479" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.705834466135289" P_Z="0.45783983128068717" STUDIES="4" TAU2="0.0" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="0.7424085754259374">
<NAME>Terlipressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="1.3176228633212326" CI_START="0.6611232510912622" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.11979112208162922" LOG_CI_START="-0.17971756883651563" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2010-02-15 08:50:23 +0000" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.17593288763724924" STUDY_ID="STD-Yildizdas-2008" TOTAL_1="30" TOTAL_2="28" VAR="0.030952380952380967" WEIGHT="20.222514274989976"/>
<DICH_DATA CI_END="1.4114857793441096" CI_START="0.5767434927059341" EFFECT_SIZE="0.9022556390977443" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.14967650700756205" LOG_CI_START="-0.23901729684648398" LOG_EFFECT_SIZE="-0.04467039491946099" MODIFIED="2010-02-17 12:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="503" O_E="0.0" SE="0.22832066444922663" STUDY_ID="STD-Morelli-2008a" TOTAL_1="19" TOTAL_2="20" VAR="0.052130325814536346" WEIGHT="12.007117850775304"/>
<DICH_DATA CI_END="1.3390534943022352" CI_START="0.36593011562643585" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.12679792713613944" LOG_CI_START="-0.4366018471076259" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-06-25 14:52:05 +0100" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="0.33094381626464864" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.10952380952380951" WEIGHT="5.715058382062388"/>
<DICH_DATA CI_END="1.194140150142612" CI_START="0.8055237770112587" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.07705530071432441" LOG_CI_START="-0.09392163578805011" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2014-10-29 12:12:55 +0000" MODIFIED_BY="Harald Herkner" ORDER="351" O_E="0.0" SE="0.10043269885098022" STUDY_ID="STD-Svoboda-2012" TOTAL_1="13" TOTAL_2="17" VAR="0.010086726998491682" WEIGHT="62.05530949217234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.330510326941122" CI_START="0.4691473217664706" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.6553898727617942" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4462871026284196">
<NAME>Terlipressin vs norepinephrine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 09:50:35 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.0" STUDY_ID="STD-Boccara-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2010-02-16 11:04:07 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Albanese-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7955908899876678" CI_START="0.42639167099208125" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.2542073933223294" LOG_CI_START="-0.3701912872777029" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="0.7158064239433395" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3640690827866449">
<NAME>Terlipressin vs vasopressin</NAME>
<DICH_DATA CI_END="1.7955908899876678" CI_START="0.42639167099208125" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.2542073933223294" LOG_CI_START="-0.3701912872777029" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-02-15 09:45:46 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8354053603053626" CI_START="0.4171421837150025" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="1.0" P_Z="0.7238703998204219" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.3532908571046114">
<NAME>Terlipressin vs dopamine</NAME>
<DICH_DATA CI_END="1.8354053603053626" CI_START="0.4171421837150025" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-05-12 17:55:54 +0100" MODIFIED_BY="Harald Herkner" ORDER="105" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.6204902861429655" CI_END="0.9264961279213366" CI_START="-3.5367136856270536" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3051087788528586" ESTIMABLE="YES" I2="39.58151394962076" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.15735516764394797" P_Q="0.7766660684032802" P_Z="0.2516937686609574" Q="0.505489609767963" RANDOM="YES" SCALE="16.84" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.724370583270042" TOTALS="SUB" TOTAL_1="95" TOTAL_2="94" UNITS="" WEIGHT="300.0" Z="1.1462451057952798">
<NAME>LOS ICU</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.956424957742852" CI_END="2.8148388202387022" CI_START="-8.609493502449142" DF="2" EFFECT_SIZE="-2.89732734110522" ESTIMABLE="YES" I2="59.64833489760336" ID="CMP-004.02.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.08389311412917577" P_Z="0.32015776318342193" STUDIES="3" TAU2="15.05979066270878" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.0" Z="0.9941337628479262">
<NAME>Terlipressin vs placebo/non-protocol vasoactive drugs</NAME>
<CONT_DATA CI_END="8.27897272035111" CI_START="-4.278972720351109" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="14.0" MODIFIED="2010-02-15 10:07:37 +0000" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="10.0" SD_2="10.0" SE="3.2036163775859374" STUDY_ID="STD-Morelli-2008a" TOTAL_1="19" TOTAL_2="20" WEIGHT="33.54217415586805"/>
<CONT_DATA CI_END="-2.2283276123033016" CI_START="-11.371672387696696" EFFECT_SIZE="-6.799999999999999" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="20.2" MODIFIED="2010-02-15 10:09:20 +0000" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="7.9" SD_2="9.7" SE="2.3325287728537187" STUDY_ID="STD-Yildizdas-2008" TOTAL_1="30" TOTAL_2="28" WEIGHT="41.43252760259534"/>
<CONT_DATA CI_END="5.516564124093669" CI_START="-11.51656412409367" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="17.0" MODIFIED="2010-06-25 15:01:41 +0100" MODIFIED_BY="[Empty name]" ORDER="472" SD_1="11.9" SD_2="11.9" SE="4.345265622874318" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="25.0252982415366"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.2131489680989755" CI_START="-13.213148968098976" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.5648059249872286" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.5757178292401444">
<NAME>Terlipressin vs vasopressin</NAME>
<CONT_DATA CI_END="7.2131489680989755" CI_START="-13.213148968098976" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="17.0" MODIFIED="2010-02-15 10:06:51 +0000" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="11.9" SD_2="16.3" SE="5.21088604110024" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.602745809763027E-33" CI_END="1.5955891314578108" CI_START="-3.3955891314578115" DF="0" EFFECT_SIZE="-0.9000000000000005" ESTIMABLE="YES" I2="100.0" ID="CMP-004.02.03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Z="0.47966956379554637" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.7068341354153995">
<NAME>Terlipressin vs dopamine</NAME>
<CONT_DATA CI_END="1.5955891314578108" CI_START="-3.3955891314578115" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.4" MODIFIED="2014-10-14 14:55:06 +0100" MODIFIED_BY="Harald Herkner" ORDER="108" SD_1="3.5" SD_2="3.7" SE="1.2732831578246844" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.747714613056853" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>LOS hospital</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs noradrenaline</NAME>
<CONT_DATA CI_END="1.9283495892684799" CI_START="-1.9283495892684799" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" MODIFIED="2014-10-14 15:18:58 +0100" MODIFIED_BY="Harald Herkner" ORDER="243" SD_1="2.2" SD_2="2.2" SE="0.9838699100999075" STUDY_ID="STD-Boccara-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs dopamine</NAME>
<CONT_DATA CI_END="7.01351340922548" CI_START="-3.4135134092254784" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="18.1" MEAN_2="16.3" MODIFIED="2014-05-12 18:07:56 +0100" MODIFIED_BY="Harald Herkner" ORDER="108" SD_1="6.4" SD_2="8.5" SE="2.6600046992439697" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration mechanical ventilation</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs placebo/non-protocol vasoactive drug</NAME>
<CONT_DATA CI_END="0.3481069207359555" CI_START="-1.1481069207359544" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.8" MODIFIED="2014-10-14 15:07:26 +0100" MODIFIED_BY="Harald Herkner" ORDER="242" SD_1="1.4" SD_2="1.5" SE="0.38169421817794963" STUDY_ID="STD-Yildizdas-2008" TOTAL_1="30" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs dopamine</NAME>
<CONT_DATA CI_END="1.1475920228469572" CI_START="-3.147592022846957" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="5.3" MODIFIED="2014-05-12 18:10:06 +0100" MODIFIED_BY="Harald Herkner" ORDER="108" SD_1="2.5" SD_2="3.6" SE="1.0957303500405564" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pressor-free days</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs dopamine</NAME>
<CONT_DATA CI_END="4.7984736507772014" CI_START="-0.19847365077720003" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="10.7" MODIFIED="2014-05-12 18:11:12 +0100" MODIFIED_BY="Harald Herkner" ORDER="108" SD_1="3.4" SD_2="3.8" SE="1.2747548783981961" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="53.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Terlipressin vs placebo/non-protocol vasoactive drug</NAME>
<DICH_DATA CI_END="5.454152632809449" CI_START="0.31353342796290196" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7367272873752065" LOG_CI_START="-0.5037161492323321" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2014-05-14 15:35:03 +0100" MODIFIED_BY="Harald Herkner" ORDER="353" O_E="0.0" SE="0.7286426149573088" STUDY_ID="STD-Svoboda-2012" TOTAL_1="13" TOTAL_2="17" VAR="0.5309200603318249" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5">
<NAME>Dopamine</NAME>
<DICH_OUTCOME CHI2="3.324649393763034" CI_END="1.1650632652692678" CI_START="0.9888335681852702" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0733376289676013" ESTIMABLE="YES" EVENTS_1="462" EVENTS_2="407" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.06634950906275135" LOG_CI_START="-0.0048767988994969196" LOG_EFFECT_SIZE="0.030736355081627222" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.7671340458484587" P_Q="0.8673152805593096" P_Z="0.09072795788649485" Q="0.02791226493150793" RANDOM="YES" SCALE="6.28" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="735" TOTAL_2="697" WEIGHT="100.00000000000001" Z="1.6915701711775895">
<NAME>Total mortality</NAME>
<GROUP_LABEL_1>Dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2950075033085513" CI_END="1.1647470254127008" CI_START="0.987563137126891" DF="5" EFFECT_SIZE="1.0725023199862" ESTIMABLE="YES" EVENTS_1="454" EVENTS_2="400" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.06623160999941756" LOG_CI_START="-0.005435129393371645" LOG_EFFECT_SIZE="0.03039824030302295" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6546061832464367" P_Z="0.09637634530831177" STUDIES="6" TAU2="0.0" TOTAL_1="719" TOTAL_2="681" WEIGHT="98.7746670550981" Z="1.6626808109903646">
<NAME>Dopamine vs norepinephrine</NAME>
<DICH_DATA CI_END="1.73589714889652" CI_START="0.32403993540606457" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.23952398985548337" LOG_CI_START="-0.48940146307208326" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-02-16 10:29:09 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-Ruokonen-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="0.9548048921313589"/>
<DICH_DATA CI_END="2.799769271617916" CI_START="0.7289230392014682" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.44712224270224005" LOG_CI_START="-0.1373183227307537" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2010-02-16 10:29:24 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.34330328116279757" STUDY_ID="STD-Martin-1993" TOTAL_1="16" TOTAL_2="16" VAR="0.11785714285714285" WEIGHT="1.4852520544265573"/>
<DICH_DATA CI_END="2.671054939630425" CI_START="0.53911283464624" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4266828209052918" LOG_CI_START="-0.26832032881004214" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-02-16 10:29:43 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Marik-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="1.050285381344494"/>
<DICH_DATA CI_END="2.0478451270923244" CI_START="0.8994023573008415" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.3112971090457378" LOG_CI_START="-0.04604597849655585" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2014-05-21 08:19:28 +0100" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.2099050984991547" STUDY_ID="STD-Mathur-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.044060150375939834" WEIGHT="3.9729225176000504"/>
<DICH_DATA CI_END="1.5113241424507584" CI_START="0.8855356527459007" EFFECT_SIZE="1.1568627450980393" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="51" LOG_CI_END="0.1793576199845615" LOG_CI_START="-0.052793948896145804" LOG_EFFECT_SIZE="0.06328183554420787" MODIFIED="2010-06-23 10:08:42 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.13636698072932701" STUDY_ID="STD-Patel-2010" TOTAL_1="134" TOTAL_2="118" VAR="0.018595953433232643" WEIGHT="9.413207243495778"/>
<DICH_DATA CI_END="1.1479939962810906" CI_START="0.9577109337326679" EFFECT_SIZE="1.0485448975117184" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="319" LOG_CI_END="0.05993961681734563" LOG_CI_START="-0.01876555441704766" LOG_EFFECT_SIZE="0.020587031200148976" MODIFIED="2010-06-15 10:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.04623180717996354" STUDY_ID="STD-De-Backer-2010" TOTAL_1="529" TOTAL_2="507" VAR="0.002137379995125328" WEIGHT="81.89819496609987"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3972641440723104" CI_START="0.5448387705665338" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.37971588968353065" LOG_CI_START="-0.26373199572815725" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="1.0" P_Z="0.723870399820422" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="1.22533294490191" Z="0.3532908571046112">
<NAME>Dopamine vs terlipressin</NAME>
<DICH_DATA CI_END="2.3972641440723104" CI_START="0.5448387705665338" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37971588968353065" LOG_CI_START="-0.26373199572815725" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-05-12 17:58:02 +0100" MODIFIED_BY="Harald Herkner" ORDER="106" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="1.22533294490191"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8598352388797718" CI_END="0.49617180500376695" CI_START="-0.7819923809075355" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14291028795188426" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.6505627060040511" P_Q="0.538483934161095" P_Z="0.6611809216796187" Q="0.37835743632890695" RANDOM="YES" SCALE="3.2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1008" TOTAL_2="955" UNITS="" WEIGHT="200.0" Z="0.43828331366715184">
<NAME>LOS ICU</NAME>
<GROUP_LABEL_1>Dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4814778025508647" CI_END="0.5713514799369851" CI_START="-0.7509041699641471" DF="1" EFFECT_SIZE="-0.08977634501358102" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.4877537357060481" P_Z="0.7901245833263106" STUDIES="2" TAU2="0.0" TOTAL_1="992" TOTAL_2="939" WEIGHT="100.0" Z="0.266148838771712">
<NAME>Dopamine vs norepinephrine</NAME>
<CONT_DATA CI_END="0.7080924052731382" CI_START="-0.7080924052731382" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" MODIFIED="2015-12-21 10:18:54 +0000" MODIFIED_BY="Harald Herkner" ORDER="190" SD_1="7.4" SD_2="7.4" SE="0.36127827391650086" STUDY_ID="STD-De-Backer-2010" TOTAL_1="858" TOTAL_2="821" WEIGHT="87.17480785520272"/>
<CONT_DATA CI_END="1.1460926599979775" CI_START="-2.546092659997978" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="7.5" MODIFIED="2010-06-24 08:49:16 +0100" MODIFIED_BY="[Empty name]" ORDER="191" SD_1="7.3" SD_2="7.6" SE="0.9419013178607979" STUDY_ID="STD-Patel-2010" TOTAL_1="134" TOTAL_2="118" WEIGHT="12.825192144797287"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.602745809763027E-33" CI_END="1.5955891314578108" CI_START="-3.3955891314578115" DF="0" EFFECT_SIZE="-0.9000000000000005" ESTIMABLE="YES" I2="100.0" ID="CMP-005.02.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.47966956379554637" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.7068341354153995">
<NAME>Dopamine vs terlipressin</NAME>
<CONT_DATA CI_END="1.5955891314578108" CI_START="-3.3955891314578115" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.4" MODIFIED="2014-05-12 17:59:57 +0100" MODIFIED_BY="Harald Herkner" ORDER="107" SD_1="3.5" SD_2="3.7" SE="1.2732831578246844" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8319839647109204" CI_END="0.7898635126481528" CI_START="-2.318144437227024" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7641404622894357" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.6596855749672276" P_Q="0.6832996668609024" P_Z="0.33516598223292005" Q="0.16643538663971508" RANDOM="YES" SCALE="11.66" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1008" TOTAL_2="955" UNITS="" WEIGHT="100.0" Z="0.9637605883712307">
<NAME>LOS hospital</NAME>
<GROUP_LABEL_1>Dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6655485780712052" CI_END="0.9648747124116541" CI_START="-2.2911409874793804" DF="1" EFFECT_SIZE="-0.6631331375338632" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.414608207694271" P_Z="0.42466848649057154" STUDIES="2" TAU2="0.0" TOTAL_1="992" TOTAL_2="939" WEIGHT="91.11528991737316" Z="0.7983481569606157">
<NAME>Dopamine vs norepinephrine</NAME>
<CONT_DATA CI_END="0.8180750946202195" CI_START="-2.8180750946202195" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="12.0" MODIFIED="2010-06-24 09:11:35 +0100" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="19.0" SD_2="19.0" SE="0.9276063789747995" STUDY_ID="STD-De-Backer-2010" TOTAL_1="858" TOTAL_2="821" WEIGHT="73.0601594249273"/>
<CONT_DATA CI_END="4.357226092032406" CI_START="-2.957226092032408" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="14.2" MEAN_2="13.5" MODIFIED="2010-06-24 09:12:06 +0100" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="16.3" SD_2="13.3" SE="1.8659659671708968" STUDY_ID="STD-Patel-2010" TOTAL_1="134" TOTAL_2="118" WEIGHT="18.05513049244585"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.968120353511277E-33" CI_END="3.4135134092254784" CI_START="-7.01351340922548" DF="0" EFFECT_SIZE="-1.800000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-005.03.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.49860232824098283" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.884710082626846" Z="0.6766905338594325">
<NAME>Dopamine vs terlipressin</NAME>
<CONT_DATA CI_END="3.4135134092254784" CI_START="-7.01351340922548" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="18.1" MODIFIED="2014-05-12 18:17:25 +0100" MODIFIED_BY="Harald Herkner" ORDER="112" SD_1="8.5" SD_2="6.4" SE="2.6600046992439697" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.884710082626846"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.26" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="874" TOTAL_2="837" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pressor-free days</NAME>
<GROUP_LABEL_1>dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="858" TOTAL_2="821" WEIGHT="0.0" Z="0.0">
<NAME>Dopamine vs norepinephrine</NAME>
<CONT_DATA CI_END="-0.4136390762295097" CI_START="-2.7863609237704896" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="14.2" MODIFIED="2014-10-14 15:39:38 +0100" MODIFIED_BY="Harald Herkner" ORDER="364" SD_1="12.5" SD_2="12.3" SE="0.6052973080772674" STUDY_ID="STD-De-Backer-2010" TOTAL_1="858" TOTAL_2="821" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.02" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Dopamine vs terlipressin</NAME>
<CONT_DATA CI_END="0.19847365077720003" CI_START="-4.7984736507772014" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="13.0" MODIFIED="2014-05-12 18:21:59 +0100" MODIFIED_BY="Harald Herkner" ORDER="112" SD_1="3.8" SD_2="3.4" SE="1.2747548783981961" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.890342599957776" CI_END="3.7775377333395044" CI_START="1.455364189542437" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.344716004497692" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="116" I2="65.4020253510913" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.5772088111445599" LOG_CI_START="0.162971684536614" LOG_EFFECT_SIZE="0.3700902478405869" METHOD="MH" MODIFIED="2015-12-21 09:37:23 +0000" MODIFIED_BY="Harald Herkner" NO="5" P_CHI2="0.08911210834012862" P_Q="1.0" P_Z="4.6149227408369945E-4" Q="0.0" RANDOM="YES" SCALE="25.27" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08256115086444962" TOTALS="YES" TOTAL_1="992" TOTAL_2="939" WEIGHT="100.0" Z="3.5021658378949327">
<NAME>Arrhythmia</NAME>
<GROUP_LABEL_1>Dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Norepinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4123584117416432" CI_START="1.5631845470777093" EFFECT_SIZE="1.9418963389551624" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="102" LOG_CI_END="0.38244183277072624" LOG_CI_START="0.19401025316074472" LOG_EFFECT_SIZE="0.2882260429657355" MODIFIED="2010-06-24 09:44:43 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.11068564261426544" STUDY_ID="STD-De-Backer-2010" TOTAL_1="858" TOTAL_2="821" VAR="0.012251311480932895" WEIGHT="62.44645937595461"/>
<DICH_DATA CI_END="5.488890041964474" CI_START="1.8747966464527979" EFFECT_SIZE="3.2078891257995736" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="14" LOG_CI_END="0.7394845307185083" LOG_CI_START="0.2729541680035239" LOG_EFFECT_SIZE="0.5062193493610161" MODIFIED="2010-06-24 09:45:02 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.2740422444213222" STUDY_ID="STD-Patel-2010" TOTAL_1="134" TOTAL_2="118" VAR="0.07509915172747571" WEIGHT="37.55354062404538"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6">
<NAME>Sensitivity analysis norepinephrine</NAME>
<DICH_OUTCOME CHI2="9.781855393044287" CI_END="1.067356268238786" CI_START="0.9281989898620797" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9953486876478013" ESTIMABLE="YES" EVENTS_1="667" EVENTS_2="695" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.02830940490221945" LOG_CI_START="-0.03235890854957175" LOG_EFFECT_SIZE="-0.0020247518236761373" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6350916708974701" P_Q="0.6744975313869823" P_Z="0.8959144082980832" Q="4.880879454438195" RANDOM="YES" SCALE="6.666361281753098" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1275" TOTAL_2="1332" WEIGHT="800.0" Z="0.1308241626064141">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Norepinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours norepinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.766850851130736E-30" CI_END="1.0441563991574272" CI_START="0.8710846949021381" DF="0" EFFECT_SIZE="0.9537026047936341" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="349" I2="100.0" ID="CMP-006.01.01" LOG_CI_END="0.01876555441704762" LOG_CI_START="-0.0599396168173456" LOG_EFFECT_SIZE="-0.020587031200148983" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.0" P_Z="0.30520208858312714" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="529" WEIGHT="100.0" Z="1.0253415136021458">
<NAME>Low risk of bias norepinephrine vs dopamine</NAME>
<DICH_DATA CI_END="1.0441563991574272" CI_START="0.8710846949021381" EFFECT_SIZE="0.9537026047936341" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="349" LOG_CI_END="0.01876555441704762" LOG_CI_START="-0.0599396168173456" LOG_EFFECT_SIZE="-0.020587031200148983" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.046231807179963544" STUDY_ID="STD-De-Backer-2010" TOTAL_1="507" TOTAL_2="529" VAR="0.0021373799951253285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.337453209488638" CI_END="1.192817406451482" CI_START="0.7234539221675018" DF="4" EFFECT_SIZE="0.9289501768808658" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="92" I2="7.779985009415742" ID="CMP-006.01.02" LOG_CI_END="0.07657396802933693" LOG_CI_START="-0.14058912451129402" LOG_EFFECT_SIZE="-0.03200757824097855" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.3622587351680695" P_Z="0.5634284904391929" STUDIES="5" TAU2="0.008277969482944946" TOTAL_1="174" TOTAL_2="190" WEIGHT="100.0" Z="0.5777565593741804">
<NAME>No low risk of bias norepinephrine vs dopamine</NAME>
<DICH_DATA CI_END="3.0860393758160356" CI_START="0.5760709962774482" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.48940146307208326" LOG_CI_START="-0.23952398985548332" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-Ruokonen-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="8.492315406227707"/>
<DICH_DATA CI_END="1.3718869430927787" CI_START="0.35717228920871935" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.13731832273075364" LOG_CI_START="-0.4471222427022401" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="0.34330328116279757" STUDY_ID="STD-Martin-1993" TOTAL_1="16" TOTAL_2="16" VAR="0.11785714285714285" WEIGHT="12.900639550125357"/>
<DICH_DATA CI_END="1.8548992636322397" CI_START="0.3743839129487778" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.26832032881004214" LOG_CI_START="-0.4266828209052918" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Marik-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="9.301363304002356"/>
<DICH_DATA CI_END="4.187314111226176" CI_START="0.8026890321172664" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6219355406990772" LOG_CI_START="-0.09545267114991446" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.4213973867690182" STUDY_ID="STD-Mathur-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.17757575757575755" WEIGHT="8.755399445931358"/>
<DICH_DATA CI_END="1.1292600099150885" CI_START="0.6616714256800023" EFFECT_SIZE="0.864406779661017" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="67" LOG_CI_END="0.05279394889614589" LOG_CI_START="-0.17935761998456146" LOG_EFFECT_SIZE="-0.06328183554420781" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.13636698072932701" STUDY_ID="STD-Patel-2010" TOTAL_1="118" TOTAL_2="134" VAR="0.018595953433232643" WEIGHT="60.550282293713224"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5984456803496063" CI_START="0.7992966777913383" DF="0" EFFECT_SIZE="1.1303239898070623" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.20369788231852334" LOG_CI_START="-0.0972919921344492" LOG_EFFECT_SIZE="0.05320294509203708" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="0.4883810126587207" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="135" WEIGHT="100.0" Z="0.6928861407139929">
<NAME>Low risk of bias norepinephrine vs epinephrine</NAME>
<DICH_DATA CI_END="1.5984456803496063" CI_START="0.7992966777913383" EFFECT_SIZE="1.1303239898070623" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" LOG_CI_END="0.20369788231852334" LOG_CI_START="-0.0972919921344492" LOG_EFFECT_SIZE="0.05320294509203708" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.17680294217758383" STUDY_ID="STD-Myburgh-2008" TOTAL_1="134" TOTAL_2="135" VAR="0.03125928036265005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>No low risk of bias norepinephrine vs epinephrine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias norepinephrine vs terlipressin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.0" STUDY_ID="STD-Boccara-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1315266092423184" CI_START="0.3002542859305412" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-006.01.06" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="1.0" P_Z="0.6553898727617942" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.4462871026284195">
<NAME>No low risk of bias norepinephrine vs terlipressin</NAME>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-12-02 08:58:33 +0000" MODIFIED_BY="Harald Herkner" ORDER="272" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Albanese-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2310661209902693" CI_END="1.3112254398058492" CI_START="0.9698962524520144" DF="1" EFFECT_SIZE="1.1277201072018879" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="174" I2="0.0" ID="CMP-006.01.07" LOG_CI_END="0.11767736663026036" LOG_CI_START="-0.013274718720699323" LOG_EFFECT_SIZE="0.05220132395478052" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7" P_CHI2="0.6307344622535991" P_Z="0.11814724528182555" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="405" WEIGHT="100.0" Z="1.5625977184322564">
<NAME>Low risk of bias norepinephrine vs vasopressin</NAME>
<DICH_DATA CI_END="6.1945337025816185" CI_START="0.06820529523052236" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7920086201523427" LOG_CI_START="-1.1661819068666315" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Lauzier-2006" TOTAL_1="10" TOTAL_2="13" VAR="1.323076923076923" WEIGHT="0.44721354309124833"/>
<DICH_DATA CI_END="1.3149196148494726" CI_START="0.971971016948821" EFFECT_SIZE="1.1305148186782843" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="172" LOG_CI_END="0.11889920385666389" LOG_CI_START="-0.01234668503963225" LOG_EFFECT_SIZE="0.053276259408515825" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.07709448481531224" STUDY_ID="STD-Russell-2008" TOTAL_1="379" TOTAL_2="392" VAR="0.0059435595889384095" WEIGHT="99.55278645690875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6410942610357304" CI_START="0.7289581658429516" DF="0" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-006.01.08" LOG_CI_END="0.21513352673986003" LOG_CI_START="-0.13729739467912067" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="8" P_CHI2="1.0" P_Z="0.6651107783092971" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="10" WEIGHT="100.0" Z="0.43286785087052343">
<NAME>No low risk of bias norepinephrine vs vasopressin</NAME>
<DICH_DATA CI_END="1.6410942610357304" CI_START="0.7289581658429516" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.21513352673986003" LOG_CI_START="-0.13729739467912067" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Luckner-2006" TOTAL_1="8" TOTAL_2="10" VAR="0.042857142857142844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5996501245803938" CI_START="0.5063607269823907" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-006.01.09" LOG_CI_END="0.20402500416841649" LOG_CI_START="-0.29553998528976677" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="9" P_CHI2="1.0" P_Z="0.7195617924698765" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.35904451038141366">
<NAME>Low risk of bias norepinephrine vs phenylephrine</NAME>
<DICH_DATA CI_END="1.5996501245803938" CI_START="0.5063607269823907" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.20402500416841649" LOG_CI_START="-0.29553998528976677" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.29344694769431684" STUDY_ID="STD-Morelli-2008b" TOTAL_1="16" TOTAL_2="16" VAR="0.08611111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.485127351190087" CI_START="0.5918053083432206" DF="0" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-006.01.10" LOG_CI_END="0.1717636964462921" LOG_CI_START="-0.2278211436467792" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="10" P_CHI2="1.0" P_Z="0.7833455664298611" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.27496182676154407">
<NAME>No low risk of bias norepinephrine vs phenylephrine</NAME>
<DICH_DATA CI_END="1.485127351190087" CI_START="0.5918053083432206" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.1717636964462921" LOG_CI_START="-0.2278211436467792" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-05-14 13:03:34 +0100" MODIFIED_BY="Harald Herkner" ORDER="231" O_E="0.0" SE="0.23471811304752896" STUDY_ID="STD-Jain-2010" TOTAL_1="27" TOTAL_2="27" VAR="0.05509259259259258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7">
<NAME>Sensitivity analysis epinephrine</NAME>
<DICH_OUTCOME CHI2="1.6197475710165687" CI_END="1.1942595185980485" CI_START="0.855167086593847" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0105896462741262" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="151" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.0770987114233703" LOG_CI_START="-0.06794902246923047" LOG_EFFECT_SIZE="0.00457484447706994" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.898851078039826" P_Q="0.7539750540344742" P_Z="0.9016038192450976" Q="1.1959535016964447" RANDOM="YES" SCALE="8.27" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="347" TOTAL_2="356" WEIGHT="400.0" Z="0.12363558077464627">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2510999079381344" CI_START="0.625607746508648" DF="0" EFFECT_SIZE="0.8847020933977455" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.0972919921344492" LOG_CI_START="-0.20369788231852334" LOG_EFFECT_SIZE="-0.05320294509203709" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="1.0" P_Z="0.4883810126587206" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="134" WEIGHT="100.0" Z="0.6928861407139931">
<NAME>Low risk of bias epinephrine vs norepinephrine</NAME>
<DICH_DATA CI_END="1.2510999079381344" CI_START="0.625607746508648" EFFECT_SIZE="0.8847020933977455" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.0972919921344492" LOG_CI_START="-0.20369788231852334" LOG_EFFECT_SIZE="-0.05320294509203709" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.1768029421775838" STUDY_ID="STD-Myburgh-2008" TOTAL_1="135" TOTAL_2="134" VAR="0.03125928036265004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>No low risk of bias epinephrine vs norepinephrine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2804583768591487" CI_START="0.8403823298065782" DF="0" EFFECT_SIZE="1.0373401534526854" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="85" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="0.10736546566724224" LOG_CI_START="-0.07552308780841675" LOG_EFFECT_SIZE="0.015921188929412734" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="1.0" P_Z="0.7329186995587811" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="169" WEIGHT="99.99999999999999" Z="0.3412455979303255">
<NAME>Low risk of bias epinephrine vs norepinephrine + dobutamine</NAME>
<DICH_DATA CI_END="1.2804583768591487" CI_START="0.8403823298065782" EFFECT_SIZE="1.0373401534526854" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="85" LOG_CI_END="0.10736546566724224" LOG_CI_START="-0.07552308780841675" LOG_EFFECT_SIZE="0.015921188929412734" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="0.10742964162454251" STUDY_ID="STD-Annane-2007" TOTAL_1="161" TOTAL_2="169" VAR="0.011541127899577636" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.41573334440192633" CI_END="1.7196434880482134" CI_START="0.6573652502732886" DF="2" EFFECT_SIZE="1.0632186378641248" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-007.01.04" LOG_CI_END="0.2354384194529677" LOG_CI_START="-0.1821932573785788" LOG_EFFECT_SIZE="0.026622581037194493" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="0.8123154274949262" P_Z="0.802678675467788" STUDIES="3" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="0.24988190744662728">
<NAME>No low risk of bias epinephrine vs norepinephrine + dobutamine</NAME>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Levy-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="58.554846198491"/>
<DICH_DATA CI_END="2.2074737659003936" CI_START="0.2899241702829271" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.34389555102994734" LOG_CI_START="-0.5377155770460601" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.5178627406773132" STUDY_ID="STD-Seguin-2002" TOTAL_1="11" TOTAL_2="11" VAR="0.2681818181818182" WEIGHT="22.44051073708648"/>
<DICH_DATA CI_END="3.766239014647583" CI_START="0.4148701115152691" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-05-14 14:53:57 +0100" MODIFIED_BY="Harald Herkner" ORDER="349" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Levy-2011" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="19.00464306442252"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.526715482911022" CI_START="0.4632045937439141" DF="0" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-007.01.05" LOG_CI_END="0.7424671075377625" LOG_CI_START="-0.3342271422259129" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="1.0" P_Z="0.45739633205779673" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.0" Z="0.7431409884809256">
<NAME>Low risk of bias epinephrine vs norepinephrine + dopexamine</NAME>
<DICH_DATA CI_END="5.5267154829110225" CI_START="0.46320459374391415" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7424671075377625" LOG_CI_START="-0.3342271422259128" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Seguin-2006" TOTAL_1="10" TOTAL_2="12" VAR="0.39999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>No low risk of bias epinephrine vs norepinephrine + dopexamine</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="8">
<NAME>Sensitivity analysis vasopressin</NAME>
<DICH_OUTCOME CHI2="6.34841274097362" CI_END="1.0202210879430202" CI_START="0.7888617457415243" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.897113921682775" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="255" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.008694296143448858" LOG_CI_START="-0.1029991036635314" LOG_EFFECT_SIZE="-0.04715240376004127" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6082662900047912" P_Q="0.9763164951593424" P_Z="0.09795819194944183" Q="0.47041443345985023" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="575" TOTAL_2="563" WEIGHT="500.0" Z="1.6548339170242767">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Vasopressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vasopressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2978412070988727" CI_END="7.673699616615933" CI_START="0.11068426756914676" DF="1" EFFECT_SIZE="0.9216061097946218" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="56.48089185141976" ID="CMP-008.01.01" LOG_CI_END="0.8850047949405593" LOG_CI_START="-0.9559141044461434" LOG_EFFECT_SIZE="-0.035454654752792164" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.12955407709017774" P_Z="0.9398210828445168" STUDIES="2" TAU2="1.4981522729564312" TOTAL_1="40" TOTAL_2="39" WEIGHT="100.0" Z="0.07549473952700998">
<NAME>Low risk of bias vasopressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="3.3474131138717054" CI_START="0.01194952598896136" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5247093131953876" LOG_CI_START="-1.922649321867425" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="1.4375905768565218" STUDY_ID="STD-Malay-1999" TOTAL_1="5" TOTAL_2="5" VAR="2.066666666666667" WEIGHT="32.802507250676314"/>
<DICH_DATA CI_END="5.095551572170946" CI_START="0.7407821948395711" EFFECT_SIZE="1.9428571428571428" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7071912014503718" LOG_CI_START="-0.13030946473845045" LOG_EFFECT_SIZE="0.28844086835596067" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.4919520370144727" STUDY_ID="STD-Choong-2009" TOTAL_1="35" TOTAL_2="34" VAR="0.2420168067226891" WEIGHT="67.19749274932369"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1683732985038606" CI_END="1.2587868190539322" CI_START="0.6273480815211014" DF="2" EFFECT_SIZE="0.8886492536302127" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="45" I2="7.764959041878778" ID="CMP-008.01.02" LOG_CI_END="0.09995218670216617" LOG_CI_START="-0.2024914257751656" LOG_EFFECT_SIZE="-0.051269619536499736" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.33817696213858495" P_Z="0.5063715482399942" STUDIES="3" TAU2="0.010020821467617588" TOTAL_1="105" TOTAL_2="112" WEIGHT="100.0" Z="0.6644981321940937">
<NAME>No low risk of bias vasopressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="33.22482779054145" CI_START="0.48156758255809334" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5214627386046446" LOG_CI_START="-0.31734275594871975" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-D_x00fc_nser-2003" TOTAL_1="24" TOTAL_2="24" VAR="1.1666666666666665" WEIGHT="2.6822725307045925"/>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="31.03819933558036"/>
<DICH_DATA CI_END="1.2844432648108726" CI_START="0.600637741055175" EFFECT_SIZE="0.8783422459893048" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.10871492578901966" LOG_CI_START="-0.22138738239838085" LOG_EFFECT_SIZE="-0.0563362283046806" MODIFIED="2014-10-29 11:44:00 +0000" MODIFIED_BY="Harald Herkner" ORDER="102" O_E="0.0" SE="0.19390372986205795" STUDY_ID="STD-Han-2012" TOTAL_1="66" TOTAL_2="73" VAR="0.03759865645441794" WEIGHT="66.27952813371505"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias vasopressin vs terlipressin</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3452615705961373" CI_START="0.5569197335406775" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-008.01.04" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="1.0" P_Z="0.7158064239433396" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.36406908278664474">
<NAME>No low risk of bias vasopressin vs terlipressin</NAME>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23106612099026952" CI_END="1.031038111006079" CI_START="0.7626453618441602" DF="1" EFFECT_SIZE="0.8867448523917972" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="189" I2="0.0" ID="CMP-008.01.05" LOG_CI_END="0.01327471872069929" LOG_CI_START="-0.11767736663026039" LOG_EFFECT_SIZE="-0.0522013239547806" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.6307344622535989" P_Z="0.11814724528182524" STUDIES="2" TAU2="0.0" TOTAL_1="405" TOTAL_2="389" WEIGHT="100.0" Z="1.5625977184322577">
<NAME>Low risk of bias vasopressin vs norepinephrine</NAME>
<DICH_DATA CI_END="14.661618230962407" CI_START="0.16143265143318902" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1661819068666315" LOG_CI_START="-0.7920086201523426" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="1.1502508087703842" STUDY_ID="STD-Lauzier-2006" TOTAL_1="13" TOTAL_2="10" VAR="1.323076923076923" WEIGHT="0.4472135430912482"/>
<DICH_DATA CI_END="1.0288372621841817" CI_START="0.7605027628357924" EFFECT_SIZE="0.884552757273122" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="188" LOG_CI_END="0.01234668503963221" LOG_CI_START="-0.11889920385666389" LOG_EFFECT_SIZE="-0.05327625940851585" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.07709448481531224" STUDY_ID="STD-Russell-2008" TOTAL_1="392" TOTAL_2="379" VAR="0.005943559588938409" WEIGHT="99.55278645690875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3718208353474188" CI_START="0.6093495198556591" DF="0" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-008.01.06" LOG_CI_END="0.13729739467912072" LOG_CI_START="-0.21513352673986" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="1.0" P_Z="0.6651107783092969" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="0.43286785087052354">
<NAME>No low risk of bias vasopressin vs norepinephrine</NAME>
<DICH_DATA CI_END="1.3718208353474188" CI_START="0.6093495198556591" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.13729739467912072" LOG_CI_START="-0.21513352673986" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Luckner-2006" TOTAL_1="10" TOTAL_2="8" VAR="0.042857142857142844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="9">
<NAME>Sensitivity analysis terlipressin</NAME>
<DICH_OUTCOME CHI2="1.6216142975260734" CI_END="1.092379073348962" CI_START="0.8144090126504878" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9432090768043865" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.03837337178981005" LOG_CI_START="-0.08915742886449209" LOG_EFFECT_SIZE="-0.025392028537341" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.9510109430791648" P_Q="0.9381162846355964" P_Z="0.43510986192469436" Q="0.8024725835596876" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" WEIGHT="500.0" Z="0.7804775187212439">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>terlipressin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours terlipressin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.194140150142612" CI_START="0.8055237770112587" DF="0" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.07705530071432441" LOG_CI_START="-0.09392163578805011" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="1.0" P_Z="0.8466893657040301" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="100.0" Z="0.19334426017878648">
<NAME>Low risk of bias terlipressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="1.194140150142612" CI_START="0.8055237770112587" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.07705530071432441" LOG_CI_START="-0.09392163578805011" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2014-05-14 15:33:07 +0100" MODIFIED_BY="Harald Herkner" ORDER="351" O_E="0.0" SE="0.10043269885098022" STUDY_ID="STD-Svoboda-2012" TOTAL_1="13" TOTAL_2="17" VAR="0.010086726998491682" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6140683181701849" CI_END="1.137340948154144" CI_START="0.6874476963380459" DF="2" EFFECT_SIZE="0.8842298427216169" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="44" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="0.055890675510513375" LOG_CI_START="-0.16276033903352172" LOG_EFFECT_SIZE="-0.05343483176150417" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.7356255112199189" P_Z="0.3380788689534452" STUDIES="3" TAU2="0.0" TOTAL_1="64" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.9579680752079296">
<NAME>No low risk of bias terlipressin vs placebo/non-protocol vasoactive drugs</NAME>
<DICH_DATA CI_END="1.3176228633212326" CI_START="0.6611232510912622" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.11979112208162922" LOG_CI_START="-0.17971756883651563" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.17593288763724924" STUDY_ID="STD-Yildizdas-2008" TOTAL_1="30" TOTAL_2="28" VAR="0.030952380952380967" WEIGHT="53.294713975380155"/>
<DICH_DATA CI_END="1.4114857793441096" CI_START="0.5767434927059341" EFFECT_SIZE="0.9022556390977443" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.14967650700756205" LOG_CI_START="-0.23901729684648398" LOG_EFFECT_SIZE="-0.04467039491946099" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="0.22832066444922663" STUDY_ID="STD-Morelli-2008a" TOTAL_1="19" TOTAL_2="20" VAR="0.052130325814536346" WEIGHT="31.64373642288198"/>
<DICH_DATA CI_END="1.3390534943022352" CI_START="0.36593011562643585" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.12679792713613944" LOG_CI_START="-0.4366018471076259" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="0.33094381626464864" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.10952380952380951" WEIGHT="15.061549601737878"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias terlipressin vs norepinephrine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.0" STUDY_ID="STD-Boccara-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.330510326941122" CI_START="0.4691473217664706" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-009.01.04" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="1.0" P_Z="0.6553898727617942" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.4462871026284196">
<NAME>No low risk of bias terlipressin vs norepinephrine</NAME>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2010-12-02 08:59:24 +0000" MODIFIED_BY="Harald Herkner" ORDER="273" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Albanese-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias terlipressin vs vasopressin</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7955908899876678" CI_START="0.42639167099208125" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-009.01.06" LOG_CI_END="0.2542073933223294" LOG_CI_START="-0.3701912872777029" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="6" P_CHI2="1.0" P_Z="0.7158064239433395" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3640690827866449">
<NAME>No low risk of bias terlipressin vs vasopressin</NAME>
<DICH_DATA CI_END="1.7955908899876678" CI_START="0.42639167099208125" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.2542073933223294" LOG_CI_START="-0.3701912872777029" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Morelli-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias terlipressin vs dopamine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8354053603053626" CI_START="0.4171421837150025" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-009.01.08" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="8" P_CHI2="1.0" P_Z="0.7238703998204219" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.3532908571046114">
<NAME>No low risk of bias terlipressin vs dopamine</NAME>
<DICH_DATA CI_END="1.8354053603053626" CI_START="0.4171421837150025" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-10-29 11:48:18 +0000" MODIFIED_BY="Harald Herkner" ORDER="105" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="10">
<NAME>Sensitivity analysis dopamine</NAME>
<DICH_OUTCOME CHI2="4.4840042581692146" CI_END="1.1458804680573547" CI_START="0.9674497803685074" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0528921156275464" ESTIMABLE="YES" EVENTS_1="449" EVENTS_2="404" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.05913931678442681" LOG_CI_START="-0.014371569642285411" LOG_EFFECT_SIZE="0.022383873571070752" METHOD="MH" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="0.6114740885948937" P_Q="0.9582742400538405" P_Z="0.23263141821483924" Q="0.08524256010592793" RANDOM="YES" SCALE="19.554986598608636" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="735" TOTAL_2="697" WEIGHT="300.0" Z="1.193607863170988">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Dopamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1479939962810906" CI_START="0.9577109337326679" DF="0" EFFECT_SIZE="1.0485448975117184" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="319" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.05993961681734563" LOG_CI_START="-0.01876555441704766" LOG_EFFECT_SIZE="0.020587031200148976" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" P_CHI2="1.0" P_Z="0.30520208858312736" STUDIES="1" TAU2="0.0" TOTAL_1="529" TOTAL_2="507" WEIGHT="100.0" Z="1.0253415136021453">
<NAME>Low risk of bias dopamine vs norepinephrine</NAME>
<DICH_DATA CI_END="1.1479939962810906" CI_START="0.9577109337326679" EFFECT_SIZE="1.0485448975117184" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="319" LOG_CI_END="0.05993961681734563" LOG_CI_START="-0.01876555441704766" LOG_EFFECT_SIZE="0.020587031200148976" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.04623180717996354" STUDY_ID="STD-De-Backer-2010" TOTAL_1="529" TOTAL_2="507" VAR="0.002137379995125328" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.33745320948864" CI_END="1.382258039328826" CI_START="0.8383512804150842" DF="4" EFFECT_SIZE="1.0764839976215925" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="78" I2="7.779985009415779" ID="CMP-010.01.02" LOG_CI_END="0.14058912451129407" LOG_CI_START="-0.07657396802933697" LOG_EFFECT_SIZE="0.0320075782409785" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="2" P_CHI2="0.36225873516806895" P_Z="0.5634284904391929" STUDIES="5" TAU2="0.008277969482944984" TOTAL_1="190" TOTAL_2="174" WEIGHT="99.99999999999999" Z="0.5777565593741802">
<NAME>No low risk of bias dopamine vs norepinephrine</NAME>
<DICH_DATA CI_END="2.799769271617916" CI_START="0.7289230392014682" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.44712224270224005" LOG_CI_START="-0.1373183227307537" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="0.34330328116279757" STUDY_ID="STD-Martin-1993" TOTAL_1="16" TOTAL_2="16" VAR="0.11785714285714285" WEIGHT="12.900639550125366"/>
<DICH_DATA CI_END="1.73589714889652" CI_START="0.32403993540606457" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.23952398985548337" LOG_CI_START="-0.48940146307208326" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-Ruokonen-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="8.492315406227714"/>
<DICH_DATA CI_END="2.671054939630425" CI_START="0.53911283464624" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4266828209052918" LOG_CI_START="-0.26832032881004214" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Marik-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="9.301363304002361"/>
<DICH_DATA CI_END="1.2458124628441516" CI_START="0.23881657153902142" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.09545267114991443" LOG_CI_START="-0.6219355406990773" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="0.4213973867690182" STUDY_ID="STD-Mathur-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.17757575757575755" WEIGHT="8.755399445931365"/>
<DICH_DATA CI_END="1.5113241424507584" CI_START="0.8855356527459007" EFFECT_SIZE="1.1568627450980393" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="51" LOG_CI_END="0.1793576199845615" LOG_CI_START="-0.052793948896145804" LOG_EFFECT_SIZE="0.06328183554420787" MODIFIED="2010-06-25 15:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.13636698072932701" STUDY_ID="STD-Patel-2010" TOTAL_1="134" TOTAL_2="118" VAR="0.018595953433232643" WEIGHT="60.55028229371318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low risk of bias dopamine vs terlipressin</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3972641440723104" CI_START="0.5448387705665338" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-010.01.04" LOG_CI_END="0.37971588968353065" LOG_CI_START="-0.26373199572815725" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4" P_CHI2="1.0" P_Z="0.723870399820422" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.3532908571046112">
<NAME>No low risk of bias dopamine vs terlipressin</NAME>
<DICH_DATA CI_END="2.3972641440723104" CI_START="0.5448387705665338" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37971588968353065" LOG_CI_START="-0.26373199572815725" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-10-29 11:50:52 +0000" MODIFIED_BY="Harald Herkner" ORDER="106" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Hua-2013" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-02-05 12:28:43 +0000" MODIFIED_BY="Jane Cracknell">
<FIGURE FILENAME="update 20141013additional figure comparisons.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Comparisons including vasopressors identified from the systematic review. The 10 interventions with 31 direct comparisons were derived from 28 studies. Line thickness is proportional to the number of included participants. Boxes indicate the two networks that we formally assessed in our network meta-analysis. <I>npvd/'placebo'</I> denotes <I>non-protocol vasoactive drugs or placebo</I>.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm0AAAHXCAIAAABh0PpnAACAAElEQVR42uy9C1xT9/3/f2z767pu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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Search flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtEAAALYCAYAAAC6xq7PAABXcElEQVR42uzdAYRVaR8/8JcxkjGy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-02-05 12:28:43 +0000" MODIFIED_BY="Jane Cracknell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZ0AAARhCAIAAAB21c8wAABUEUlEQVR42u2dsU7kyNaALSEhgg4I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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-02-05 12:28:43 +0000" MODIFIED_BY="Jane Cracknell" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiIAAAFLCAMAAADceRcXAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAfWklEQVR42u1da3Ab13U+lLgvACS4SzIRrYwriUz6Q7/qRIplk24E
WpbZPFR56onGUVrHP+g47SSTSSex3ZnUPzq1x64nVhxnYjWtYzvOTCYZTWS3laMHEhtUJqFaddIZ
uRkXlBQ6IpiQ2CUlkovFgmTvY58ASIIUSIDk+fTA7r3nPrD74d5zF/fDAUAgFkUDqHgREIvA2ILX
ALE4kCIIpAgCKYJAiiCQIgikCAIpgtiwaMRLUAoDL0HgiSpSZBOPraVvc9Y9mMeJBoGfFwRSBIEU
QSBFEEiRKkBf84KIIgS3FCXIvwEhMlbGLJGsUf8Us3zbqj21eA8XKOikFWfNtwYpZeCid14tfzGS
yeRo43RdvYt9pFflxgjztysr6L7TovOCiaNOpUTSrhQA2hVR0shHrUUWyYsdkSil7KgQtWmiJL5k
ymKKmZuipKRonhgjeYMRWUvw0Yj80yNSVGcFJJPkybQWJw2ordRCjOyYyGqN94mmVw9p2OlDgv2h
6bxtt90fia1gCpLM2hZoGfDqsuVeryBpJeL3gbWrsJoA2hRBJj1KiaLcBsJMJ3Kh0rFmlwAwFc1P
0MFkbiRGXlQ5Q8ef1pM2uS8kMXPuCx0j53qZdXPMOn03yZvI07zET0eyfk23TlpvqqzARBxgv3I1
56cB7BEzc7RWg5UEeO1cs1cPfGMEbkTz0WnyaWef99aTPH3ebffLImv7DG07zfvF6pLIUYvy6xm3
YEKy5Fu9PrB2r43zJ8rTuh2ZAeiN5c+QOas9j1yohCKJREIsRMjYMA7KneT8qqaTl0Jaozf+yG0w
RG4yZLWefZe1nm5WQsqndlsAlgA6ebF3a4XA4C1Aj8JqUYhxYajD9NOIr3CZ1UpKGqQkXNF6erx6
4JAGuXGgjXNYTttX3HZn3yVt27ztDl7GK10YGs95fRiCtO31gU2tmiLzAVBhDQhWajcxf7eAXKjE
XU2CqV0no0h21+zsviTz6cg/Mc9e6JlkuYmOw2e3fOblpnHu6OZBsD1L+sIT3bOk5xGzD2z/8XJG
/ll2V2GO98EpLOYD7dI+0babxwJl6JH4pttS+YL+u9B3zhbuSEL2VrvhagfvD7qrS7qr5LMtfYX8
fxTGYgEW6UA/iAM66PPFVQrTT0XIMH2eOLrkpt3FLZ0lp5Po1xJKG3JqDRkFihyF8et+ul60iO3R
eds3gjXQozfdlvyCPaGStlvTdhDfprPT9KhylHR4CIeLCok08V3iAZ4bNy0/KdcJbeRF7oJOubi4
bGqvE+ZJGVCjABcUoF7BeVOnHCRjiukX+FVXRmFpL/GJ5sIuaBsgFdigRjwjpx6Kc2fMVn6PaXpx
25+6RIqmWNtyu1uG1HWW1PXLznaZMZrgaQW6fhXqcZx8DNjB3G/Se+iHIqW9Qd7ypV8iFyodayYP
6DDZ1BFIv5CXG6gPYon5bLF1kyayWeGDYo7c+attErWciG/T6MKyRVRv+IP3zE5y05Jx8RE+OFy1
mG22Rbg96hk59bB+3MX6IGyDcm0/QTyLpgO8bdMtQ+p6ltT1M/M6IYrICu5rFXPhBe6k3H6VHUQf
6qBEjh6QeicBukXkQgW+SFWwjIdsmmmu+NnpLTeEavY6u31EQ1+kvC9SdYpIVmV2f/tN2PrW3hU3
o+oN1ex1TDDw6epaUWQjADcmBjYmGrgxcbHLgwDcDIBAiiCQIgikCKK2QHcVVzRLuOxIkdqNrfUz
gs+WpKDUCoG+CAIpgkCKIJAiiM1MkVVUHOi17wJSpAJoCbrTw9FDlMH2BXMqwmJlv85fzGNLlPl6
+WoS5a1jJlKhuhTJD7Ytmr+4zumm8A4fI9R9S9stQ2o1rOKoU1WK6LZR8C6prkiRQSbPIp/EjCLK
Z12dkx4RFd1TbBHYSlBPFWe6KV7OUUm1K5LETRMtUr9p9gkpX2fF7BN8ALgo7QVNEhWTq7cGeU+i
ItVVZRTJLNZoxRVHowXtEdYnry1NFJQUqWsXcmEBbAVl+YWeiM3KfyfAziv07wvyVNO/5mGLOBEv
wDsXtzS9PHtlZ5LmPNU03fxPedh57b3vTLPnd3FmowrTEcWCnZn3+hJzTrmvnYHYF38Bc7EbU1tm
WcXXfveFxpa3/6x3FlQDmkget6dVE5z4j5dgLjLdfCANL/zsO9dfamDtzUByrwUvipEGtwukrShr
a5i2RbDzveHjX2fWTluzkZkbPyrA2Vds//3lGtbk2jfUDQvmS5M8WuRWNIocF0H0ZCd2mqmZHrgs
5ABOKWB4AinZ0zk5oqk8s7GG4LKvruLlnhfAeB6ovsqVRGW1cUfRRRVUz3v2HA/sBmjUzfQp0v5e
cMRTigA9eVrjmLc5MtwWsKMxbu209UzBNEkHdn8Gh4sFmbz8LVZ6B7nj5zNaiZqJZO148PgdycV0
TlCUHJJg2W2Fu6xkQK61kGSLSq30D8zOx4ulVil7aakVT3DaGtxvQ7I7vOfWwO9oFpZaVQRlazKZ
3HrJOfuFDnSrMRe8bN/yfV8XcZ7nQDABuGarJI3rpeIw/npJc2E1lr+m1WYyscOkfS+bCrVsV0Hj
lC3WaEG72yenrb3To9FeXCNXmclUyQTyvc5Z4yXoFACEXTZJnhPS9LvjFPMfBQW6QlIGbvPFLtgl
F6VRxVUUoMD1VWE4Cir3pjOfQSRTZZ+pwcuk/UHQ+MSZ4zousbNdcu3kUFsUM/AhLrVy2pI1bYRM
xQp+5V1NivSkyX/pWeeDN3zwXmsY4P+s2BmA6NSjdEUiMYdiuFXMDQcLcpsnLcHOFqVlW/pzhAaT
r3ScKGku2yJ80ldjCUxK+pP3A1zQhKkJ0sr+e2e4vNTgOi4jd3jCtbti9dthfVhaMa+yA6etK6Z4
mJi+/yRyoYq+SB1A70jtrWZ9gz2ZtZdarRNfZL3qaDSrqr+mdKw/uPZHiqDUagngxkSUWlV6eRCA
mwEQSBEEUgSBFEHUFuiu4opmCZcdKbJexta17VMBJxoE+iIIpAgCKYJAiiCQIh70FWUtt4gezMJt
ZNXCCnbAJ64s2/CbC8dp+J/0sms7FqpN25r3052GiC2pt1xHnbTirFg0FzjLNdThnVrbPs3d5A74
ZWMRXZS1/NruCA0dphFIdxpKsnqXIbUycjjqVHeiSag83pUsazRylKgM0jRJUtskmp7QWCwpgsGo
GBlkqic94qU59rQe9qddEV/y41vRAFRmnxiOVxVlYq02WXIiXTlxtwg6ZwQ/ndWnyk69iUDfXLUX
6bMT1SoVEeUWoLGxlDYQBIxqVWVfZHYkNgXwbaXpowB75LxMYzLMZiYsO0PTIZuRf8js9kzks3ez
EFM/nLSyTjwrx975OCfBfCP+CECjkD9Jn/XOZc5q21479ypA67A95sSrEkfpDtSpM9bEX7Ain2Yx
ryieGAik81hWI069gbZ4fym+O/Imr/Oen+apmO9LMev0fQDiE8iF6lLkqqZ3A3x1aOwUgJyGIZml
KbdfYelQ0NI/ZnayAAqfSr5Mju7maY69h/xtYzkmzGqmyTRq1hWNbqG2Wt3C1pB2gU6LPaBw1+Vb
Xsyrr+4OplMMBXah+n3THQnXh7Ue7naYPUwV9gM7tfs4wLuvIxcWdIKWvcUqELfKUy8Jdkgc5emZ
fPWTH88qbB+qJqCKChVxAmvZ7bYT6co5crL89FDfnJNA34JRrQYPsKhWtmptaRrn9XieCX5HU1Cr
czG4TIoqqoqqsd0UR/0EwYBVvr3jIg6UUWCFizTwvPjcm06kq/j8uBN3i8aw8tPL9LCob+1uK3c1
iFQVJkz9nsbl0htwuFgNbjZ2ZsgoLlyCzlw4oxW6+A925GymgyK3/znbVUQ59k7sqy4dxItUvGUp
cDG8vJGybsQr6SLsIC9Hs7upHyHaUPDibj2tBNN9JV4XOxKU4r5NwyUutZrnqjAnLtelp5ELq0GR
n5k7yC00DkpW0Q6LLaJ1gY9SccmMsdhUH24RZ97iadx+Ir7te+TsB9tAefY6OS+0CYfCj0+yfyTm
uMYqe0iit3Mfj7aVisFk0/1Oz5+Qg+mf3+YW/gE7SrYW9+3n8r1cexX9yDYqXW9SWWysbnRXq+iL
VOStrBmqE9/Kbr5W71GtauaLrApFxLWMi1yV+FbzrUE/CCkSpMiq7Dpb08jZRjUczYawpzxXhxSp
WZ9wY2K5gQkvQc2GLwRSBIEUQSBFEAh0V5deJOElQKkVjq1LvE2UWiHw84JAiiCQIgikCAIpclPQ
12XVGxErCjZy00jspAjLnRJXfAEUOeB6qrAkyv5EGV1WiaBqcSkYyQ0Lv8qY5zbJLsVF3mZAalWj
5yLJxVPJwR3JUrvC2yuvO5C7L1m5OaK2E02kDVLHIGGKEb4FmoahkqmEKuFGr0qwoFj9TuS694ug
HxOjOkTbwIw5tuCqtiDVL8pt7EiPMl0XKSq58bT6NXbuVK1/pZ/ruvqoOY/FhahDipye1g/sA2gf
lbzBrEVpnuGfbe/TPT/y2Tg/mt0K6r78uAqRGb3VgJZj3NZF74/zBg91oorWC/QJ8tyII8hqkV6g
pg2uCkt96vg43RG95TWa+9DpvPIkcqG+KJKggO6ZV6W9AIY2JHlzydBY0W56GpGKy6R0+12Q94Ki
wNiTtzYKULg/bCtaKWdfvDIEh+hk6sXTslnsLF+F9bAAyhHymmYJp3rAmEcuLIDa+iIDd9MADgJo
HkXu1EpsNWcuSV4SNKB3fADgH/KjWomt0ZLY0jZOj+7QQBPcohTdml8VRZrU97KXoO+YVJAK9bno
/fiWXWwR6i9Dzy+wIk0mk/CpKU9+ZTVeDNvSQ2H698qUW0tYYdVVRsXli3ZuaWi9gVSoS4oM2tdy
g/R7505vFGnsaud63/N2iXn+e2QJxmJYtdu/e9aGxpOuLVdtySktwzcB03haoTlIZrGzHKQGQbJd
FRfzdsQ0fuNdn77I/ph2Zj8NletHnpqYucFvXWOspNDsUTKZfEycuQ6mrp1QYeIRx3Yivo3OGLF7
xOZJljCsSbnQpo/HWOwsB1I3ZFvE3JCXEJ3apiEVFn56UvPt3om6ezJh4H6Rasm+q4MB/KDiimZx
5Ovvqsxtjps/t14oUn9AqVX9LHoRSBEEUgSBFEHgigZRApRaodRqXY+tK/2p3GVZz+NEg0BfBIEU
QSBFEEgRBFIEsRGwYRa9iWQidJ5cxHKxU8SGpQgjhXO7l3XXkSGbeqJpU8RelUmsaNysVJ8otdDk
PhvsPjBFSUlxjZbINFqITUiRaT3/31TJNz9y7mGAe07kI0zXd/598L7z0ByzTvMgSr2x/Jkp5MKm
pIipgE6DLXK1FjkzmPJKtMD+d5Dyqd1cKCFYqd055MJmowjdYQ96PMa0EY6iKh77G3YwPqfbu8GY
T3Tw6WUYejsyyIXNRhGqzYLtIAZ+TOCWhrFvOKPLjkaNKrMifHppnR5VjiIXNuVEM/eb9B7/bF4w
nQXcwBHRi2dFoKS0N1LIhU1JkehDHYGtyr6ianf6DwBNmuisjqMHpN5J5MICaNiU273bps3Fsg3c
LzKvro+LsWq4jj93Vjk2566z/BK/FVHXUqs5pEjtgVKrzeOuIpAiCKQIAimCwBXNOgRKrVBqhWPr
Am/Te76GUisEfl4QSBEEUgSBFEEgRW4O+vKy9KrVjghjzaNavf3bSWevxuLRp4piT4UwPVhamKTB
kvX6WaT2he02b1Qrf63rR7Va81Hkx4MV/s7qvoWz3ikjkHqnkjqTwdpRY1WfE43+neE8GeTtqEj3
COoRKTpIz/rNhBeciseYorGn7KgQdeJdmRI9alckSXNjXtkxkUWmiitiyo2CFa5XEwUqprJlSWV2
LEhWipZyqtAVKTJIpViSZCIX6oQiXaImdgG0iqM0MsCtP7fG9wA0Sk+1+yYP6Xnl4yz2VGvallp5
YntGIEc3otbElBvxqtXIi4/Rg2uTCS8tVO9UxNYPAKhy0+0k8blrrKa+UbHVNb9VsWRKrbnMRBy5
UCcUyf4EGslNtIY0+kWIvRcUGeDhtDbsm5xyFVFwpAP0IzxxWLtskXlxHJRu184SwHgeqI5K6fHS
QvU+UzDNHA1pNX6KJB7SnJqGjrjmdhrSdJi6qvnVIko8ljXdYqVvI7diYFQT80ycTT/BA3mQLH7G
hdv6jgeP35F0s88zwRzNImXstsJdVtKxdQo7pfhm9nC9gx8rQLLbyQrYkfYSbi20SCIZloob+B1N
7bY3dwnJZFLoggd5JCsnRpUf14q+bN/yfSfGVCD2FLF4ECAO4697dQ04hYMI17t3ZjTaWxwpqyiG
lt6A40RdTTQFkX7Us9DcyUYvgcWoAqkTdtB7ntL/kToGAosxRWNPtXuxp3bArmZS/IxJfZMB5sPK
NqhRnzAsLVyvomkjZBkndLb1+V3gMbQGGE+ES4S0SIK6okiehpIakvXHH6Jxc2F4v/RAjDgotkj7
ce7Vju8CVUQ9SvOkbrgy48We2tpfeBxg8pWOE/TOsohX2Zb+nB+87BmWFq73sim2kBfj/hsn/C6Q
SY44Q+KjzC85KOWGkQR15YssjMV/NqZ6PyVUSU3oiwR9kbqhiLjoEzXBXpt2kCKlFKmbXWeL3zl7
jdpxgFGtAsCNiWWAUqsauqsIpAgCKYJAiiAQ6K4uuejFS4BSq/oaW2s+lJf+ghFKrRDoiyCQIgik
CAIpgkCK1BiopkKKOEiEXnxsL01L4A3HUSQAVFMhRXz4CquI7iqnXEGWLGlUoyVKmmetsBhXERbj
KhHvc8shNjBFGrnC6tVJK0sfHM9lJlpcNdW3leaPAnw6mo9Ou9bqG/FHAO75KY9xtfU1rxxi41JE
HtIukJevCaBQufJVTbnTzfrq0NgpgG+Ng+4l5W8bywGYPVzRlda8coiyn78N8S7mNdhLJhUa42wA
3CBWHHeyE7vd9nfhdbMkfecs+2pC88shNu4o0hBWbgXBdVbx+fFYUdItDeJ1N6FMOcTGooh0kWm1
nrOZwsoBV1M93ZmRAQrjpuVlCBfbZRrjKu0OoeFyiI1Ikewh6Rh5+XCLOPOWl/j5bWzpa+6IAEw2
3e+/U+XZ6wbAxEe2HXcSwuUQRUM0bvcuhYH7RTZ9VCvEplvRVBtzG7o5pMjNA+fejeeuIpAiCKQI
AimCwBXNBgJKrVBqtWHH1pvtOEa1QqAvgkCKIJAiCKQIAimyStDruLYNjTreL6KZs41ZfzNYZKbC
cov8+K6fpZiL2Bm46F0X+0XaPno6n1XbvPPbq1AnRrXaUBNN7pc9oMhjbrAr+iej0OBTTqyrxFmp
XzPlfpKSjYrRLCuUjfZT+utRpp3SRFExXbVVoqWPRbUy+wNRrVxtlixpyIV1RxGbBgi4LPkDQBKe
lJpbABpP2iJ9KHxfZp+5beSzcYAnJ/LSk8xqp/gUHSvVCeuFHQDT0bx+H0CL0kwnqS2vMRP5qZOP
uTosVbJkps0a8YVYiHVDESaA0ULRYl68PGYBPHwbDFHmZLXP7bui9XQDPC+A/jyzODKkXaWehgCf
yxMy6Zp5CqAwRKVVVFPF5lbttuc9j2QI0jJQbZYvxEKsG3dVHCW3VO+wAuGo/PBUkpccCGIF4MXH
IocpG/QPzELzWGlUKx7IyjkR7A0U1WpzuatiJ/mvMxdconJlDA1F9Vch0y5fKuVrroi7os1kIofL
RLV60D2mVeGToXU70ShmClJmOyGGpu/g/BA728kMk+uCzhdDps02qDxulbSLaa5yNrxElst9ptbw
Mplvuqi0ygWPjzXAIj8LCpzMIQnWK0XGjHvEg8Y4QGy6g3qn4jZQcofPEtfCEvPhSOBPtgi5/+Qr
Gluithfi0iPXAR7XhOkJgImZG370K9gq0vhYIouoOaxJf30BSbBefZFVwsaOarW5fJFVQhcOCziK
3DxwY2JgY6KBGxMXuzwIwM0ACKQIAimCQIogagt0V3FFs4TLjhRZq7G1anXOrsUVQKkVAn0RBFIE
gRRBIEUQSBEEUmSNkEgkJKW9bEyqRMnBgjaJYqPFzhDrbBRJJi3l0+VzSg4WrQfv9waeaPR/Jv+9
JIkayDYMKqBJomyyz77dR2NUkYO2hyVJdWNaQUoUZUfKl+mLDHoDSYtMA2ANRqgpjYYVs+mZ2IJU
WOcU0VXa0S9lYtMgvQUHRZiO5CNcF6N+hcaoIpg6ak1QwdRcZiIO0BvLn5nihf/4tag/jcyNkDog
IWfoQ8rWibzYCrDnhdE5pMK6pkgi0ZGjsWOYIurf/hzsUWi0tbTJMnmMKoJcDyjdzIq+CFZqt7O5
PauN+duhuaqqkNaowtMSQLcAlENMoIVY176IKYATrarH1h8w4b25qUfbWWa3q8a1W46x3xHg58PQ
25HhGULwV9Z57pxGU+FO4gnPA/ylBijp3UiL3pwqk1s6M/ojHpRqwBVSNc83X/etWqdHlaP8sA30
hqI6GnQgPogbzmqInyE2CkVa5VeoEMuV+4oXbS6kmh0/1OpbKSntjRQ/NOFDxXqqXCdQX1bKgBoF
OMvPEBuFIuk7xwBOcxUV5cKzMb6/48WmjsBgET0g9U7yw4gyU6ynupCXqW32g2KOTE6GJeMjxAWx
DkUSqYMzq9yCgftFAlKrrbDu4gYOj5ur7e00rMqHsVp3b02ushK4GCgaKR1F8BKg1KrCy4MA/KYX
gRRBIEUQSBFEbYHuKq5olnDZkSJrNbaui/Eao1oh0BdBIEUQSBEEUgSBFKkIGFUKKVIMTWGxYVxs
X4MmK9ZY2RExkkEu1JgibX9yOq9/ot0737em73IJjdVjYr7xIeRCjSmSu9gDyn/9YeEYVS1Sv2n2
CSmmf4ry3capiEAjCplcNaVJbBzSI1J0kEasEpQUz/PLJOIKpARPY9UeUXRvIOEKLFL6LEmwY8xe
V5ji6vnLcPUccqHGFCkTo+qDLEZVq8BjVM1lTmgdryV7mf5JeoxZ3ZO1adDEeCwfmwKqrlLuA7j1
59b4HoCpiK0fYHlnyEurmBfo3ubnrkGiKX/mBm/F+l3Mf47MFViqnHmTjhtGXiRt3PptpriyNPjQ
VuRCjSlSJkbVAyxG1ZHLMPQwUD3U+L7LLEaV5cWoMhWguijh71Pv5miMKjN9ipBtLygywDMF08zR
PJMqqqwhuEwqg0MaiPnUbou3cEUb86OMcAWWktYeBxYHyyBt2Ic0HlPPnkL/eSGs1cZEcWAvwGB3
flkxqgYPzBbuSILdYvf8epzGqJqPj7nZg/ttSHa7eX6sKprS0DTuVh0KYEX+kfNAG84ZQEScCHTW
wO9oahBJQjxIJw4ruOD1Y1SFTQe8GFV/2iDSKUOYHn1sisWoih0G+AXP3js9Gu318gb8WkiK4oh5
y2istnBVldPGFreYfRlHi1pzWzZNSOVGy8eoCguhZBvO8hBDs/+bbmRlNWmOxagCGqNqkCygSaKm
jcx7eXIX7HLmFDmlZZwPQxmNldkJj/E2qMaKnO3gFEHBZs0pMm5o4kGjg8aoepR6huKjYOQOT/AY
VeFhJNsifDLKjs7u6qDjXZMq9pIFxwVNmCIFhvffOxMjfoYpHo55eVesfpt7FRD7oegKN9OKWbz1
w7Ckf2Ft9OcIDY28fKLMoxJELXyRdQX0RTZ1VCvEcoG7zsphbp3UiRSpFXDuXXczJAIpgkCKIJAi
CKQIAimCQCBFEEgRBFJkbWDUuHx9VYAUQeAogkCKIFYVuF9kNWbyDQD8Uc0Kr88KKXazH7s6qAAn
GgT6IgikCALdVUR9+O7ori7kransRa3c9fPKsNdlFfVdRHVlbfsuplpxD3iW3+uFGkWKLHT1yD/2
t2KGuBdXdc4qLxpaSK2kbb+4AZX2wCh6pws2ir5IlRfKK19uGmrVuF3V1nAUqfaNM1bMFqP4gczy
21Yr7oFa8RtGiiw2MBj0r1GxR+/OM+R1uUXBK7nCtkvqWVEPypVBiiw5u6vL+jSrKy6q3nTbN9uD
8mXQF6nePGPc5DRx83OcevPeTWkZpEiV2bTyrwCr9eVhtb+ExEdni3qOhvt8YVlPJZZbtOTBykor
UJfT+XLPRcqUMZAiiCV4hxMNYgkgRRBIEQRSBIEUQSBFEHWMxqKFPQLBoZahCD4hQZQbMHCiQaAv
gkCKIJAiCKQIYn0sehdZ/tbpWgf7WTOKFI8tc+uk94V67WdR4KR5nGgQ6IsgkCKVTKgL5JbYGYaf
ugYP+Y2yDRl113evnws1Xy+XtFoiiaWko/Xsp9W472qdX9LlTzSG4TDfY7LB/jg5wU8ItzSKmO+Y
+darNpy4DQV77r4YddN3Xi+E+lpPl3TZo0g51aihhnOC566K2BPwhIXGq8oR1f9b2rDfr9r3ndYZ
aqieLukKJxrVcP4UjXVqyThYMh6qazZGqmXbUcOvteu7UXRFSztTH5e0ioJNNfADG0tfGtVYc89k
Ef+uFn2vQJlVF5e0sbqfWsr2JWSkRuBHUtaWI2qo/XXR93ro1pYVDxkqFP1YSaWr4oCjuypX1SgZ
mI0lVsT10HfjZh40rOolbVzmm1AXHs38HM6dsKVqeJk8Z9UmmqKagw3TI6f9uup72T7VyyUNCDaN
BQM8z9Xr12PF39HUaz+Lv6NRl3rYUQd9Vhe4yIja3A+o429/kSL1gLreHFCeIusleHlhnfRzfj3z
t3HdkRr7ucbAzQAIpAgCKYJAiiCQIgikCGJjLHrx1yMQi1MEfzsCgRMNAimCQIogkCIIpAgCKYJA
iiAQCISP/wcP666VeD6dxgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-02-05 12:28:43 +0000" MODIFIED_BY="Jane Cracknell" NO="5" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 norepinephrine, outcome: 1.1 mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAHMCAMAAAA+pyYmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-02-05 12:28:43 +0000" MODIFIED_BY="Jane Cracknell" NO="6" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Norepinephrine, outcome: 1.1 Total mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8oAAAPQCAMAAADZ/HL7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="netplot_pressors.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Graphical representation of the evidence network including vasopressors showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfIAAAGACAIAAADZGXdNAABch0lEQVR42uydB1BVZ/73UzbZmWQy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</FILE>
</FIGURE>
<FIGURE FILENAME="netforest_pressors_nor.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Network forest plot comparing seven vasopressor regimens vs norepinephrine (reference) from 22 studies with 24 pair-wise comparisons. Heterogeneity/inconsistency: tau<SUP>2</SUP> &lt; 0.0001; I<SUP>2</SUP> statistic = 0%. Test of heterogeneity/inconsistency: Q = 8.48 (d.f. 18), P value = 0.97; 'NPVD' denotes non-protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed-effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl0AAAJHCAYAAACqz+PWAABHaUlEQVR42u3dCdjlY/0/8PnZsu9b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</FILE>
</FIGURE>
<FIGURE FILENAME="netplot_epi.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Graphical representation of the evidence network including vasopressors and combinations with beta-agonist action showing available direct comparisons. The lines represent direct comparisons, and line thickness is proportional to precision of the estimates (1/SE).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxoAAAIjCAYAAACEQm2DAAArUElEQVR42u3dB7BddYHH8dBUekcp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</FILE>
</FIGURE>
<FIGURE FILENAME="forest_epi_nor.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Network forest plot comparing four vasopressor regimens with a beta-agonist component vs norepinephrine (reference) from 6 studies with 6 pair-wise comparisons. Heterogeneity/inconsistency: tau<SUP>2</SUP> &lt; 0.0001; I<SUP>2</SUP> statistic = 0%. Test of heterogeneity/inconsistency: Q = 0.42(d.f. 3), P value = 0.94; 'nor_' denotes norepinephrine added to the other drugs as described. RR denotes risk ratio, as calculated by a fixed-effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxoAAAIjCAYAAACEQm2DAAA80UlEQVR42u3dB7hl46E/flfC1Wv0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</FILE>
</FIGURE>
<FIGURE FILENAME="netforest_pressors_sepsis_only_nor.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Subgroup analysis in patients with septic shock: network forest plot comparing 7 vasopressor regimens vs norepinephrine (reference) from 18 studies with 20 pair-wise comparisons. Heterogeneity/inconsistency: tau<SUP>2</SUP> &lt; 0.0001; I<SUP>2</SUP> statistic = 0%. Test of heterogeneity/inconsistency: Q = 5.21, d.f. = 14, P value = 0.98; 'NPVD' denotes non-protocol vasoactive drugs with or without placebo. RR denotes risk ratio, as calculated by a fixed-effect model. RR &gt; 1 indicates increased mortality risk; RR &lt; 1 indicates reduced mortality risk vs norepinephrine (reference).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl0AAAJHCAYAAACqz+PWAABGI0lEQVR42u3dB7RcVd034LwgSO9S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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2015-05-14 21:52:15 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2011-03-22 07:10:16 +0000" MODIFIED_BY="[Empty name]">Search filter for the Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>#1 MeSH descriptor Shock explode all trees<BR/>#2 MeSH descriptor Systemic Inflammatory Response Syndrome explode all trees<BR/>#3 MeSH descriptor Shock, Cardiogenic explode all trees<BR/>#4 MeSH descriptor Shock, Hemorrhagic explode all trees<BR/>#5 MeSH descriptor Shock, Septic explode all trees<BR/>#6 MeSH descriptor Shock, Surgical explode all trees<BR/>#7 MeSH descriptor Shock, Traumatic explode all trees<BR/>#8 MeSH descriptor Hypotension explode all trees<BR/>#9 MeSH descriptor Intensive Care, Neonatal explode all trees<BR/>#10 MeSH descriptor Intensive Care explode all trees<BR/>#11 circulatory near failure<BR/>#12 shock or Sepsis Syndrome or Cardiogenic Shock or Hemorrhagic Shock or Haemorrhagic Shock or Septic Shock or Surgical Shock or Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock<BR/>#13 hypotension and ((critical near care) or (intensive near care))<BR/>#14 neonatal near intensive near care<BR/>#15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)<BR/>#16 MeSH descriptor Vasoconstrictor Agents explode all trees<BR/>#17 MeSH descriptor Epinephrine explode all trees<BR/>#18 MeSH descriptor Norepinephrine explode all trees<BR/>#19 MeSH descriptor Catecholamines explode all trees<BR/>#20 MeSH descriptor Orciprenaline explode all trees<BR/>#21 MeSH descriptor Dobutamine explode all trees<BR/>#22 MeSH descriptor Dopamine explode all trees<BR/>#23 MeSH descriptor Vasopressins explode all trees<BR/>#24 MeSH descriptor Arginine Vasopressin explode all trees<BR/>#25 MeSH descriptor Deamino Arginine Vasopressin explode all trees<BR/>#26 MeSH descriptor Lysine Vasopressin explode all trees<BR/>#27 MeSH descriptor Felypressin explode all trees<BR/>#28 MeSH descriptor Ornipressin explode all trees<BR/>#29 Vasoconstrictor near Agents<BR/>#30 Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin<BR/>#31 (#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30)<BR/>#32 (#15 AND #31)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-05-14 21:52:15 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2010-07-01 15:25:35 +0100" MODIFIED_BY="Jane Cracknell">Search terms for MEDLINE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>1. exp Vasoconstrictor Agents/ or exp Epinephrine/ or exp Norepinephrine/ or exp Catecholamines/ or exp Orciprenaline/ or exp dobutamine/ or exp Vasopressins/ or exp Argipressin/ or exp Deamino Arginine Vasopressin/ or exp Lypressin/ or exp Felypressin/ or exp Ornipressin/ <BR/>2. (Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin or (Vasoconstrictor* adj3 Agent*)).mp. <BR/>3. 2 or 1 <BR/>4. exp Shock, Cardiogenic/ or exp Shock, Hemorrhagic/ or exp shock/ or exp Sepsis Syndrome/ or exp Shock, Septic/ or exp Shock, Surgical/ or exp Shock, Traumatic/ or exp hypotension/ or exp Intensive Care, Neonatal/ or exp Intensive Care/ <BR/>5. (shock or Sepsis Syndrome or Cardiogenic Shock or Hemorrhagic Shock or Haemorrhagic Shock or Septic Shock or Surgical Shock or Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock).mp. <BR/>6. ((circulatory adj6 failure) or ((hypotension or neonatal) and (care adj5 (critical or intensive)))).mp. <BR/>7. 4 or 5 or 6 <BR/>8. 3 and 7 <BR/>9. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) and humans.sh. <BR/>10. 8 and 9 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell" NO="3">
<TITLE MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell">Search filter for EMBASE (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>1. Vasoconstrictor Agent/ or Adrenalin/ or Noradrenalin/ or Catecholamine/ or Orciprenaline/ or Dobutamine/ or Vasopressin Derivative/ or Argipressin/ or "Argipressin[1 Deamino]"/ or Lypressin/ or Felypressin/ or Ornipressin/ <BR/>2. (Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin or (Vasoconstrictor* adj3 Agent*)).ti,ab. <BR/>3. 1 or 2 <BR/>4. Cardiogenic Shock/ or Hemorrhagic Shock/ or Septic Shock/ or Shock/ or Sepsis/ or Traumatic Shock/ or Hypotension/ or Newborn Intensive Care/ or Intensive Care/ (141799)<BR/>5. (shock or Sepsis Syndrome or Cardiogenic Shock or Hemorrhagic Shock or Haemorrhagic Shock or Septic Shock or Surgical Shock or Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock or ((circulatory adj6 failure) or ((hypotension or neonatal) and (care adj5 (critical or intensive))))).ti,ab. <BR/>6. 4 or 5 <BR/>7. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) and human*.ec,hw,fs. <BR/>8. 6 and 3 and 7 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="4">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Search filter for CINAHL (EBSCO Host)</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-11 10:20:23 +0000" MODIFIED_BY="Jane Cracknell">
<P>S1. TX circulatory failure <BR/>S2. MW (shock or Sepsis Syndrome or Carcinogenic Shock or Hemorrhagic Shock or Hemorrhagic Shock or Septic Shock or Surgical Shock Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock)<BR/>S3. TX (hypotension and ((critical care) or (intensive care) or (neonatal intensive care))) <BR/>S4. S3 or S2 or S1 <BR/>S5. TX Vasopressor or Vasoconstrictor or Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin <BR/>S6. S5 and S4 <BR/>S7. TX (PLACEBO* or random* or trial* or control* or compar* or blind*)<BR/>S8. S6 and S7</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell" NO="5">
<TITLE MODIFIED="2015-06-16 13:04:41 +0100" MODIFIED_BY="Jane Cracknell">Search filter for BIOSIS Previews and ISI Web of Science</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-16 11:11:30 +0000" MODIFIED_BY="Harald Herkner">
<P>#1 TS=(circulatory failure or shock or Sepsis Syndrome or ((Cardiogenic or Hemorrhagic or Haemorrhagic or Septic or Surgical or Traumatic or Anaphylactic or Allergic or Burn) SAME Shock) or (hypotension SAME (critical care or intensive care or neonatal intensive care)))<BR/>#2 TS=(Vasopressor* or Vasoconstrictor* or Epinephrine or Norepinephrine or Catecholamine* or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin)<BR/>#3 TS=(PLACEBO* or random* or ((clinical or controlled) same trial*))<BR/>#4 #1 and #2 and #3</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-03-22 07:10:36 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-03-22 07:10:36 +0000" MODIFIED_BY="[Empty name]">Search filter for PsycINFO (Ovid SP)</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-11 10:20:22 +0000" MODIFIED_BY="Jane Cracknell">
<P>1. (circulatory failure or shock or Sepsis Syndrome or Cardiogenic Shock or Hemorrhagic Shock or Haemorrhagic Shock or Septic Shock or Surgical Shock or Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock or (hypotension and (critical care or intensive care or neonatal intensive care))).af. <BR/>2. (Vasopressor or Vasoconstrictor or Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin).ti,ab. <BR/>3. (PLACEBO* or random* or trial*).af. <BR/>4. 1 and 2 and 3 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell" NO="7">
<TITLE MODIFIED="2016-02-05 12:28:14 +0000" MODIFIED_BY="Jane Cracknell">Search filter for Pascal BioMed</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-10 11:02:18 +0000" MODIFIED_BY="Harald Herkner">
<P>S1. TX circulatory failure<BR/>S2. MW (shock or Sepsis Syndrome or Carcinogenic Shock or Hemorrhagic Shock or Hemorrhagic Shock or Septic Shock or Surgical Shock Traumatic Shock or Anaphylactic Shock or Allergic Shock or Burn Shock)<BR/>S3. TX (hypotension and ((critical care) or (intensive care) or (neonatal intensive care)))<BR/>S4. S3 or S2 or S1<BR/>S5. TX Vasopressor or Vasoconstrictor or Epinephrine or Norepinephrine or Catecholamines or Orciprenaline or dobutamine or dopamine or adrenaline or noradrenaline or Vasopressins or Argipressin or Desmopressin or Lypressin or Felypressin or Ornipressin or Terlipressin or Glypressin<BR/>S6. S5 and S4<BR/>S7. TX (PLACEBO* or random* or trial* or control* or compar* or blind*)<BR/>S8. S6 and S7</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included&lt;/p&gt;&lt;p&gt;n=28&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full text assessed&lt;/p&gt;&lt;p&gt;n=168&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Other sources&lt;/p&gt;&lt;p&gt;n=1&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Full paper review&lt;/p&gt;&lt;p&gt;n=167&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Database Search&lt;/p&gt;&lt;p&gt;n=1776&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;Excluded&lt;/p&gt;&lt;p&gt;n=1607&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Full report not yet retrievable listed under 'studies awaiting classification'&lt;/p&gt;&lt;p&gt;n=2&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Excluded after full text assessment&lt;/p&gt;&lt;p&gt;n=140&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Among these 140 studies 18 studies are listed and described in more detail:&lt;/p&gt;&lt;p&gt;13 studies listed in the 'excluded studies',&lt;/p&gt;&lt;p&gt;5 studies listed in the 'ongoing studies'&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>